<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Claude Code transcript - Index</title>
    <style>
:root { --bg-color: #f5f5f5; --card-bg: #ffffff; --user-bg: #e3f2fd; --user-border: #1976d2; --assistant-bg: #f5f5f5; --assistant-border: #9e9e9e; --thinking-bg: #fff8e1; --thinking-border: #ffc107; --thinking-text: #666; --tool-bg: #f3e5f5; --tool-border: #9c27b0; --tool-result-bg: #e8f5e9; --tool-error-bg: #ffebee; --text-color: #212121; --text-muted: #757575; --code-bg: #263238; --code-text: #aed581; }
* { box-sizing: border-box; }
body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; background: var(--bg-color); color: var(--text-color); margin: 0; padding: 16px; line-height: 1.6; }
.container { max-width: 800px; margin: 0 auto; }
h1 { font-size: 1.5rem; margin-bottom: 24px; padding-bottom: 8px; border-bottom: 2px solid var(--user-border); }
.header-row { display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 12px; border-bottom: 2px solid var(--user-border); padding-bottom: 8px; margin-bottom: 24px; }
.header-row h1 { border-bottom: none; padding-bottom: 0; margin-bottom: 0; flex: 1; min-width: 200px; }
.message { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.message.user { background: var(--user-bg); border-left: 4px solid var(--user-border); }
.message.assistant { background: var(--card-bg); border-left: 4px solid var(--assistant-border); }
.message.tool-reply { background: #fff8e1; border-left: 4px solid #ff9800; }
.tool-reply .role-label { color: #e65100; }
.tool-reply .tool-result { background: transparent; padding: 0; margin: 0; }
.tool-reply .tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.message-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.role-label { font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; }
.user .role-label { color: var(--user-border); }
time { color: var(--text-muted); font-size: 0.8rem; }
.timestamp-link { color: inherit; text-decoration: none; }
.timestamp-link:hover { text-decoration: underline; }
.message:target { animation: highlight 2s ease-out; }
@keyframes highlight { 0% { background-color: rgba(25, 118, 210, 0.2); } 100% { background-color: transparent; } }
.message-content { padding: 16px; }
.message-content p { margin: 0 0 12px 0; }
.message-content p:last-child { margin-bottom: 0; }
.thinking { background: var(--thinking-bg); border: 1px solid var(--thinking-border); border-radius: 8px; padding: 12px; margin: 12px 0; font-size: 0.9rem; color: var(--thinking-text); }
.thinking-label { font-size: 0.75rem; font-weight: 600; text-transform: uppercase; color: #f57c00; margin-bottom: 8px; }
.thinking p { margin: 8px 0; }
.assistant-text { margin: 8px 0; }
.tool-use { background: var(--tool-bg); border: 1px solid var(--tool-border); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-header { font-weight: 600; color: var(--tool-border); margin-bottom: 8px; display: flex; align-items: center; gap: 8px; }
.tool-icon { font-size: 1.1rem; }
.tool-description { font-size: 0.9rem; color: var(--text-muted); margin-bottom: 8px; font-style: italic; }
.tool-result { background: var(--tool-result-bg); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-result.tool-error { background: var(--tool-error-bg); }
.file-tool { border-radius: 8px; padding: 12px; margin: 12px 0; }
.write-tool { background: linear-gradient(135deg, #e3f2fd 0%, #e8f5e9 100%); border: 1px solid #4caf50; }
.edit-tool { background: linear-gradient(135deg, #fff3e0 0%, #fce4ec 100%); border: 1px solid #ff9800; }
.file-tool-header { font-weight: 600; margin-bottom: 4px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.write-header { color: #2e7d32; }
.edit-header { color: #e65100; }
.file-tool-icon { font-size: 1rem; }
.file-tool-path { font-family: monospace; background: rgba(0,0,0,0.08); padding: 2px 8px; border-radius: 4px; }
.file-tool-fullpath { font-family: monospace; font-size: 0.8rem; color: var(--text-muted); margin-bottom: 8px; word-break: break-all; }
.file-content { margin: 0; }
.edit-section { display: flex; margin: 4px 0; border-radius: 4px; overflow: hidden; }
.edit-label { padding: 8px 12px; font-weight: bold; font-family: monospace; display: flex; align-items: flex-start; }
.edit-old { background: #fce4ec; }
.edit-old .edit-label { color: #b71c1c; background: #f8bbd9; }
.edit-old .edit-content { color: #880e4f; }
.edit-new { background: #e8f5e9; }
.edit-new .edit-label { color: #1b5e20; background: #a5d6a7; }
.edit-new .edit-content { color: #1b5e20; }
.edit-content { margin: 0; flex: 1; background: transparent; font-size: 0.85rem; }
.edit-replace-all { font-size: 0.75rem; font-weight: normal; color: var(--text-muted); }
.write-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #e6f4ea); }
.edit-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff0e5); }
.todo-list { background: linear-gradient(135deg, #e8f5e9 0%, #f1f8e9 100%); border: 1px solid #81c784; border-radius: 8px; padding: 12px; margin: 12px 0; }
.todo-header { font-weight: 600; color: #2e7d32; margin-bottom: 10px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.todo-items { list-style: none; margin: 0; padding: 0; }
.todo-item { display: flex; align-items: flex-start; gap: 10px; padding: 6px 0; border-bottom: 1px solid rgba(0,0,0,0.06); font-size: 0.9rem; }
.todo-item:last-child { border-bottom: none; }
.todo-icon { flex-shrink: 0; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center; font-weight: bold; border-radius: 50%; }
.todo-completed .todo-icon { color: #2e7d32; background: rgba(46, 125, 50, 0.15); }
.todo-completed .todo-content { color: #558b2f; text-decoration: line-through; }
.todo-in-progress .todo-icon { color: #f57c00; background: rgba(245, 124, 0, 0.15); }
.todo-in-progress .todo-content { color: #e65100; font-weight: 500; }
.todo-pending .todo-icon { color: #757575; background: rgba(0,0,0,0.05); }
.todo-pending .todo-content { color: #616161; }
pre { background: var(--code-bg); color: var(--code-text); padding: 12px; border-radius: 6px; overflow-x: auto; font-size: 0.85rem; line-height: 1.5; margin: 8px 0; white-space: pre-wrap; word-wrap: break-word; }
pre.json { color: #e0e0e0; }
code { background: rgba(0,0,0,0.08); padding: 2px 6px; border-radius: 4px; font-size: 0.9em; }
pre code { background: none; padding: 0; }
.user-content { margin: 0; }
.truncatable { position: relative; }
.truncatable.truncated .truncatable-content { max-height: 200px; overflow: hidden; }
.truncatable.truncated::after { content: ''; position: absolute; bottom: 32px; left: 0; right: 0; height: 60px; background: linear-gradient(to bottom, transparent, var(--card-bg)); pointer-events: none; }
.message.user .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--user-bg)); }
.message.tool-reply .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.tool-use .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-bg)); }
.tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-result-bg)); }
.expand-btn { display: none; width: 100%; padding: 8px 16px; margin-top: 4px; background: rgba(0,0,0,0.05); border: 1px solid rgba(0,0,0,0.1); border-radius: 6px; cursor: pointer; font-size: 0.85rem; color: var(--text-muted); }
.expand-btn:hover { background: rgba(0,0,0,0.1); }
.truncatable.truncated .expand-btn, .truncatable.expanded .expand-btn { display: block; }
.pagination { display: flex; justify-content: center; gap: 8px; margin: 24px 0; flex-wrap: wrap; }
.pagination a, .pagination span { padding: 5px 10px; border-radius: 6px; text-decoration: none; font-size: 0.85rem; }
.pagination a { background: var(--card-bg); color: var(--user-border); border: 1px solid var(--user-border); }
.pagination a:hover { background: var(--user-bg); }
.pagination .current { background: var(--user-border); color: white; }
.pagination .disabled { color: var(--text-muted); border: 1px solid #ddd; }
.pagination .index-link { background: var(--user-border); color: white; }
details.continuation { margin-bottom: 16px; }
details.continuation summary { cursor: pointer; padding: 12px 16px; background: var(--user-bg); border-left: 4px solid var(--user-border); border-radius: 12px; font-weight: 500; color: var(--text-muted); }
details.continuation summary:hover { background: rgba(25, 118, 210, 0.15); }
details.continuation[open] summary { border-radius: 12px 12px 0 0; margin-bottom: 0; }
.index-item { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); background: var(--user-bg); border-left: 4px solid var(--user-border); }
.index-item a { display: block; text-decoration: none; color: inherit; }
.index-item a:hover { background: rgba(25, 118, 210, 0.1); }
.index-item-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.index-item-number { font-weight: 600; color: var(--user-border); }
.index-item-content { padding: 16px; }
.index-item-stats { padding: 8px 16px 12px 32px; font-size: 0.85rem; color: var(--text-muted); border-top: 1px solid rgba(0,0,0,0.06); }
.index-item-commit { margin-top: 6px; padding: 4px 8px; background: #fff3e0; border-radius: 4px; font-size: 0.85rem; color: #e65100; }
.index-item-commit code { background: rgba(0,0,0,0.08); padding: 1px 4px; border-radius: 3px; font-size: 0.8rem; margin-right: 6px; }
.commit-card { margin: 8px 0; padding: 10px 14px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 6px; }
.commit-card a { text-decoration: none; color: #5d4037; display: block; }
.commit-card a:hover { color: #e65100; }
.commit-card-hash { font-family: monospace; color: #e65100; font-weight: 600; margin-right: 8px; }
.index-commit { margin-bottom: 12px; padding: 10px 16px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 8px; box-shadow: 0 1px 2px rgba(0,0,0,0.05); }
.index-commit a { display: block; text-decoration: none; color: inherit; }
.index-commit a:hover { background: rgba(255, 152, 0, 0.1); margin: -10px -16px; padding: 10px 16px; border-radius: 8px; }
.index-commit-header { display: flex; justify-content: space-between; align-items: center; font-size: 0.85rem; margin-bottom: 4px; }
.index-commit-hash { font-family: monospace; color: #e65100; font-weight: 600; }
.index-commit-msg { color: #5d4037; }
.index-item-long-text { margin-top: 8px; padding: 12px; background: var(--card-bg); border-radius: 8px; border-left: 3px solid var(--assistant-border); }
.index-item-long-text .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--card-bg)); }
.index-item-long-text-content { color: var(--text-color); }
#search-box { display: none; align-items: center; gap: 8px; }
#search-box input { padding: 6px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; width: 180px; }
#search-box button, #modal-search-btn, #modal-close-btn { background: var(--user-border); color: white; border: none; border-radius: 6px; padding: 6px 10px; cursor: pointer; display: flex; align-items: center; justify-content: center; }
#search-box button:hover, #modal-search-btn:hover { background: #1565c0; }
#modal-close-btn { background: var(--text-muted); margin-left: 8px; }
#modal-close-btn:hover { background: #616161; }
#search-modal[open] { border: none; border-radius: 12px; box-shadow: 0 4px 24px rgba(0,0,0,0.2); padding: 0; width: 90vw; max-width: 900px; height: 80vh; max-height: 80vh; display: flex; flex-direction: column; }
#search-modal::backdrop { background: rgba(0,0,0,0.5); }
.search-modal-header { display: flex; align-items: center; gap: 8px; padding: 16px; border-bottom: 1px solid var(--assistant-border); background: var(--bg-color); border-radius: 12px 12px 0 0; }
.search-modal-header input { flex: 1; padding: 8px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; }
#search-status { padding: 8px 16px; font-size: 0.85rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
#search-results { flex: 1; overflow-y: auto; padding: 16px; }
.search-result { margin-bottom: 16px; border-radius: 8px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.search-result a { display: block; text-decoration: none; color: inherit; }
.search-result a:hover { background: rgba(25, 118, 210, 0.05); }
.search-result-page { padding: 6px 12px; background: rgba(0,0,0,0.03); font-size: 0.8rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
.search-result-content { padding: 12px; }
.search-result mark { background: #fff59d; padding: 1px 2px; border-radius: 2px; }
@media (max-width: 600px) { body { padding: 8px; } .message, .index-item { border-radius: 8px; } .message-content, .index-item-content { padding: 12px; } pre { font-size: 0.8rem; padding: 8px; } #search-box input { width: 120px; } #search-modal[open] { width: 95vw; height: 90vh; } }
</style>
<link rel="stylesheet" href="../../steno-transcript.css">
</head>
<body>
<button class="theme-toggle" onclick="document.body.classList.toggle('dark')" style="position:fixed;top:1rem;right:1rem;z-index:1000;padding:0.5rem 1rem;border:1px solid #ddd;border-radius:0.5rem;background:#fff;cursor:pointer;font-size:0.875rem;">Toggle Dark Mode</button>
    <div class="container">
        <div class="header-row">
            <h1>Claude Code transcript</h1>
            <div id="search-box">
                <input type="text" id="search-input" placeholder="Search..." aria-label="Search transcripts">
                <button id="search-btn" type="button" aria-label="Search">
                    <svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35"></path></svg>
                </button>
            </div>
        </div>
        

<div class="pagination">
<span class="current">Index</span>
<span class="disabled">&larr; Prev</span>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<a href="page-003.html">3</a>
<a href="page-004.html">4</a>
<a href="page-001.html">Next &rarr;</a>
</div>

        <p style="color: var(--text-muted); margin-bottom: 24px;">19 prompts · 108 messages · 38 tool calls · 0 commits · 4 pages</p>
        
<div class="index-item"><a href="page-001.html#msg-2025-12-13T03-19-35-710Z"><div class="index-item-header"><span class="index-item-number">#1</span><time datetime="2025-12-13T03:19:35.710Z" data-timestamp="2025-12-13T03:19:35.710Z">2025-12-13T03:19:35.710Z</time></div><div class="index-item-content"><p>I work on the FGT microbiome, particulatly in women living in South Africa. We are interested in how the FGT alters infection, health an immunity. We have relied heavily on 16S rRNA surveys for this work and define most of our thinking aorund the idea of cervicotypes. We have consistenly struggled with deciding between 16S surveys and metagneomics. While metagenomics gives us better taxonomic assignments, MAGS and functional reat outs, it is quite expensive as we need to sequence through a tremendous amount of host background. I am starting to think a PCR or hybrid captrue based approach may actually be the better approach. In short, we are sometimes just trying to define lactobacillus high vs. low and are interested in species speficic absolute abundances of various lactobacillus speices or potentially inlammaorty species (in the higher CT groups) such as gardeneralla or mycomplasma. Is this biology better assayed using specific assays or broadly defined using survey omics apprpoaches</p></div></a></div>
<div class="index-item"><a href="page-001.html#msg-2025-12-13T03-19-37-738Z"><div class="index-item-header"><span class="index-item-number">#2</span><time datetime="2025-12-13T03:19:37.738Z" data-timestamp="2025-12-13T03:19:37.738Z">2025-12-13T03:19:37.738Z</time></div><div class="index-item-content"><p>[Request interrupted by user]</p></div></a></div>
<div class="index-item"><a href="page-001.html#msg-2025-12-13T03-19-55-353Z"><div class="index-item-header"><span class="index-item-number">#3</span><time datetime="2025-12-13T03:19:55.353Z" data-timestamp="2025-12-13T03:19:55.353Z">2025-12-13T03:19:55.353Z</time></div><div class="index-item-content"><p>this is a new project so no need to explore the current directory. lets just discuss</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>This is a great question that gets at a fundamental tension in microbiome research: <strong>breadth vs. precision</strong>.</p>
<h2>The Case for Targeted Assays (qPCR/ddPCR/Hybrid Capture)</h2>
<p>For your specific use case, targeted approaches have compelling advantages:</p>
<ol>
<li>
<p><strong>You know what matters</strong> - Cervicotypes are defined by a relatively small set of organisms (Lactobacillus species, Gardnerella, Prevotella, Atopobium, Mycoplasma, etc.). You're not doing discovery work.</p>
</li>
<li>
<p><strong>Absolute quantification</strong> - qPCR/ddPCR gives you copies/swab or copies/mL, which is far more biologically meaningful than relative abundance. A "low Lactobacillus" sample could be low in absolute terms or just dominated by something else.</p>
</li>
<li>
<p><strong>Cost efficiency</strong> - You avoid paying to sequence host DNA (often 90%+ of reads in FGT samples).</p>
</li>
<li>
<p><strong>Sensitivity</strong> - Targeted assays can detect low-abundance organisms that get lost in sequencing noise.</p>
</li>
<li>
<p><strong>Clinical translatability</strong> - If you want this to become a diagnostic, qPCR panels are the path forward.</p>
</li>
</ol>
<h2>The Case for Keeping Surveys</h2>
<ol>
<li>
<p><strong>Unknown unknowns</strong> - What if there's a species or strain variant you haven't considered that's driving inflammation?</p>
</li>
<li>
<p><strong>Community context</strong> - Interactions between species matter; a panel misses this.</p>
</li>
<li>
<p><strong>Strain-level resolution</strong> - Metagenomics can distinguish L. crispatus clades with different functional properties.</p>
</li>
</ol>
<h2>A Hybrid Strategy Worth Considering</h2>
<p>Many groups are moving toward:</p>
<ul>
<li><strong>Targeted qPCR panel</strong> for core questions (Lactobacillus species-specific, key BV-associated bacteria, total bacterial load)</li>
<li><strong>Shallow metagenomics</strong> on a subset for validation and discovery</li>
<li><strong>Deep sequencing</strong> only on outliers or hypothesis-generating samples</li>
</ul>
<p>Would you like to discuss specific panel designs or the tradeoffs between qPCR vs. hybrid capture for your organisms of interest?</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-001.html#msg-2025-12-13T03-21-38-002Z"><div class="index-item-header"><span class="index-item-number">#4</span><time datetime="2025-12-13T03:21:38.002Z" data-timestamp="2025-12-13T03:21:38.002Z">2025-12-13T03:21:38.002Z</time></div><div class="index-item-content"><p>yes, lets think this through. I am also interested in other genes for amplicon surveys such as cpn60: https://cdnsciencepub.com/doi/10.1139/cjm-2021-0296</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Great paper to bring up. The cpn60 (chaperonin-60, also called groEL or hsp60) approach addresses one of the fundamental limitations of 16S for vaginal microbiome work.</p>
<h2>Why cpn60 Makes Sense for FGT</h2>
<p><strong>The core problem with 16S in vaginal samples:</strong>
- Lactobacillus species are notoriously difficult to resolve with 16S (L. crispatus, L. iners, L. jensenii, L. gasseri have very similar 16S sequences)
- Gardnerella is now recognized as multiple species - 16S can't reliably distinguish them
- The V3-V4 region many labs use is particularly poor for Lactobacillus discrimination</p>
<p><strong>cpn60 advantages:</strong>
- Higher sequence divergence between closely related species
- Single copy gene (vs. variable 16S copy number - which distorts relative abundance)
- The cpn60 barcode database (cpnDB) has good coverage of vaginal taxa
- Better resolution of Gardnerella species complex</p>
<h2>But Let's Think About Your Actual Questions</h2>
<p>You mentioned you're often trying to answer:</p>
<ol>
<li><strong>Lactobacillus high vs. low</strong> - This is really a question of absolute bacterial load + community composition</li>
<li><strong>Species-specific absolute abundances</strong> - Relative abundance from any amplicon survey can't give you this</li>
<li><strong>Inflammatory species detection</strong> - Presence/absence or threshold-based</li>
</ol>
<p>Here's my concern: <strong>Neither 16S nor cpn60 amplicon sequencing solves your absolute quantification problem.</strong></p>
<h2>A Practical Framework</h2>
<table>
<thead>
<tr>
<th>Question</th>
<th>Best Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total bacterial load</td>
<td>qPCR (16S universal or cpn60 universal)</td>
</tr>
<tr>
<td>Lactobacillus vs. non-Lactobacillus dominance</td>
<td>Amplicon OR targeted qPCR</td>
</tr>
<tr>
<td>Which Lactobacillus species?</td>
<td>cpn60 amplicon OR species-specific qPCR</td>
</tr>
<tr>
<td>Absolute copies of L. crispatus</td>
<td>Species-specific qPCR/ddPCR only</td>
</tr>
<tr>
<td>Gardnerella species resolution</td>
<td>cpn60 amplicon (16S fails here)</td>
</tr>
<tr>
<td>Functional potential</td>
<td>Metagenomics only</td>
</tr>
</tbody>
</table>
<h2>Questions to Clarify Your Path</h2>
<ol>
<li>
<p><strong>How many samples are we talking about?</strong> (Hundreds? Thousands?) - This affects cost calculations dramatically.</p>
</li>
<li>
<p><strong>What's your key outcome?</strong> If you're correlating with HIV acquisition, inflammation markers, or BV recurrence, the precision needed differs.</p>
</li>
<li>
<p><strong>Do you need Gardnerella species-level resolution?</strong> The recent splitting of Gardnerella into multiple species (G. vaginalis, G. leopoldii, G. swidsinskii, etc.) may or may not matter for your biology.</p>
</li>
<li>
<p><strong>Are you interested in strain-level variation within species?</strong> For example, L. crispatus strains vary in their H2O2 production and D-lactic acid production.</p>
</li>
</ol>
<p>Would a combined approach work for you - something like:
- <strong>cpn60 amplicon</strong> for community profiling with better species resolution
- <strong>Multiplex qPCR panel</strong> for absolute quantification of 8-10 key targets
- <strong>Selective deep metagenomics</strong> on interesting samples?</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-001.html#msg-2025-12-13T03-25-34-630Z"><div class="index-item-header"><span class="index-item-number">#5</span><time datetime="2025-12-13T03:25:34.630Z" data-timestamp="2025-12-13T03:25:34.630Z">2025-12-13T03:25:34.630Z</time></div><div class="index-item-content"><p>Thousands of samples. Our primary endpoint for our current work is HIV acquisition. I am a CO-PI of the FRESH cohort with Doug Kwon (I am Scott Handley at washington university). But we would like to extend to other areas, particularly given the advancements in HIV therapeutics. Gardnderall species resoltuon would be great as they are likely key players in the pro-inflammatory response (which would recruit T-cells which is not good given sexually transmitted HIV). Yes to strain variation. I am really interested in the combined approach. It would also be great to have an assay we could run on the ground in South Africa which does not always have access to sequence resources or compute. But we have extensive resources (Wash U and the Ragon)</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Scott, great to have this context - the FRESH cohort is exactly the kind of setting where getting this right matters. High-risk young women, longitudinal sampling, and a clear biological endpoint.</p>
<h2>The Strategic Picture</h2>
<p>You have a unique opportunity here:</p>
<ol>
<li><strong>Thousands of samples</strong> - economies of scale for panel development</li>
<li><strong>Two major resource centers</strong> (Wash U, Ragon) - can handle complex assays</li>
<li><strong>Field site needs</strong> - requires something deployable in Durban</li>
<li><strong>Clear mechanism</strong> - inflammation → T-cell recruitment → HIV target cells</li>
</ol>
<p>This argues for a <strong>tiered approach</strong> with different assays serving different purposes.</p>
<h2>Proposed Tiered Framework</h2>
<h3>Tier 1: Field-Deployable Screening (South Africa)</h3>
<p><strong>Goal:</strong> Rapid stratification of samples, real-time data for clinical correlation</p>
<p><strong>Approach:</strong> Multiplex qPCR panel (8-12 targets)</p>
<p>Candidates:
- Total bacterial load (universal 16S or cpn60)
- <em>L. crispatus</em>
- <em>L. iners</em> (the "controversial" Lactobacillus - associated with instability)
- <em>L. gasseri / L. jensenii</em> (combined or separate)
- <em>Gardnerella</em> (genus level for screening)
- <em>Prevotella</em> (genus)
- <em>Atopobium vaginae</em>
- <em>Megasphaera</em>
- <em>Sneathia</em>
- <em>Mycoplasma genitalium</em>
- <em>Mycoplasma hominis</em></p>
<p><strong>Platform options:</strong>
- QuantStudio or similar (likely already available)
- Could consider FilmArray-style cartridge if you want true point-of-care
- Bio-Rad ddPCR for absolute quantification (more infrastructure)</p>
<p><strong>Advantages:</strong>
- Results in hours, not weeks
- Absolute quantification
- Low cost per sample once validated (~$10-20/sample)
- Can run in Durban with minimal compute</p>
<h3>Tier 2: Detailed Profiling (Wash U/Ragon)</h3>
<p><strong>Goal:</strong> Full community characterization, species-level resolution, discovery</p>
<p><strong>Approach:</strong> cpn60 amplicon sequencing</p>
<p><strong>Why cpn60 over 16S:</strong>
- Resolves Gardnerella species (G. vaginalis, G. leopoldii, G. swidsinskii, G. piotii)
- Better Lactobacillus species discrimination
- Single copy gene = more accurate relative abundance
- The Links lab (originators of the paper you cited) has good protocols</p>
<p><strong>Practical considerations:</strong>
- Can batch ship samples (DNA or swabs in appropriate buffer)
- Run on MiSeq/NextSeq
- ~$30-50/sample at scale
- 2-4 week turnaround</p>
<h3>Tier 3: Deep Characterization (Selected Samples)</h3>
<p><strong>Goal:</strong> Strain resolution, functional insights, mechanism discovery</p>
<p><strong>Approach:</strong> Deep metagenomics OR hybrid capture</p>
<p><strong>Sample selection criteria:</strong>
- Seroconverters (precious samples!)
- Matched non-converters
- Unusual Tier 1/2 profiles
- Samples with discordant qPCR vs. amplicon results</p>
<p><strong>For strain-level resolution, consider:</strong>
- PacBio HiFi for complete genomes/MAGs
- Or deep Illumina with strain-resolution tools (StrainPhlAn, inStrain)</p>
<p><strong>Hybrid capture option:</strong>
- Custom probe set for vaginal bacteria
- Could enrich bacterial DNA from host-heavy samples
- Twist Bioscience or Agilent SureSelect
- Reduces sequencing cost by avoiding host reads</p>
<h2>The L. iners Question</h2>
<p>This deserves special attention. L. iners is:
- Often dominant in South African women
- Associated with community instability
- Produces only L-lactic acid (not D-lactic acid like L. crispatus)
- Has a smaller genome, more auxotrophies
- Contains inerolysin (cholesterol-dependent cytolysin)</p>
<p><strong>Strain variation in L. iners may matter for your HIV outcome.</strong> Some strains have different inerolysin variants, different metabolic capabilities. This is where Tier 3 metagenomics earns its keep.</p>
<h2>Practical Development Path</h2>
<pre><code>Phase 1 (6 months)
├── Design and validate qPCR panel
├── Test on 100-200 archived samples with known 16S data
├── Establish correlation with existing cervicotype calls
└── Set up protocol in Durban

Phase 2 (6-12 months)
├── Implement cpn60 sequencing pipeline
├── Run on same validation samples
├── Build reference database for your population
└── Compare species calls to qPCR

Phase 3 (12-18 months)
├── Deploy Tier 1 in field
├── Batch Tier 2 at Wash U
├── Select samples for Tier 3
└── Correlate with HIV outcomes
</code></pre>
<h2>Key Questions for You</h2>
<ol>
<li>
<p><strong>What's your current sample archive like?</strong> Do you have DNA, swabs in buffer, or would this be prospective?</p>
</li>
<li>
<p><strong>For the qPCR panel, do you want genus or species level for Gardnerella?</strong> Species-specific primers exist but add complexity.</p>
</li>
<li>
<p><strong>Is there appetite for a custom hybrid capture panel?</strong> This could be a shared resource across FGT microbiome studies - I could see this being valuable beyond FRESH.</p>
</li>
<li>
<p><strong>What's your tolerance for novel method development vs. using established protocols?</strong> The cpn60 approach is less mature than 16S in terms of widely-used pipelines.</p>
</li>
<li>
<p><strong>Are there other targets beyond bacteria?</strong> Fungi (Candida), viruses (HSV-2, HPV), or host markers (cytokines, defensins) that should be integrated?</p>
</li>
</ol>
<p>This is a fundable methods development aim, by the way. An R21 or U01 supplement for developing a validated multi-tier FGT microbiome assessment platform would be competitive, especially with the FRESH cohort as the validation population.</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-002.html#msg-2025-12-13T03-29-19-364Z"><div class="index-item-header"><span class="index-item-number">#6</span><time datetime="2025-12-13T03:29:19.364Z" data-timestamp="2025-12-13T03:29:19.364Z">2025-12-13T03:29:19.364Z</time></div><div class="index-item-content"><p>Swabs in buffer. Species for Gardnerella. We can do some comparative genomics to define new primers. This is also true for other important genera. Yes to custom capture hybrid and we are good at novel method development. I am a bit concerned about the state and content of the cpn60 database, can you search the web and review. We do look at fungus and viruses as well, but that might be out of scope for this project</p></div></a><div class="index-item-stats"><span>4 search · 3 fetch</span>
</div></div>
<div class="index-item"><a href="page-002.html#msg-2025-12-13T03-58-07-705Z"><div class="index-item-header"><span class="index-item-number">#7</span><time datetime="2025-12-13T03:58:07.705Z" data-timestamp="2025-12-13T03:58:07.705Z">2025-12-13T03:58:07.705Z</time></div><div class="index-item-content"><p>[Request interrupted by user for tool use]</p></div></a></div>
<div class="index-item"><a href="page-002.html#msg-2025-12-13T03-58-15-670Z"><div class="index-item-header"><span class="index-item-number">#8</span><time datetime="2025-12-13T03:58:15.670Z" data-timestamp="2025-12-13T03:58:15.670Z">2025-12-13T03:58:15.670Z</time></div><div class="index-item-content"><p>you have been stuck for a while. are you still researching? can you pick up where you left off</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Yes, let me summarize what I've found and give you my assessment.</p>
<h2>cpnDB Status: Concerns and Realities</h2>
<p><strong>The good:</strong>
- ~28,800 sequences covering 1,802 genera (as of early 2024)
- Strong Gardnerella coverage - can resolve the 4 named species (G. vaginalis, G. piotii, G. leopoldii, G. swidsinskii) plus 9 genomospecies
- The <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6022438/">VOGUE Reference Assembly</a> exists specifically for vaginal samples
- <a href="https://www.nature.com/articles/s43705-023-00283-z">Recent work</a> (2023) has improved taxonomic classification using Naïve Bayesian classifiers</p>
<p><strong>The concerns (your instinct is correct):</strong>
1. <strong>Geographic bias</strong> - Most vaginal cpn60 work is from Canadian cohorts (Janet Hill's group). The <a href="https://peerj.com/articles/9684/">sub-Saharan African vaginal microbiome review</a> explicitly calls out major gaps in African populations.</p>
<ol>
<li>
<p><strong>Database maintenance</strong> - The cpndb.ca site certificate has expired, which is not a great sign for active curation.</p>
</li>
<li>
<p><strong>Population-specific taxa</strong> - African women show distinct profiles (more L. iners, different Prevotella species, potentially novel taxa) that may not be well-represented.</p>
</li>
<li>
<p><strong>The 16S vs cpn60 gap</strong> - Most reference genomes have 16S but not all have quality cpn60 sequences.</p>
</li>
</ol>
<h2>My Recommendation: Build Your Own Reference</h2>
<p>Given your resources and the FRESH cohort's value, I'd argue you should:</p>
<p><strong>1. Create a South African FGT cpn60 reference database</strong>
- Isolate and sequence key taxa from your population
- Deposit in cpnDB (improve the resource for everyone)
- This becomes a citable, fundable output</p>
<p><strong>2. Design species-specific primers de novo using comparative genomics</strong></p>
<p>Rather than relying solely on cpn60, consider a <strong>multi-locus approach</strong> for your qPCR panel:</p>
<table>
<thead>
<tr>
<th>Target</th>
<th>Gene choice</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactobacillus species</td>
<td>cpn60 or species-specific genes</td>
<td>Well-established</td>
</tr>
<tr>
<td>Gardnerella species</td>
<td>cpn60 + sialidase genes</td>
<td>Sialidase correlates with virulence</td>
</tr>
<tr>
<td>Prevotella</td>
<td>Species-specific markers</td>
<td>cpn60 coverage variable</td>
</tr>
<tr>
<td>BVAB1/2/3</td>
<td>May need custom targets</td>
<td>Poorly cultivated</td>
</tr>
<tr>
<td>Mycoplasma</td>
<td>16S or species-specific</td>
<td>Small genomes, fewer options</td>
</tr>
</tbody>
</table>
<p><strong>3. Hybrid capture panel - this is where I'd invest</strong></p>
<p>A custom capture panel solves multiple problems:
- Enriches bacterial DNA from host-heavy samples
- Can target multiple genes per organism (redundancy)
- Captures strain-level variation
- Works on degraded/archived samples
- One assay, comprehensive output</p>
<p>You could design probes for:
- Full cpn60 for all target genera
- Key functional genes (sialidases, inerolysin, lactic acid pathway genes)
- Strain-discriminating regions</p>
<h2>Proposed Path Forward</h2>
<pre><code>Phase 1: Reference Building
├── Select 50-100 archived samples spanning cervicotypes
├── Deep shotgun metagenomics (PacBio HiFi ideal)
├── Assemble MAGs, extract cpn60 + other targets
├── Build South African FGT reference database
└── Comparative genomics for primer design

Phase 2: Assay Development  
├── Design/validate qPCR panel (Tier 1)
├── Design hybrid capture probe set
├── Validate on characterized samples
└── Establish in Durban

Phase 3: Deploy on FRESH
├── qPCR on full cohort
├── Capture-seq on selected samples
├── Correlate with HIV outcomes
</code></pre>
<p>Want to dig into the hybrid capture design or the comparative genomics strategy for primer development?</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-002.html#msg-2025-12-13T04-02-17-450Z"><div class="index-item-header"><span class="index-item-number">#9</span><time datetime="2025-12-13T04:02:17.450Z" data-timestamp="2025-12-13T04:02:17.450Z">2025-12-13T04:02:17.450Z</time></div><div class="index-item-content"><p>lets think about this from the research perspective. i believe what you have proposed here is heavily waited towards a diagnostic in Durban. What about research at Wash U and Ragon. For exmapled, what about cpn60 AND ITS PCR and other combined a more complex approaches</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>You're absolutely right - I got too focused on the field-deployable endpoint. Let's think about this from a research discovery standpoint.</p>
<h2>Reframing: What Do You Want to Learn?</h2>
<p>The FRESH cohort is a discovery resource. The questions aren't just "who has high Lactobacillus" - they're:</p>
<ol>
<li><strong>Which specific strains/species drive inflammation and T-cell recruitment?</strong></li>
<li><strong>Are there novel taxa or variants unique to this population?</strong></li>
<li><strong>What's the functional capacity of these communities?</strong></li>
<li><strong>How do bacteria, fungi, and viruses interact in the FGT ecosystem?</strong></li>
<li><strong>What temporal dynamics precede seroconversion?</strong></li>
</ol>
<h2>A Multi-Amplicon Research Platform</h2>
<p>Instead of cpn60 OR 16S, why not a combined amplicon panel?</p>
<table>
<thead>
<tr>
<th>Target</th>
<th>Resolution</th>
<th>What it tells you</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpn60</td>
<td>Species/strain for bacteria</td>
<td>Community composition, Gardnerella species</td>
</tr>
<tr>
<td>ITS1/ITS2</td>
<td>Fungal species</td>
<td>Candida species, other fungi</td>
</tr>
<tr>
<td>16S V4</td>
<td>Broad bacterial</td>
<td>Cross-study comparability, rare taxa</td>
</tr>
<tr>
<td>Functional genes</td>
<td>Specific pathways</td>
<td>Direct readout of capability</td>
</tr>
</tbody>
</table>
<h3>The Case for Functional Gene Amplicons</h3>
<p>This is where it gets interesting for mechanism. You could add amplicons for:</p>
<p><strong>Inflammation-relevant:</strong>
- Sialidase genes (Gardnerella virulence, mucin degradation)
- Vaginolysin/Inerolysin (cytolysins)
- Prolidase (tissue degradation)</p>
<p><strong>Protective factors:</strong>
- D-lactate dehydrogenase (L. crispatus vs L. iners distinction)
- H2O2 production genes
- Bacteriocin genes</p>
<p><strong>Metabolic:</strong>
- Biogenic amine synthesis (tyramine, putrescine - inflammatory)
- Short-chain fatty acid pathways</p>
<p>This gives you <strong>functional readouts without metagenomics cost</strong>.</p>
<h2>Nested Study Design</h2>
<pre><code>All FRESH samples (n = thousands)
│
├─► Tier 1: Multiplexed amplicon panel
│   ├── cpn60 (bacteria, species-level)
│   ├── ITS2 (fungi)
│   ├── 16S V4 (compatibility, rare taxa)
│   └── Functional gene panel (5-10 targets)
│   
│   Output: Comprehensive profiles, functional scores
│   Platform: Illumina, multiplexed (cost ~$50-75/sample)
│
├─► Tier 2: Deep metagenomics (n = 200-500)
│   ├── Seroconverters + matched controls
│   ├── Unusual amplicon profiles
│   ├── Longitudinal series around key events
│   │
│   Output: MAGs, strain resolution, full functional potential
│   Platform: Illumina deep or PacBio HiFi
│
└─► Tier 3: Isolate genomics + functional validation
    ├── Cultivate key taxa from interesting samples
    ├── Whole genome sequencing
    ├── In vitro functional assays
    │
    Output: Mechanistic validation, reference genomes
</code></pre>
<h2>The Multi-Amplicon Technical Approach</h2>
<p>There are a few ways to do this:</p>
<p><strong>Option A: Separate PCRs, pooled sequencing</strong>
- Individual PCR for each target
- Pool amplicons per sample, dual-index
- Demultiplex computationally
- More flexible, easier troubleshooting</p>
<p><strong>Option B: Multiplexed PCR in single reaction</strong>
- Requires careful primer design (no cross-reactivity)
- Fewer handling steps
- Risk of amplification bias</p>
<p><strong>Option C: Targeted capture on amplicons</strong>
- Amplify broadly, capture specifically
- Can include many more targets
- Higher upfront cost, lower per-sample cost</p>
<p><strong>Option D: Loop-seq or similar long-read amplicons</strong>
- Full-length cpn60, full ITS, full 16S
- Better strain resolution
- PacBio or ONT
- Higher cost, lower throughput</p>
<h2>What About Viral Detection?</h2>
<p>You mentioned viruses are out of scope, but worth flagging: HSV-2 and HPV status likely interact with your bacterial findings and HIV outcome. Could be qPCR add-ons without complicating the amplicon panel.</p>
<h2>Questions to Shape the Design</h2>
<ol>
<li>
<p><strong>What's your tolerance for novel bioinformatics development?</strong> Multi-amplicon analysis pipelines exist but are less mature than 16S-only workflows.</p>
</li>
<li>
<p><strong>Do you want cross-study comparability?</strong> Keeping 16S V4 allows meta-analysis with published cohorts (even if cpn60 is your primary).</p>
</li>
<li>
<p><strong>How important is the fungal component?</strong> Candida is common in FGT, interacts with Lactobacillus, but less studied in HIV context.</p>
</li>
<li>
<p><strong>Are there specific functional hypotheses you want to test?</strong> This should drive which functional genes to include.</p>
</li>
<li>
<p><strong>What's your sequencing capacity/budget at Wash U?</strong> This affects whether you go broad (many samples, fewer reads) or deep (fewer samples, more resolution).</p>
</li>
</ol>
<p>The hybrid capture approach I mentioned earlier actually pairs well with this - you could do amplicons for broad profiling and capture-seq for deep dives on the same samples.</p>
<p>Want to sketch out a specific amplicon panel design?</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-002.html#msg-2025-12-13T04-04-36-343Z"><div class="index-item-header"><span class="index-item-number">#10</span><time datetime="2025-12-13T04:04:36.343Z" data-timestamp="2025-12-13T04:04:36.343Z">2025-12-13T04:04:36.343Z</time></div><div class="index-item-content"><p>We are very good at novel bioinformatics development. Yes to cross study comparability. We already do ITS so lets avoid this for the current concept. We have a significant budget</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>This changes everything. Let me think about this more ambitiously.</p>
<h2>The Vision: A Comprehensive FGT Bacterial Profiling Platform</h2>
<p>With strong bioinformatics capacity and significant budget, you can build something that becomes <strong>the</strong> reference approach for FGT microbiome research.</p>
<h3>Core Amplicon Panel</h3>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Purpose</th>
<th>Length</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>Cross-study compatibility</td>
<td>~250bp</td>
<td>Keep for meta-analysis</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>Lactobacillus resolution</td>
<td>~500bp</td>
<td>Better than V4 for Lactobacillus</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>Species-level bacteria</td>
<td>~550bp</td>
<td>Gardnerella species, strain hints</td>
</tr>
<tr>
<td>rpoB</td>
<td>Orthogonal species ID</td>
<td>~350bp</td>
<td>Good for Lactobacillus, less database bias</td>
</tr>
</tbody>
</table>
<h3>Why rpoB?</h3>
<p>This is underutilized but powerful:
- RNA polymerase beta subunit, single copy
- Excellent Lactobacillus species discrimination
- Independent validation of cpn60 calls
- Less database baggage than cpn60
- You'd be building novel reference data</p>
<h3>Functional Gene Amplicons</h3>
<p>These give you mechanistic readouts without metagenomics:</p>
<p><strong>Inflammation/Virulence:</strong>
| Gene | Organism | Function | HIV relevance |
|------|----------|----------|---------------|
| nanH (sialidase) | Gardnerella, Prevotella | Mucin degradation, epithelial damage | Barrier disruption |
| vly (vaginolysin) | Gardnerella | Cytolysin, cell lysis | Inflammation, T-cell recruitment |
| ily (inerolysin) | L. iners | Cholesterol-dependent cytolysin | Epithelial damage |</p>
<p><strong>Protective/Metabolic:</strong>
| Gene | Organism | Function | HIV relevance |
|------|----------|----------|---------------|
| ldhD (D-lactate dehydrogenase) | L. crispatus | D-lactic acid production | Acidification, protection |
| ldhL (L-lactate dehydrogenase) | All Lactobacillus | L-lactic acid (less protective) | Distinguishes species |</p>
<p><strong>Biogenic Amines:</strong>
| Gene | Organism | Function | HIV relevance |
|------|----------|----------|---------------|
| tyrDC (tyrosine decarboxylase) | Various BV-associated | Tyramine production | Inflammation |
| hdc (histidine decarboxylase) | Various | Histamine production | Inflammation |
| aguA (agmatine deiminase) | Various | Polyamine metabolism | Inflammation |</p>
<h2>The Technical Build</h2>
<pre><code>Sample (swab in buffer)
    │
    ▼
DNA Extraction (optimize for Gram+ lysis)
    │
    ▼
Multiplexed PCR (2-3 pools to avoid primer conflicts)
    │
    ├── Pool 1: 16S V4 + 16S V1-V3
    ├── Pool 2: cpn60 + rpoB  
    └── Pool 3: Functional genes (6-8 targets)
    │
    ▼
Amplicon pooling + dual indexing
    │
    ▼
Illumina sequencing (NovaSeq for scale)
    │
    ▼
Bioinformatics pipeline
    ├── DADA2/Deblur for ASVs
    ├── Multi-marker taxonomic integration
    ├── Functional gene quantification
    └── South African reference database
</code></pre>
<h2>Novel Bioinformatics Opportunity</h2>
<p>Here's where your strength matters. Nobody has built a robust <strong>multi-marker integration pipeline</strong> for vaginal microbiome. You could develop:</p>
<ol>
<li>
<p><strong>Concordance scoring</strong> - Do cpn60, rpoB, and 16S agree on taxonomy? Discordance flags novel taxa or database gaps.</p>
</li>
<li>
<p><strong>Strain-level inference</strong> - Combine ASV patterns across markers to infer strain composition without full metagenomics.</p>
</li>
<li>
<p><strong>Functional scoring</strong> - Quantitative "inflammation potential" or "protection score" based on functional gene ratios:
   <code>Protection score = (ldhD abundance × L. crispatus) / (sialidase + vaginolysin)</code></p>
</li>
<li>
<p><strong>Population-specific reference building</strong> - Your South African data fills a major gap in existing databases.</p>
</li>
</ol>
<h2>Hybrid Capture Layer</h2>
<p>On top of amplicons, a capture panel for deep samples:</p>
<p><strong>Design targets:</strong>
- Full genomes of 20-30 key FGT species
- Strain-variable regions (for resolution)
- Accessory gene content (functional variation)
- Antimicrobial resistance genes</p>
<p><strong>When to deploy:</strong>
- All seroconverters
- Matched controls
- Discordant cases (amplicon says one thing, qPCR says another)
- Longitudinal series at key timepoints</p>
<p><strong>Output:</strong>
- Near-complete genomes from complex communities
- Strain tracking over time
- Functional gene content per strain</p>
<h2>The Complete Platform</h2>
<pre><code>┌─────────────────────────────────────────────────────────────────┐
│                    FRESH FGT Microbiome Platform                │
├─────────────────────────────────────────────────────────────────┤
│                                                                 │
│  TIER 1: Multi-Amplicon Panel (all samples, n=thousands)        │
│  ├── Taxonomic: 16S V4, 16S V1-V3, cpn60, rpoB                 │
│  ├── Functional: sialidase, vaginolysin, inerolysin, ldhD/L    │
│  ├── Output: Integrated species + functional profiles          │
│  └── Cost: ~$75-100/sample                                      │
│                                                                 │
│  TIER 2: Hybrid Capture Metagenomics (n=300-500)               │
│  ├── Custom probe panel for FGT bacteria                       │
│  ├── Strain-level resolution                                   │
│  ├── Full functional gene content                              │
│  └── Cost: ~$300-500/sample                                     │
│                                                                 │
│  TIER 3: Reference Building                                     │
│  ├── Deep metagenomics (PacBio HiFi) on 50-100 samples         │
│  ├── Cultivation + isolate sequencing                          │
│  ├── South African FGT reference database                      │
│  └── Deposit in public databases                                │
│                                                                 │
│  FIELD (Durban): qPCR panel derived from above                  │
│  └── Rapid stratification for clinical correlation             │
│                                                                 │
└─────────────────────────────────────────────────────────────────┘
</code></pre>
<h2>Immediate Next Steps</h2>
<ol>
<li>
<p><strong>Primer design sprint</strong> - Comparative genomics to design/validate rpoB and functional gene primers for your target taxa</p>
</li>
<li>
<p><strong>Pilot study</strong> - Run full panel on 50-100 characterized samples with existing 16S data</p>
</li>
<li>
<p><strong>Reference database construction</strong> - Deep sequencing on diverse subset to build South African reference</p>
</li>
<li>
<p><strong>Pipeline development</strong> - Multi-marker integration, concordance metrics, functional scoring</p>
</li>
</ol>
<h2>Questions</h2>
<ol>
<li>
<p><strong>Which functional genes resonate most with your mechanistic hypotheses?</strong> I listed candidates but you know the biology better.</p>
</li>
<li>
<p><strong>Do you have existing isolate collections from FRESH or related cohorts?</strong> These would accelerate reference building.</p>
</li>
<li>
<p><strong>What's your timeline?</strong> This could be an R01-scale methods aim or faster if you want to bootstrap with existing funds.</p>
</li>
<li>
<p><strong>Interest in making this an open resource?</strong> A "FRESH FGT Database" with protocols, primers, reference sequences, and pipelines could have major impact.</p>
</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-003.html#msg-2025-12-14T18-59-23-149Z"><div class="index-item-header"><span class="index-item-number">#11</span><time datetime="2025-12-14T18:59:23.149Z" data-timestamp="2025-12-14T18:59:23.149Z">2025-12-14T18:59:23.149Z</time></div><div class="index-item-content"><p>can you explain how the Hybrid Capture Metagenomics works in more detail and how it would work with high host (human) contamination</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><h2>Hybrid Capture Metagenomics: How It Works</h2>
<h3>The Core Problem</h3>
<p>FGT samples are brutal for metagenomics:
- <strong>90-99% human DNA</strong> in many samples
- Shotgun sequencing wastes most reads on host
- To get 10M bacterial reads, you might need 100M+ total reads
- Cost scales linearly with this inefficiency</p>
<h3>The Solution: Capture Enrichment</h3>
<p>Hybrid capture uses synthetic oligonucleotide probes (typically 80-120bp) that are complementary to your targets of interest. These probes are biotinylated, allowing you to physically pull down the sequences you want.</p>
<pre><code>                    WORKFLOW OVERVIEW

     Total DNA from FGT sample
     (95% human, 5% bacterial)
                │
                ▼
     Fragment to ~300-500bp
     Add sequencing adapters
                │
                ▼
     Denature (make single-stranded)
                │
                ▼
     Hybridize with biotinylated probes
     (probes complementary to bacterial targets)
                │
      ┌─────────┴─────────┐
      │                   │
   Bacterial           Human DNA
   fragments           (no probes
   with probes         bound)
   hybridized             │
      │                   │
      ▼                   ▼
   Streptavidin        WASHED
   magnetic beads      AWAY
   pull down              
   biotinylated           
   complexes              
      │
      ▼
   Wash stringently
   (remove non-specific binding)
      │
      ▼
   Elute captured fragments
      │
      ▼
   PCR amplify (optional, low cycles)
      │
      ▼
   Sequence
   (now 70-95% bacterial)
</code></pre>
<h3>Enrichment Efficiency</h3>
<table>
<thead>
<tr>
<th>Sample type</th>
<th>Pre-capture bacterial</th>
<th>Post-capture bacterial</th>
<th>Fold enrichment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low host</td>
<td>30%</td>
<td>90%</td>
<td>3x</td>
</tr>
<tr>
<td>Medium host</td>
<td>10%</td>
<td>85%</td>
<td>8.5x</td>
</tr>
<tr>
<td>High host</td>
<td>1%</td>
<td>70-80%</td>
<td>70-80x</td>
</tr>
<tr>
<td>Very high host</td>
<td>0.1%</td>
<td>50-60%</td>
<td>500-600x</td>
</tr>
</tbody>
</table>
<p>The worse your starting material, the more capture helps.</p>
<h3>Probe Design Strategy for FGT</h3>
<p><strong>Option 1: Whole genome probes</strong></p>
<p>Design probes tiling across complete genomes of target organisms:</p>
<pre><code>Target species list (example):
├── Lactobacillus crispatus (complete genome, ~2.0 Mb)
├── Lactobacillus iners (~1.3 Mb)
├── Lactobacillus jensenii (~1.5 Mb)
├── Lactobacillus gasseri (~1.9 Mb)
├── Gardnerella vaginalis (~1.6 Mb)
├── Gardnerella leopoldii (~1.5 Mb)
├── Gardnerella swidsinskii (~1.5 Mb)
├── Gardnerella piotii (~1.5 Mb)
├── Prevotella bivia (~2.5 Mb)
├── Prevotella amnii (~2.3 Mb)
├── Atopobium vaginae (~1.4 Mb)
├── Sneathia amnii (~1.3 Mb)
├── Sneathia sanguinegens (~1.4 Mb)
├── Megasphaera type 1 (~2.0 Mb)
├── Megasphaera type 2 (~1.9 Mb)
├── Mycoplasma hominis (~0.7 Mb)
├── Mycoplasma genitalium (~0.6 Mb)
├── BVAB1 (Candidatus Lachnocurva vaginae)
├── BVAB2
├── BVAB3
└── ... (20-40 species total)

Total target space: ~40-60 Mb
Probe count: ~300,000-500,000 probes (80bp, 2x tiling)
</code></pre>
<p><strong>Option 2: Conserved gene probes (more economical)</strong></p>
<p>Target universal + discriminatory genes only:</p>
<pre><code>Per organism:
├── cpn60 (full gene, ~1.6 kb)
├── rpoB (full gene, ~4 kb)
├── 16S rRNA (full gene, ~1.5 kb)
├── 23S rRNA (partial, ~1 kb)
├── recA (~1 kb)
├── gyrB (~2 kb)
└── Species-specific markers (~2-5 kb)

Plus functional genes of interest:
├── Sialidases (nanH family)
├── Cytolysins (vly, ily)
├── Lactate dehydrogenases
├── Biogenic amine genes
└── AMR genes

Total target space: ~2-5 Mb
Probe count: ~20,000-50,000 probes
</code></pre>
<p><strong>Option 3: Hybrid approach (recommended)</strong></p>
<pre><code>Full genome coverage:
├── Top 10 most abundant/important species (full genomes)
└── ~20 Mb target space

Conserved gene coverage:
├── Next 30-50 species (marker genes only)
└── ~5 Mb target space

Functional gene panel:
├── All known variants of key genes
└── ~1-2 Mb target space

Total: ~25-30 Mb, ~200,000-250,000 probes
</code></pre>
<h3>How Strain Resolution Works with Capture</h3>
<p>This is where it gets powerful. Unlike amplicons that give you one short region, capture gives you <strong>multiple genomic regions per organism</strong>:</p>
<pre><code>Example: Two L. crispatus strains in same sample

                    Strain A genome                 Strain B genome
                    ────────────────                ────────────────
Region 1 (cpn60):   ATGCGATCGATCG...               ATGCGATCGATCG...  (identical)
Region 2 (CRISPR):  CRISPR-A-specific              CRISPR-B-specific (different)
Region 3 (prophage):Present                        Absent
Region 4 (surface): Variant A                      Variant B
Region 5 (metabolic):Gene X present               Gene X absent

Capture recovers ALL of these regions
→ Computational deconvolution identifies both strains
→ Can track which strain dominates over time
→ Can associate specific strains with outcomes
</code></pre>
<p>Tools like <strong>StrainGE</strong>, <strong>StrainPhlAn</strong>, <strong>inStrain</strong>, or <strong>MIDAS2</strong> can resolve strains from this data.</p>
<h3>Practical Protocol</h3>
<p><strong>Day 1: Library Prep</strong></p>
<pre><code>1. Extract DNA (your existing protocol)
2. Quantify (Qubit)
3. Fragment to 350-500bp (Covaris or enzymatic)
4. End repair + A-tailing
5. Adapter ligation (unique dual indexes)
6. Size selection (beads or gel)
7. Pre-capture PCR (6-8 cycles)
8. QC: Bioanalyzer + qPCR
</code></pre>
<p><strong>Day 2: Capture</strong></p>
<pre><code>1. Pool 8-16 libraries (equal mass, ~500ng total)
2. Add blocking oligos (block adapters + human Cot-1)
3. Denature (95°C, 5 min)
4. Add probe pool
5. Hybridize (65-68°C, 16-24 hours)
</code></pre>
<p><strong>Day 3: Wash + Sequence</strong></p>
<pre><code>1. Bind to streptavidin beads
2. Stringent washes (increasing temperature)
3. Elute captured DNA
4. Post-capture PCR (8-12 cycles)
5. QC: Bioanalyzer + qPCR
6. Pool for sequencing
7. Sequence: NovaSeq S4, 2x150bp
</code></pre>
<h3>Expected Performance for FGT Samples</h3>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Shotgun (no capture)</th>
<th>With capture</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reads per sample</td>
<td>50-100M needed</td>
<td>10-20M sufficient</td>
</tr>
<tr>
<td>Bacterial reads</td>
<td>1-10M</td>
<td>8-18M</td>
</tr>
<tr>
<td>Species detected</td>
<td>15-30</td>
<td>20-40 (better sensitivity)</td>
</tr>
<tr>
<td>Strain resolution</td>
<td>Marginal</td>
<td>Good</td>
</tr>
<tr>
<td>Cost per sample</td>
<td>$400-800</td>
<td>$200-400</td>
</tr>
<tr>
<td>Novel taxa detection</td>
<td>Yes</td>
<td>Limited to related sequences</td>
</tr>
</tbody>
</table>
<h3>The Trade-off: Discovery vs. Enrichment</h3>
<p><strong>Capture limitations:</strong>
- Only enriches sequences similar to probes
- Truly novel organisms (no close relative in design) will be missed
- ~15-20% sequence divergence is typical capture limit</p>
<p><strong>Mitigation strategies:</strong>
1. Include diverse representatives of each genus
2. Use degenerate probe designs for variable regions
3. Run a subset of samples with shotgun (no capture) for discovery
4. Iteratively update probe design as you find new taxa</p>
<h3>Recommended Workflow for FRESH</h3>
<pre><code>┌────────────────────────────────────────────────────────────────────┐
│                                                                    │
│   Phase 1: Discovery + Probe Design                                │
│   ├── Deep shotgun metagenomics on 50 diverse samples             │
│   │   (accept the host contamination cost for discovery)          │
│   ├── Assemble MAGs, identify population-specific taxa            │
│   ├── Design probe set based on YOUR population                   │
│   └── Include reference genomes + your novel MAGs                 │
│                                                                    │
│   Phase 2: Validation                                              │
│   ├── Capture on same 50 samples                                  │
│   ├── Compare: What did shotgun find that capture missed?         │
│   ├── Iterate probe design if needed                              │
│   └── Establish sensitivity/specificity                           │
│                                                                    │
│   Phase 3: Scale                                                   │
│   ├── Capture on 300-500 samples                                  │
│   ├── Strain-level analysis                                       │
│   ├── Correlate with HIV outcomes                                 │
│   └── Identify candidate strains/genes for mechanism              │
│                                                                    │
│   Phase 4: Validation of findings                                  │
│   ├── qPCR for specific strain markers                            │
│   ├── Test on full cohort                                         │
│   └── Functional studies on isolates                              │
│                                                                    │
└────────────────────────────────────────────────────────────────────┘
</code></pre>
<h3>Vendors and Costs</h3>
<table>
<thead>
<tr>
<th>Vendor</th>
<th>Product</th>
<th>Probes</th>
<th>Cost (probes)</th>
<th>Cost/rxn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Twist Bioscience</td>
<td>Custom panels</td>
<td>Up to 1M</td>
<td>$15-25K</td>
<td>~$50-80</td>
</tr>
<tr>
<td>Agilent</td>
<td>SureSelect XT</td>
<td>Up to 6M</td>
<td>$20-40K</td>
<td>~$80-120</td>
</tr>
<tr>
<td>IDT</td>
<td>xGen Lockdown</td>
<td>Up to 500K</td>
<td>$10-20K</td>
<td>~$40-70</td>
</tr>
<tr>
<td>Roche</td>
<td>SeqCap EZ</td>
<td>Custom</td>
<td>$25-50K</td>
<td>~$100-150</td>
</tr>
<tr>
<td>Arbor Biosciences</td>
<td>myBaits</td>
<td>Custom</td>
<td>$8-15K</td>
<td>~$30-60</td>
</tr>
</tbody>
</table>
<p>At your scale (hundreds of samples), per-reaction cost dominates. Twist or Arbor are probably most cost-effective.</p>
<h3>Questions</h3>
<ol>
<li>
<p><strong>Do you have deep shotgun data on any FRESH samples already?</strong> This would jumpstart probe design.</p>
</li>
<li>
<p><strong>What's your target depth for strain resolution?</strong> 10x coverage of a genome gives species; 30-50x gives confident strain calls.</p>
</li>
<li>
<p><strong>Interest in capturing AMR genes systematically?</strong> Easy to add, potentially high-impact finding if BV-associated bacteria carry resistance.</p>
</li>
<li>
<p><strong>Would you want to include phage/mobile elements in the capture?</strong> These drive strain evolution and could explain longitudinal dynamics.</p>
</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-003.html#msg-2025-12-14T22-31-24-844Z"><div class="index-item-header"><span class="index-item-number">#12</span><time datetime="2025-12-14T22:31:24.844Z" data-timestamp="2025-12-14T22:31:24.844Z">2025-12-14T22:31:24.844Z</time></div><div class="index-item-content"><p>i think i want to skip the hybrid capture for now and just focus on our PCR and amplicon survey approaches</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Smart call. Hybrid capture adds complexity and you can always layer it in later once the amplicon foundation is solid. Let's focus.</p>
<h2>Refined Platform: Multi-Amplicon FGT Profiling</h2>
<h3>Core Amplicon Panel</h3>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Target</th>
<th>Length</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>Bacteria (broad)</td>
<td>~250bp</td>
<td>Cross-study compatibility, rare taxa</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>Bacteria (Lactobacillus-optimized)</td>
<td>~500bp</td>
<td>Better Lactobacillus species resolution</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>Bacteria (species-level)</td>
<td>~550bp</td>
<td>Gardnerella species, strain hints</td>
</tr>
<tr>
<td>rpoB</td>
<td>Bacteria (orthogonal)</td>
<td>~350bp</td>
<td>Independent species validation, Lactobacillus</td>
</tr>
</tbody>
</table>
<h3>Functional Gene Amplicons</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target organisms</th>
<th>Biological readout</th>
</tr>
</thead>
<tbody>
<tr>
<td>nanH (sialidase)</td>
<td>Gardnerella, Prevotella</td>
<td>Mucin degradation, virulence</td>
</tr>
<tr>
<td>vly (vaginolysin)</td>
<td>Gardnerella</td>
<td>Cytolysis, inflammation</td>
</tr>
<tr>
<td>ily (inerolysin)</td>
<td>L. iners</td>
<td>Epithelial damage potential</td>
</tr>
<tr>
<td>ldhD</td>
<td>L. crispatus, others</td>
<td>D-lactate production (protective)</td>
</tr>
</tbody>
</table>
<h3>Key Development Questions</h3>
<ol>
<li>
<p><strong>Primer design</strong> - Use existing published primers or design de novo from comparative genomics?</p>
</li>
<li>
<p><strong>Multiplexing strategy</strong> - How many pools? Single reaction vs. separate PCRs?</p>
</li>
<li>
<p><strong>Sequencing platform</strong> - Illumina short-read vs. PacBio/ONT for full-length amplicons?</p>
</li>
<li>
<p><strong>Reference database</strong> - Build South African-specific or augment existing?</p>
</li>
</ol>
<p>Where do you want to dig in first? I'd suggest starting with comparative genomics for primer design - that's foundational and plays to your strengths.</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-003.html#msg-2025-12-14T22-33-15-940Z"><div class="index-item-header"><span class="index-item-number">#13</span><time datetime="2025-12-14T22:33:15.940Z" data-timestamp="2025-12-14T22:33:15.940Z">2025-12-14T22:33:15.940Z</time></div><div class="index-item-content"><p>lets discuss primer design first. can you search the web and also consider novel designs or optimizations. perhaps there are new tech developments or approaches we could build in that would improve our technique, increase sequence quality or minimize contamination issues. I am fine sticking with published primer sets but would also be interested in enhancements</p></div></a><div class="index-item-stats"><span>14 search · 4 fetch</span>
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Good, I've gathered comprehensive information. Let me synthesize this into a coherent response.</p>
<h2>Primer Design: State of the Art and Novel Enhancements</h2>
<p>Based on my search, here are the key developments and strategies to consider:</p>
<hr />
<h3>1. Published Primer Sets vs. De Novo Design</h3>
<p><strong>For your core amplicons:</strong></p>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Published primers</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>515F/806R (Earth Microbiome Project)</td>
<td>Use established - cross-study compatibility</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>27F/534R variants</td>
<td>Consider optimization for Lactobacillus</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>H279p/H280p (Hill lab)</td>
<td>Use established, validated for vaginal</td>
</tr>
<tr>
<td>rpoB</td>
<td>Multiple options, <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">new 2024 DPO-based assay</a></td>
<td>Promising - ~550bp, improved species resolution</td>
</tr>
</tbody>
</table>
<p><strong>For functional genes:</strong> You'll likely need de novo design since these are less standardized.</p>
<hr />
<h3>2. Key Technical Enhancements to Consider</h3>
<h4>A. Dual Priming Oligonucleotide (DPO) Technology</h4>
<p>This is compelling for your application:</p>
<pre><code>Standard primer:     5'------------------3'
                     (entire sequence primes)

DPO primer:          5'-----[poly-I linker]-----3'
                     18-25nt              6-12nt
                     (stable annealing)   (specificity gate)
</code></pre>
<p><strong>Advantages:</strong>
- Dramatically reduces non-specific amplification
- Works across wide annealing temperature range (40-65°C)
- Better multiplexing (less primer competition)
- The <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">2024 rpoB paper</a> uses this for direct clinical samples</p>
<p><strong>Application for you:</strong> Design DPO versions of your functional gene primers to reduce off-target amplification.</p>
<hr />
<h4>B. Unique Molecular Identifiers (UMIs)</h4>
<p><a href="https://www.nature.com/articles/s41592-020-01041-y">High-accuracy long-read amplicons with UMIs</a> can achieve <strong>&gt;99.99% accuracy</strong>:</p>
<pre><code>Standard amplicon:
[Primer]---[Target sequence]---[Primer]

UMI amplicon:
[Primer]-[UMI]-[Target sequence]-[UMI]-[Primer]
          ↓
    Random 8-12nt barcode tags each original molecule
          ↓
    Post-sequencing: group reads by UMI → consensus → error correction
</code></pre>
<p><strong>What this gives you:</strong>
- True absolute quantification (count molecules, not reads)
- PCR bias correction
- Chimera elimination (&lt;0.02% rate)
- Strain-level accuracy</p>
<p><strong>Recent advance:</strong> <a href="https://www.nature.com/articles/s41592-024-02168-y">Nature Methods 2024</a> showed that homotrimeric UMI blocks (AAA, TTT, CCC, GGG repeats) provide error-correcting capability.</p>
<p><strong>Recommendation:</strong> Add UMIs to your cpn60 and rpoB primers for strain-level work.</p>
<hr />
<h4>C. Synthetic Spike-in Standards for Absolute Quantification</h4>
<p><a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">January 2025 paper in ISME Communications</a> describes "rDNA-mimics":</p>
<pre><code>Spike-in design:
[Conserved primer binding sites] + [Unique synthetic variable region]
           ↓
Add known copy number to sample before DNA extraction
           ↓
Sequencing reads of spike-in calibrate total microbial load
           ↓
Convert relative → absolute abundance
</code></pre>
<p><strong>For your application:</strong>
- Design cpn60 and rpoB spike-ins with your primer binding sites
- Add defined copies before extraction
- Enables cross-sample comparison of absolute loads
- No separate qPCR needed</p>
<hr />
<h4>D. PNA/LNA Blocking Oligos for Host Reduction</h4>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">2025 paper on PNA clamps</a> shows 46-99% reduction in host amplification:</p>
<pre><code>Without blocker:
Human mitochondrial 16S ←──── Primers bind ────→ Amplified (waste)

With PNA clamp:
Human mitochondrial 16S ←── PNA binds, blocks polymerase ──→ NOT amplified
</code></pre>
<p><strong>FGT relevance:</strong> Your samples have high host DNA. PNA blockers against human mitochondrial sequences could improve bacterial signal for 16S. Less relevant for cpn60/rpoB (bacteria-specific).</p>
<hr />
<h4>E. Long-Read Amplicon Sequencing</h4>
<p><a href="https://academic.oup.com/pnasnexus/article/3/10/pgae411/7816023">Full-length 16S with Nanopore + UMIs</a> now achieves Illumina-level accuracy:</p>
<table>
<thead>
<tr>
<th>Approach</th>
<th>Accuracy</th>
<th>Strain resolution</th>
<th>Cost/sample</th>
</tr>
</thead>
<tbody>
<tr>
<td>Illumina V4 (250bp)</td>
<td>99.9%</td>
<td>Poor</td>
<td>$15-20</td>
</tr>
<tr>
<td>Nanopore full 16S + UMI</td>
<td>99.99%</td>
<td>Good</td>
<td>$20-30</td>
</tr>
<tr>
<td>PacBio HiFi full 16S</td>
<td>99.99%</td>
<td>Excellent</td>
<td>$25-40</td>
</tr>
<tr>
<td>Full rRNA operon (16S+23S)</td>
<td>99.99%</td>
<td>Excellent</td>
<td>$30-50</td>
</tr>
</tbody>
</table>
<p><strong>For cpn60:</strong> The ~550bp amplicon is perfect for long-read - you'd get the full universal target with no assembly required.</p>
<hr />
<h4>F. AI-Assisted Primer Design</h4>
<p><a href="https://www.nature.com/articles/s41551-025-01455-z">PrimeGen</a> (Nature Biomedical Engineering, July 2025):
- LLM-powered multi-agent system for primer design
- Handles up to 955 amplicons with uniform amplification
- Minimizes dimer formation
- Could be useful for your functional gene panel design</p>
<hr />
<h3>3. Contamination Control: 2025 Guidelines</h3>
<p>The <a href="https://www.nature.com/articles/s41564-025-02035-2">new Nature Microbiology consensus statement</a> on low-biomass studies recommends:</p>
<ol>
<li><strong>Extraction blanks</strong> at every batch</li>
<li><strong>PCR no-template controls</strong> on every plate</li>
<li><strong>Positive controls</strong> (mock community) for each run</li>
<li><strong>Computational decontamination</strong> (e.g., <a href="https://www.frontiersin.org/journals/bioinformatics/articles/10.3389/fbinf.2025.1556361/full">micRoclean</a> R package)</li>
<li><strong>Report contaminant profiles</strong> - don't just filter silently</li>
</ol>
<hr />
<h3>4. Recommended Enhanced Primer Strategy</h3>
<p>Here's what I'd propose for your multi-amplicon panel:</p>
<pre><code>┌────────────────────────────────────────────────────────────────────────┐
│                    ENHANCED PRIMER DESIGN STRATEGY                     │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  TAXONOMIC AMPLICONS                                                   │
│  ──────────────────                                                    │
│  16S V4:        Standard 515F/806R (cross-study compatibility)         │
│                 + PNA blocker for human mitochondria                   │
│                                                                        │
│  16S V1-V3:     Optimized for Lactobacillus (evaluate published sets)  │
│                 Consider long-read (Nanopore/PacBio) for full V1-V9   │
│                                                                        │
│  cpn60:         H279p/H280p (established)                              │
│                 + UMI tags for strain resolution                       │
│                 + Spike-in standard for absolute quantification        │
│                                                                        │
│  rpoB:          New DPO-based primers (~550bp)                         │
│                 + UMI tags                                             │
│                 + Spike-in standard                                    │
│                                                                        │
│  FUNCTIONAL AMPLICONS                                                  │
│  ────────────────────                                                  │
│  All functional genes:                                                 │
│                 De novo design using comparative genomics              │
│                 DPO format for specificity                             │
│                 Degenerate positions optimized with ARDEP/DegePrime    │
│                 Validate in silico against South African MAGs          │
│                                                                        │
│  CONTROLS                                                              │
│  ────────────────                                                      │
│  Spike-ins:     Synthetic cpn60/rpoB mimics (known copy number)        │
│  Mock:          Defined community (commercial + custom FGT isolates)   │
│  Blanks:        Extraction + PCR negatives every batch                 │
│                                                                        │
└────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h3>5. Development Workflow</h3>
<pre><code>Phase 1: Primer Design (3-4 months)
├── Compile reference genomes for FGT taxa
├── Download/generate South African MAGs (if available)
├── Use DegePrime/ARDEP for degenerate optimization
├── Design DPO versions for functional genes
├── Add UMI sequences to cpn60/rpoB primers
├── Design synthetic spike-in standards
└── In silico validation (coverage, specificity)

Phase 2: Wet Lab Validation (3-4 months)
├── Test on mock communities (defined composition)
├── Test on archived samples with known 16S profiles
├── Optimize multiplexing pools
├── Validate spike-in quantification against qPCR
├── Establish SOP for each primer pool
└── Cross-validate between Wash U and Ragon

Phase 3: Pipeline Development (concurrent)
├── Multi-amplicon demultiplexing
├── UMI-based error correction
├── Spike-in normalization
├── Taxonomic integration across markers
└── Functional gene quantification
</code></pre>
<hr />
<h3>Questions to Refine</h3>
<ol>
<li>
<p><strong>Long-read vs. short-read?</strong> For cpn60/rpoB, long-read (Nanopore or PacBio) would give you the full amplicon without assembly. Worth the extra cost?</p>
</li>
<li>
<p><strong>UMI complexity?</strong> Full UMI workflow adds cost and bioinformatics complexity. Essential for strain work, maybe overkill for community profiling.</p>
</li>
<li>
<p><strong>How many functional genes?</strong> I listed 6-8 candidates. Want to prioritize based on mechanistic hypotheses?</p>
</li>
<li>
<p><strong>Spike-in design?</strong> Would you want to design these in-house or use commercial options (Zymo, ATCC)?</p>
</li>
</ol>
<p>Sources:
- <a href="https://www.nature.com/articles/s41551-025-01455-z">PrimeGen - Nature Biomedical Engineering 2025</a>
- <a href="https://www.nature.com/articles/s41592-020-01041-y">UMI long-read amplicons - Nature Methods</a>
- <a href="https://www.nature.com/articles/s41592-024-02168-y">UMI error correction - Nature Methods 2024</a>
- <a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">rDNA-mimics spike-ins - ISME Communications 2025</a>
- <a href="https://www.nature.com/articles/s41564-025-02035-2">Low-biomass contamination guidelines - Nature Microbiology 2025</a>
- <a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">PNA clamps - Environmental Microbiome 2025</a>
- <a href="https://academic.oup.com/pnasnexus/article/3/10/pgae411/7816023">Nanopore full 16S - PNAS Nexus 2024</a>
- <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC1874606/">DPO technology</a>
- <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">rpoB for clinical microbiology 2024</a></p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-003.html#msg-2025-12-14T22-55-05-022Z"><div class="index-item-header"><span class="index-item-number">#14</span><time datetime="2025-12-14T22:55:05.022Z" data-timestamp="2025-12-14T22:55:05.022Z">2025-12-14T22:55:05.022Z</time></div><div class="index-item-content"><p>Here is the content of a grant I have to do this work. Would you recommend any changes to our approach including what functional genes to address: SPECIFIC AIMS
The female genital tract (FGT) plays a pivotal role in the acquisition of HIV infection in women and heterosexual transmission to men. Although the majority of new infections globally occur in women following exposure to HIV through the mucosal membranes of the FGT, there remain significant gaps in our understanding of the local mucosal factors influencing susceptibility. Our previous work demonstrated that relative to vaginal communities dominated by Lactobacillus crispatus, high diversity vaginal bacterial communities comprised of mixed anaerobes with low Lactobacillus abundance were associated with elevated levels of inflammatory chemokines and cytokines in genital secretions, increased numbers of activated CD4+ T cells (“HIV target cells”) in the cervix, and a greater than four-fold increased risk of HIV acquisition2,3. Importantly, these high risk vaginal bacterial communities were present in two-thirds of young, healthy, black South African women in our FRESH (Females Rising through Education, Support and Health) cohort, suggesting that this risk factor is highly prevalent among South African women of reproductive age3. Furthermore, vaginal microbiota and genital inflammation have been shown to significantly reduce the efficacy of vaginal microbicides for preventing HIV4,5. These findings underscore the critical need to understand the mechanisms by which vaginal microbiota increase genital inflammation and HIV acquisition risk, particularly for women living in sub-Saharan Africa.
To address these knowledge gaps, we will utilize 3600 samples from 1200 FRESH participants with longitudinal blood and genital sampling, including pre-infection samples from 102 women who went on to acquire HIV. In Aim 1.1 we will generate multi-omics datasets characterizing vaginal microbiota utilizing metagenomics, metatranscriptomics, fungal internally transcribed spacer (ITS) sequencing, culturomics, microbial whole genome sequencing (WGS), and metabolomics. We will complement this in Aim 1.2 with a comprehensive characterization of the host FGT by assessing genital inflammatory chemokines and cytokines, cervical flow cytometric cell phenotype, and cervical single cell RNA sequencing (scRNAseq) profiles, combined with in-depth behavioral and demographic metadata. These complex multi-omics datasets will then be integrated in Aim 1.3 following critical quality control, transformation, and imputation of data from each modality. Modern supervised integration techniques will be used to identify multi-omics profiles predictive of genital inflammation and HIV acquisition. Candidate vaginal bacterial strains, functions, and/or metabolites will then be validated in Aim 2 using innovative in vitro and in vivo models, including an organ-on-a-chip model co-developed by the co-PI, cervical and vaginal organoids, and a humanized mouse model. Our preliminary data indicate promising candidates that can already be tested directly. Overall, this project will identify specific bacterial strains and molecules, along with host cellular lineages and sensing pathways, that mediate microbiota-induced genital inflammation and increased HIV acquisition risk. It will also validate much needed novel model systems that test the interactions of microbiota, host, and HIV to provide critical resources to develop the mechanistic understanding needed to advance the field. 
This proposal leverages the complementary expertise of Drs. Doug Kwon and Scott Handley to define the role of vaginal microbiota in genital inflammation and HIV acquisition. Dr. Kwon has studied the vaginal microbiome, mucosal immunology, and HIV pathogenesis, and has extensive experience working with clinical cohorts in sub-Saharan Africa, including over 10 years as the co-PI of the FRESH study. Dr. Handley is an expert in using microbial genomics and metagenomics to understand the impact of microbiota on human diseases. The co-PIs have a long history of productive collaboration, including multiple R01s together and seminal findings on the role of the microbiome in HIV2,6,7. They will work with Drs. Kris Sankaran and Laura Symul, biostatisticians with extensive expertise with latent variable modeling, visualization of multi-omics data, and multi-resolution analysis of the microbiome. In this proposal, we will build on our prior work and utilize an integrated multi-omics approach to address critical questions: 1) what are the specific bacterial strains, mediators and/or functions that induce host genital inflammation, 2) what are the host cellular lineages that sense bacteria in the FGT, 3) what host pathways are triggered by inflammatory bacteria in the FGT, and 4) can inhibitors of host microbial sensing be used to reduce HIV acquisition risk. We will answer these questions using samples from a unique clinical cohort of South African women living in an area of extraordinarily high HIV incidence and prevalence, innovative multi-omic approaches, advance biostatistical methods, a library of primary FGT bacterial isolates, and novel in vitro and in vivo models. This research has the potential to inform strategies for reducing new HIV infections in women, particularly for those living in sub-Saharan Africa. In this proposal, the following Aims will be addressed:
Aim 1: Utilize integrated multi-omics characterization of the female genital tract to identify drivers of genital inflammation and HIV acquisition risk
Aim 2: Investigate candidate pathways of microbiota-mediated genital inflammation and HIV acquisition risk using novel in vitro and in vivo models 
RESEARCH STRATEGY
    SIGNIFICANCE
The central role of the female genital tract (FGT) in HIV transmission. In the over four decades since the identification of HIV as the causative agent of AIDS, HIV has caused over 40 million deaths and left nearly 39 million living with disease8. Of the 1.2 million new infections each year, almost 70% occur in sub-Saharan Africa and most occur in young women of reproductive age. Heterosexual intercourse is responsible for the majority of global HIV transmission, with women being twice as likely to contract HIV through heterosexual sex as men9. Mucosal tissues in the FGT therefore represent the frontline of transmission in most incident infections. Understanding the mucosal environment of the FGT is critical for developing strategies to prevent HIV transmission. Studies in nonhuman primates have shown that soon after HIV exposure, viral replication occurs within tissue resident CD4+ T cells (“HIV target cells”) in the mucosa of the cervix and vagina for 5-7 days prior to systemic dissemination10,11. This early phase has been referred to as a “window of opportunity”, since interventions which reduce the viral reproductive rate (R0) to &lt;1 could prevent systemic viral dissemination12. Effective strategies to prevent HIV in women will require a detailed understanding of the critical mucosal factors in the FGT that modulate HIV susceptibility.
The cervicovaginal microbiome, genital inflammation, and HIV susceptibility. Inflammation in the FGT is associated with an increased risk of HIV infection3,13,14. Cervicovaginal bacteria have been shown to be closely associated with genital inflammation3, but the mechanisms by which specific bacteria increase inflammation and HIV risk remain unclear. We characterized vaginal microbiota in FRESH (Females Rising through Education, Support, and Health), a prospective cohort study of healthy HIV-uninfected South African women monitored for nine months with twice weekly HIV testing. Sequencing of the bacterial 16S rRNA gene from vaginal swabs revealed four cervicovaginal bacterial community types, or “cervicotypes” (CTs), two of which had low diversity and were dominated by either Lactobacillus crispatus (CT1, 9% of participants) or Lactobacillus iners (CT2, 28%), and two high diversity CTs dominated by mixed anaerobes, including Gardnerella vaginalis (CT3, 28%) or other mixed anaerobes (CT4, 35%) (Fig. 1A)2,3. The most abundant taxa in CT4 were Prevotella, Gardnerella, Sneathia and Megasphaera. Individuals with CT3 and CT4 communities were at over 4-fold higher risk of acquiring HIV compared to those with L. crispatus dominance (Fig. 1B)2. This risk was associated with elevated genital cytokine levels3 (Fig. 1C) and a 17-fold increase in the number of cervical HIV target cells (activated tissue resident CD4+ T cells) (Fig. 1D)2, providing a potential biologic mechanism for the observed increase in infection. We identified specific bacterial taxa linked with HIV infection, showing that Prevotella melaninogenica, P. bivia and Sneathia sanguinegens, among other anaerobes, were significantly more abundant in individuals who subsequently acquired HIV2. The specific mechanisms by which FGT bacteria induce genital inflammation and increased HIV risk are unknown. 
The lack of robust testing in model systems. Mechanistic understanding of FGT biology has been limited by the lack of robust testing in model systems. Existing models of host-microbiota interactions in the FGT range from epithelial cells alone in a simple monolayer15 or polarized in a transwell16 to murine models of herpes infection17,18 and a nonhuman primate model of IUD insertion19. Each of these models has critical limitations, and none successfully recapitulate the complex conditions of the genital tract in women20. We propose the use of multiple complementary and innovative models to evaluate mechanisms underlying observed phenotypes in women in FRESH to better understand the most important biological interactions between microbiota, host cells, and HIV infection. Validation of these model systems will lead to much needed mechanistic insight and provide a significant advance for the field.</p>
<pre><code>INNOVATION
</code></pre>
<p>Utilization of longitudinal samples from the FRESH study. This proposal utilizes multiple innovative approaches, starting with the use of 3600 longitudinal samples from a unique cohort of 1200 participants in the FRESH study21,22. FRESH has been highly effective at engaging women in research and has previously provided valuable insights into factors impacting HIV acquisition risk and early immune responses against HIV2,3,22-26. Among these samples are those from 102 women who later became HIV-infected, providing a unique opportunity to investigate how vaginal microbiota contribute to genital inflammation and HIV acquisition. Comprehensive multi-omic approaches. This proposal employs multiple innovative ‘omics approaches to comprehensively characterize vaginal microbiota and the host environment. This includes the application of metagenomics, metatranscriptomics, culturomics, bacterial whole genome sequencing (WGS), and metabolomics. Additionally, Seq-Well, a newly developed single cell sequencing method, will allow the agnostic identification of specific host lineages in the FGT that respond to vaginal microbiota using small input cell numbers. Cutting-edge biostatistical data integration. Our comprehensive multi-omics datasets will be integrated using modern techniques for multi-omics quality control, supervised dimensionality reduction, and interaction network inference resulting in a statistically rigorous, unified description of specific features underlying genital inflammation and HIV acquisition. These innovative methods leverage newly developed statistical approaches, including those developed by the co-investigators, Drs. Kris Sankaran and Laura Symul. Novel in vitro and in vivo models. Importantly, we will validate and mechanistically explore identified features using innovative model systems, including a vagina-on-a-chip co-developed by Dr. Kwon27, cervical and vaginal organoids, and humanized mice. Overall, these highly innovative approaches promise to move beyond associations to define specific mechanisms by which vaginal microbiota impact the tissue environments of the FGT and adverse women’s health outcomes.</p>
<pre><code>APPROACH
</code></pre>
<p>Aim 1: Utilize integrated multi-omics characterization of the female genital tract to identify drivers of genital inflammation and HIV acquisition risk
We hypothesize that vaginal microbiota communities with low Lactobacillus abundance and high diversity are sensed by multiple cellular lineages in the FGT and that these interactions result in alterations in the frequency, phenotype, and function of these cells in ways which lead to elevated levels of genital inflammation and increased biological susceptibility to HIV infection. These responding host cells may include components of the innate and adaptive immune system, as well as mucosal epithelial and stromal cells, which are responding to specific bacterial products, metabolites, and/or functions. In Aim 1, we will address these hypotheses by comprehensively characterizing vaginal microbiota communities using multi-omics approaches (Aim 1.1). We will complement this with an assessment of the host genital inflammation (Aim 1.2), measuring soluble cytokines and chemokines in genital secretions, cellular phenotypes with flow cytometry, and performing scRNAseq using methods optimized for small cellular input (SeqWell). These multi-omic datasets will then be integrated using supervised dimensionality reduction and interaction network inference to identify specific features that predict genital inflammation and HIV acquisition (Aim 1.3).  These features will then be validated and further tested using novel in vitro and in vivo model systems that capture the complex interactions between microbiota, host cells, and HIV in Aim 2 (Fig. 2).</p>
<p>Aim 1.1: Characterize FGT bacterial and fungal communities and microbial expression profiles in women living in sub-Saharan Africa
Patient cohort, clinical characterization, and sample collection. The FRESH cohort consists of HIV-uninfected young women aged 18-23 living in Umlazi, South Africa21,22. In this region, &lt;1% of 14-year-old girls are HIV positive but over 60% of 24-year-old women are HIV infected28. FRESH combines a behavioral program along with basic science research examining HIV acquisition and hyperacute HIV infection. Participants in FRESH engage in an intensive poverty alleviation program that provides job skills training, education on self-esteem, and classes on HIV prevention and health maintenance. Women participate in classes twice a week for three hours per visit over the course of nine months. At each visit, HIV viral load testing is performed through finger prick blood PCR. Paired blood and genital mucosal sampling occurs every three months with specific collection of plasma, PBMCs, cervical and vaginal swabs, cervical cytobrush, and cervicovaginal lavage (CVL). Questionnaires are collected at each visit detailing symptomatic and sexual behavior data, diet, vaginal hygiene practices, contraceptive use, medical history, last menstrual period, and demographic factors. All participants undergo regular STI testing. This proposal will utilize stored samples from 1200 FRESH participant who have samples from three longitudinal time points at 3-month intervals, including samples from 102 women who acquired HIV during the study. This proposal leverages an existing major investment to collect and store these unique samples. The quality of these samples has been validated extensively in published work2,3,6,29-31 and in our preliminary data.
Characterization of bacterial communities in the FGT of FRESH participants. We will use a combination of both 16S rRNA gene amplicon and metagenomic sequencing to classify bacterial communities of 3600 genital tract samples (1200 participants with three timepoints each). While metagenomic sequencing provides lower-level taxonomic resolution and gene-level functional profiles, 16S sequencing is an efficient and cost-effective tool to rapidly characterize genital microbiota. The combination of both tools will enable both rapid community classification as well as rich metagenome data generation useful for strain-level and gene content investigation. Both 16S and metagenomic data will be used in Aim 1.3 for signature identification with host inflammatory and HIV acquisition readouts.
16S rRNA amplicon surveys. Bacterial community profiles will be characterized using 16S rRNA amplicon sequencing (see Fig. 1). We will amplify a region of 16S rRNA using the 515F-806R primer set32 and sequence to a depth of approximately 50-60,000 paired-end reads using the Illumina MiSeq 2x225 protocol. Reads will be demultiplexed and resolved into sequence variants using DADA233 and taxonomically classified using GreenGenes v234. Taxonomic assignments and per sample abundances will be combined with sample data into a phyloseq object35 to facilitate analysis of bacterial presence and absence, relative abundance and diversity.
Metagenomic sequencing. Libraries for metagenomic sequencing will be prepared using Illumina Nextera XT kits and sequenced on the Illumina NovaSeq X Plus instrument using the 10B flow cell at the GTAC@MGI sequencing facility at Washington University with the goal of generating approximately 100 million 2x150 reads per sample. Raw metagenomic sequencing data will undergo adapter removal using fastp36. Human reads will be removed using DeconSeq37. Taxonomic abundances will be calculated using MetaPhlAn438 supplemented with strain-level analysis using StrainPhlAn39. Initial shotgun metagenomic data from FRESH shows geographic distribution of strains of L. crispatus between South Africa and North America (Fig. 3).
Assessment of metatranscriptomes in the FGT of women living in sub-Saharan Africa. A metatranscriptome represents the collective transcriptomes of a given environment40. Metatranscriptomic data can be used to study gene expression of a community and identify active elements. Alterations in microbial responses and activities can be revealed by comparing gene expression across conditions, clinical parameters, and over time. To assess the metatranscriptomes of the FGT of women living in sub-Saharan Africa we will first isolate RNA and remove contaminating rRNA from samples using the protocol detailed in Deng et al.41. RNA will be converted to cDNA and prepared for sequencing using the Illumina TruSeq RNA sample prep kit. Libraries will be sequenced on the Illumina NovaSeq X Plus instrument using the 10B flow cell at the GTAC@MGI sequencing facility at Washington University with the goal of generating approximately 100 million 2x150 reads per sample. Metatranscriptomic functional profiles will be determined using HUMAnN242 with differential abundances tested with edgeR43.
Creation of bacterial strain library. Swabs collected at quarterly visits are also frozen in 10% glycerol solution. Upon thawing, isolates will be grown in a variety of media to allow broad propagation of multiple species. Once pure isolates have been obtained, DNA will be extracted and submitted to WGS. Isolates will be identified based on alignment to universal single copy marker genes. As part of this proposal, we will culture, sequence, and store 600 primary bacterial strains. Strains that demonstrate differences in inflammatory potential in the model systems described below will undergo comparative genomic analysis to identify genetic differences that may be the source of altered host-microbe interactions. Our preliminary data (Fig. 4) indicate sub-species structure within isolates from different geographies and support the utility and feasibility of this approach. 
Characterization of fungal communities in the FGT of women living in sub-Saharan Africa. The FGT is commonly colonized by fungal species, most frequently by species of Candida44. In women from Western countries, approximately 30-50% of women are affected by vulvovaginal candidiasis (VVC) at least once during their lifetime44. While Candida is the dominant fungal genera of the female genital tract, cultivation-independent sequencing efforts have identified previously hidden species diversity45. Fungal colonization of the female genital tract has been associated with changes to resident bacterial communities46 with C. glabrata detection correlated with bacteria from the genus Prevotella. Fungal colonization is also associated with vaginal inflammation with Interleukin (IL)-17 responses thought to play a major role in controlling colonization in mouse models of VVC47. Studies using Gram-staining have associated VVC with increased HIV risk48 and persistent, asymptomatic VVC is associated with elevated cervical Th17-like cells and cytokines49. Understanding fungal colonization patterns in women living in sub-Saharan Africa is required for a full understanding of how the microbiome influences genital inflammation and HIV acquisition risk.
ITS2 rRNA amplicon surveys. Fungal community profiles will be characterized using ITS2 rRNA amplicon sequencing. We will amplify a region of ITS2 using the ITS1f-ITS2 primer set50 and sequence to a depth of approximately 50-60,000 paired-end reads using the Illumina MiSeq 2x225 protocol. Reads will be demultiplexed and resolved into sequence variants using DADA233 and taxonomically classified using the UNITE database51. Taxonomic assignments and per sample abundances will be combined with sample data into a phyloseq object35 to facilitate analysis of fungal presence and absence, relative abundance and diversity. Preliminary ITS sequencing from 220 FRESH participants shows high relative abundance of diverse fungal taxa (Fig. 5). 
Measurement of the vaginal metabolome. The vaginal metabolome is inextricably linked to both microbiota and host function. Metabolome shifts in bacterial vaginosis (BV) have been widely recognized for decades15,16, but detailed understanding of how these metabolic disturbance impact the host are lacking. In preliminary data from 143 FRESH participants, we used ultra-high-performance liquid chromatograph/tandem mass spectrometry (in collaboration with Metabolon, Inc.) and found marked metabolomic differences by vaginal microbiota composition, including alterations of metabolites known to have well-documented adverse host effects at other body sites (Fig. 6). For this proposal, metabolomics data will be generated on all 3600 FRESH CVL samples with Metabolon and then used in Aim 1.3 for feature identification with host inflammatory and HIV acquisition endpoints.</p>
<p>Aim 1.2: Identify specific host genital cellular lineages and microbial sensing pathways that mediate microbiota-associated inflammation and HIV acquisition risk
Assessment of inflammation in the FGT. Luminex will be used to assess the level of inflammation in the FGT of women, using a panel of 28 cytokines validated in our prior work (Fig. 1)2,3. We will also measure other soluble mucosal immune markers, such as human defensins, secretory leukocyte peptidase inhibitor (SLPI), lactoferrin, myeloperoxidase and human neutrophil peptides (HNPs), which have been reported to be differentially expressed in the FGT and may represent important readouts of genital inflammation52,53.
Quantitation of reproductive hormone levels. Reproductive hormones have been reported to alter both the vaginal microbiome and HIV acquisition risk54 and a study of the temporal dynamics of the vaginal microbiome across the menstrual cycle demonstrated a subset of women have significant variation in the bacterial communities55. These observations suggest a possible linkage between reproductive hormones, the vaginal microbiome, and HIV acquisition risk, and suggest that more detailed studies are needed to understand the relationships between these factors. Systemic progesterone, estradiol, and MPA (medroxyprogesterone acetate, found in DMPA) will be measured by liquid chromatography-mass spectrometry (LC-MS) performed by the Massachusetts General Hospital Clinical Pathology Core. This will allow us to accurately assess the stage in the menstrual cycle sampling was performed for all women56. We will integrate these levels with metadata regarding days since last menstrual period (LMP) and use of hormonal contraception. 
Characterization of frequency, activation state and co-receptor expression of cervical cells. Cervical cytobrush samples from FRESH participants will be phenotypically characterized by flow cytometry for subset frequency (CD4+ and CD8+ T cells, CD14+ macrophages, CD11c+ and CD123+ DCs, EpCAM+ epithelial cells, and neutrophils), activation state (HLA-DR, CD38, CD69), and HIV co-receptor expression (i.e. CD4 and CCR5) (Fig. 1). These panels have been utilized before in over 300 FRESH cytobrush samples.
Use of Seq-Well to perform agnostic high throughput single cell profiling of FGT cellular subsets in women with defined cervicovaginal microbiota. In collaboration with Dr. Alex Shalek at MIT  (see LOS), we will utilize a new high throughput microwell technology called Seq-Well to perform single cell RNA sequencing57 (Fig. 7A) from cytobrush samples from the FRESH Study. Seq-Well confines uniquely barcoded mRNA capture beads and single cells in a PDMS microwell array (containing ~ 100,000 wells) sealed with a semi-permeable membrane. Cytobrush, cells are distributed in the plate; the plate is then sealed and frozen for storage. To date, we have successfully captured and generated high quality sequencing libraries from up to 5,000 cells from frozen cervical cytobrushes from participants in the FRESH study from women with both L. crispatus (CT1) and highly diverse (CT4) vaginal microbial communities (Fig. 7B). Using a single device, an average of 40,000-50,000 transcripts per cell can be captured. Once single cell RNAseq has been performed, linear models using the Bioconductor package LIMMA will be utilized for transcriptional profile analyses (i.e. to identify genes which are differentially expressed between specific cell lineages in women with distinct vaginal microbial communities). Differentially expressed genes will be identified based on false discovery rate (FDR) adjusted p value using empirical Bayes moderated tests. The FDR will be controlled using the Benjamini Hochberg procedure. Pathways and interactive networks analysis will be performed on differentially expressed genes using Ingenuity Pathway Analysis, gene set enrichment analysis, and protein interaction databases (STRING58 and FunctionalNet59) to identify candidate host pathways that mediate sensing of inflammatory cervicovaginal microbiota. These candidate pathways will be validated using in vitro and in vivo models in Aim 2. Additionally, exponential random graph models (ERGM) will be used to identify networks of interacting cellular lineages, displayed as an “interactome” of differentially regulated pathways that are predicted to interact between distinct lineages (Fig. 7C). Due to cost, not all cytobrush samples can be analyzed with Seq-Well. We will guide the selection of an informative subset using available microbiome and host data. Specifically, we will embed the non-Seq-Well data into a lower dimensional space and use archetypal analysis to identify representatives for Seq-Well analysis. Since samples with more extreme inflammation (i.e. very high or very low) or microbiome profiles (i.e. L. crispatus dominant or non-dominant) are expected to contain stronger signals, we will adjust the loss function to increase their probability of selection.</p>
<p>Aim 1.3: Clarify disease profiles and candidate mechanisms through integrated multi-omics analysis
The data generated by Aims 1.1 and 1.2 have the potential to identify the host-microbiota interactions leading to genital inflammation and HIV acquisition. However, care must be taken to address the challenges of multi-omics data integration. Our approach considers the following challenges: 
    Preprocessing and quality assurance: Careful preprocessing is needed to reduce biases and enhance biological signals in downstream analysis.
    Characterization of longitudinal changes:  Within patient trends in relevant features may provide additional information than their absolute expression levels.
    Defining disease profiles using integrative dimensionality reduction: The number and high dimensionality of the data modalities complicate the definition of disease profiles.
    Identifying disease pathways using multi-omics networks: Forming a mechanistic description of disease development requires reasoning about integrated network interactions and causality.
Our approach first preprocesses each modality with normalization, batch effect correction, and temporal featurization methods. This boosts true signals and accounts for dependence between samples. Next, we will fit multiblock Partial Least Squares (PLS)60 and iterative Random Forest (iRF)61,62 models to learn integrated disease profiles and interaction networks. For longitudinal samples we will define summary variables for each feature to quantify the longitudinal variability and trends for each participant. Finally, we will share intermediate data and modeling artifacts through web and code interfaces, ensuring that our analysis effort is transparent and can be reused by the community. Our approach will be applied to integrate and interrogate data generated in Aim 1.1 and Aim 1.2 with the goal of identifying microbes, microbial products, host cell and host-responses that define genital inflammation and HIV acquisition. These features will serve as substrate for Aim 2.
Preliminary Data: We previously completed an integrative, multi-omics analysis to evaluate a probiotic intervention, Lactin-V, which is intended to reduce the rate of recurrent BV (rBV) after antibiotic treatment63. We quantified feature and block importance from host demographic, behavioral, immunological, and microbiome data using PLS (Fig. 8). Since all blocks were included in the model simultaneously, the effect of any one block can be interpreted as conditional on all others being held fixed. We found that past microbiota composition and perturbations (e.g., vaginal hygiene practices) of the vaginal environment are more predictive of treatment success than all demographic or sexual behavioral characteristics. Further, a Canonical Correlation Analysis (CCA)64,65 found a strong association between microbiome subcommunity composition and host cytokine activity (Fig. 9), with the top two canonical dimensions having correlations of 0.7 and 0.32.
Research Design:
Protocols for preprocessing and quality assurance. Distinguishing technical from biological variation is a central difficulty in multi-omics analysis, and careful data preparation is vital for valid inference. To facilitate this analysis, we will sequence negative control samples across modalities. Negative controls represent background variation due to sample preparation and assay noise. If batch effects are detected, these negative controls can be input to either CellAnova66 or RUV467,68 for correction, depending on whether the assay is sequencing-based. Further, we must be mindful of missing data, especially for metabolomics, which will be processed with a peak-detection pipeline. Different mechanisms can lead to missingness – for example, falling below the lower limit of quantification or peak-detection failure during alignment – and we will impute values in a way that respects these differences69. We will apply variance stabilizing transformations to 16S/ITS, metagenomic, metatranscriptomics, cytokine, cellular phenotype, and scRNAseq data to improve the statistical efficiency of downstream analysis. We will compute quality metrics on these normalized data using Scater70 and will exclude low-quality outliers from analysis. These sample-level checks will be coupled with cohort-level visualization of sampling times to flag inconsistencies. Finally, beyond sample processing, errors can result from inaccurate sample tracking. We will link metadata to digital metadata files that are curated and QC’d, mitigating the risks associated with manual data entry and transfer. 
Characterizing longitudinal changes. Each participant of the FRESH study provided samples approximately every three months for three time points. Because of the low sampling frequency relative to the typical dynamics of microbiota composition in individuals (previous studies have shown that the microbiota composition can drastically change over a few days or weeks71) dynamical models of the vaginal ecosystems are unlikely to accurately describe temporal changes between visits. Instead, we will define summary variables for each feature to quantify the longitudinal variability and trends for each participant. Specifically, each feature will be summarized for each participant by its mean value and trend. Trends will be computed as the slope of the line regressed over the available time points and considered missing for participants with a single time point. If we observe many features with large variances but small trends (e.g., a sequence of high-low-high values), we will include the variance in the summary variables. Since this increases the number of features (but not the number of samples), we would then use regularization in downstream analyses to impose sparsity in the profiles associated with genital inflammation or HIV acquisition (see below). 
Defining disease profiles using integrative dimensionality reduction. Given the preprocessed data, we will generate an integrated, exploratory overview of disease-associated features using PLS or sparse PLS (sPLS). PLS is a foundational method in multi-omics analysis72-74 and has been applied to a variety of settings, including childhood asthma75, diabetes76, and COVID-1977. In our context, it will produce latent profiles of genital inflammation and HIV acquisition across modalities. Specifically, we will apply the mixOmics60 R package with longitudinally summarized 16S/ITS, metagenomic, metatranscriptomic, cytokine, cellular phenotypic, metabolomic, scRNAseq, demographic, and behavioral data as input blocks and inflammation and HIV infection status as the response variables. The number of factors will be tuned by cross-validation. This supervised dimensionality reduction mirrors the approach used on the preliminary data but with inflammation and HIV status. By including demographic and behavioral features as inputs, we will control for them, helping illuminate microbiological and immunological effects beyond superficial host differences. The model will output latent profiles ─ patterns of features that are predictive of the inflammatory and infection response variables ─ for each input block. Features with strong associations (i.e., factor loadings with large magnitudes) may play a direct role in disease development and are natural candidates for follow up studies in Aim 2. Of particular interest are the latent profiles associated with immunological activity. From prior work, we expect these profiles to be highly predictive of HIV infection risk. If these findings are replicated, the resulting profiles will be reliable proxies for infection risk that could be used during model-system experiments. Further, the PLS analysis will return importance scores for each modality. These scores will prioritize relevant disease-associated features, since large effects tend to be proximate to underlying disease mechanisms.
Identifying disease pathways using multi-omics networks. The PLS analysis provides an exploratory view of disease associations. However, a more precise description of cellular interactions is necessary to guide experimental investigation. Multi-omics interaction networks, which are analogs to gene expression networks that tie modalities together, can reveal specific pathways of disease development. To build these networks, we will apply iRF61,62, a random forest-based interaction discovery method. Our input and response will be formatted as in the PLS; however, the output of the iRF model are feature-level interactions that are predictive of either inflammatory or HIV state. For example, a bacterial taxon (16S data) may increase the levels of an immune cell type (scRNAseq data or cell phenotyping) that is targeted by HIV, ultimately resulting in increased disease risk. This mechanism would systematically elevate the expression of that pair of taxonomic and immunological features within HIV-infected women. The feature pair defines a predictive association rule and hence can be learned by iRF. We can subsequently build a general interaction network by combining association rules from across the model.
One limitation of this analysis is that the learned iRF interactions are associational, not causal. In the example above, an interaction between a bacterial taxon and an immune cell type may be visible, but we would not be able to conclude that the taxon leads to alterations in immune cell frequency. In general, causal discovery is a challenging statistical problem. However, the diversity of our multi-omics data allows us to apply a causal invariance analysis to the network, helping to screen away non-causal effects. Specifically, for each node in the undirected association network, we will apply stabilized regression78 with that node as the response, direct neighbors as candidate causal features, and all other nodes as the background environment. Stabilized regression is built on the observation that upstream causal nodes in a biological pathway maintain consistent associations even in shifting environments, while noncausal, downstream associations tend to be sensitive to environmental perturbation. By iterating this procedure across neighborhoods in the estimated network, we can identify and prioritize stable directed edges (i.e. pointing at specific microbial taxa or immune cells) for experimental follow-up.
Enhancing Transparency and Reproducibility. We will prepare data, model outputs, and code notebooks so that they can become a resource for the microbiome multi-omics research community. We will host raw data on a permanent URL through our library system, except for sequencing reads, which we will deposit in the Sequence Read Archive. Preprocessed data will be shared as an R Bioconductor ExperimentData package and in a language-agnostic form through Zenodo79,80.Estimated model parameters, including the learned PLS profiles and iRF network, will be hosted publicly as RData objects and CSV files. A helper R package will encapsulate the low-level operations of our analysis. These functions will be called in compiled Rmarkdown reports that discuss the analysis, allow others to reproduce it, and support adaptation to new data81. These notebooks will be hosted on GitHub, and we will document the repository to clarify the workflow and engage the community. 
Power analysis for Aim 1. To ensure sufficient power to identify meaningful multi-omic signatures given the collected number of samples, we relied on simulations. We generated synthetic data associated with each modality, introduced hypothetical HIV-associated shifts, and measured recovery of the true effect. We used the sparseDOSSA282 and ZINB-WaVE83 models to simulate baseline vaginal 16S rRNA and metagenomic sequencing data. Though ZINB-WaVE was designed for scRNAseq data, it uses a low-rank negative binomial factorization that has been competitive in metagenomics benchmarks84. We simulated metabolomics and behavioral data from gamma and categorical distributions, respectively. We then defined a sparse regression model where 10% of features from each modality relate to the response, fixed the signal-to-noise ratio to 3, and calculated error rates across sample sizes. When enforcing a False Discovery Rate control level of 0.15, a sample with 1200 subjects has an average power of 88.7% across assays (75% power for the simulated survey, 90% for the 16S, 90% for the metagenomic, and 100% for the metabolomic data). In contrast, applying the analysis with a sample of size 600 had low average power (55.0%), and a larger sample size of 1800 yielded diminishing returns (93.8% average power). Hence, the intended sample size balances efficacy with economy.
Potential pitfalls and alternative approaches for Aim 1. Multi-omics analysis can be sensitive to specific preprocessing hyperparameters, like the choice of variance stabilization function or the selection of confounding variables during batch effect correction. Though the large sample size of the proposed study partially mitigates these risks, we must still guard against potential spurious associations that preprocessing can introduce. To this end, we will measure the concordance of selected candidate features/interactions on different data splits when using different hyperparameter choices. Our final analysis will only incorporate hyperparameter selections with high between-split concordance. A second potential pitfall is that imbalance between the number of FRESH participants who do and do not acquire HIV may degrade model performances. Since we will use supervised methods to predict the binary variable flagging HIV acquisition, we may address this class imbalance by increasing the weight of samples (participants) from the minority class, or, equivalently, by altering the loss function. Another potential pitfall is computational rather than statistical. If the learned interaction network is dense with many potential connections, then stabilizing regression can become computationally challenging, even after parallelization across the high-performance computer cluster used by our team. In this case, we will restrict the causal invariance analysis to the subset of edges with the strongest associations, sacrificing the completeness of the causal characterization for improved computational efficiency.</p>
<p>Aim 2: Investigate candidate pathways of microbiota-mediated genital inflammation and HIV acquisition risk using novel in vitro and in vivo models
A significant technical problem in the field is the lack of a single accepted model for the human FGT20, particularly one that incorporates microbiota, host cells, and HIV infection. We have developed three model systems that we will use to test candidate bacterial strains and metabolites chosen based upon our preliminary work as well as from features identified in Aim 1: 1) a 3D vagina-on-a-chip (“V-Chip”), 2) vaginal organoids, and 3) humanized mice. These complementary systems will allow us to characterize mechanistic relationships between candidate mediators and readouts of host inflammation and/or HIV acquisition. To begin with, we will define a set of candidate mediators based upon our prior work and published literature while work described in Aim 1 occurs in parallel to define additional candidate features.</p>
<p>Candidate mediators of genital inflammation and HIV acquisition risk to test in model systems. Our preliminary results have already identified several candidate bacterial species, metabolites, and host inflammatory pathways to test in model systems. This includes biogenic amines, such as the metabolites putrescine and cadaverine, which are highly enriched in the vagina of women with CT3 and CT4 microbiota and have been described as having pro-viral effects at other body sites (Fig. 10A). Putrescine has small molecule synthesis inhibitors that can also be tested using our model systems. In addition, RNA transcriptional analysis of cervical antigen presenting cells (APCs) demonstrated strong upregulation of bacterial lipopolysaccharide (LPS) signaling via toll-like receptor 4 (TLR4) pathways (Fig. 10B). This coincides with significant increases in LPS in CT3 and CT4 communities based upon bacterial metagenomic analysis. Regarding candidate vaginal bacterial species that may mediate increased HIV acquisition, we previously identified Prevotella melaninogenica, Veillonella montpellierensis, Mycoplasma, Sneathia sanguinegens, and two strains of Prevotella bivia as being associated with both increased genital inflammation and HIV acquisition in FRESH (Fig. 10C). These candidate metabolites, host pathways, and bacterial species will be used initially in model systems to explore mechanistic relationships to genital inflammation and HIV infection.
3D organ-on-a-chip vaginal epithelial model (V-Chip). One of the challenges in the vaginal microbiome field is that there has not been a robust way to study how living human vaginal epithelium interacts directly with living microbes because conventional co-cultures lead to bacterial overgrowth and cell death85-88. In addition, they fail to recapitulate physiologically relevant tissue-tissue interfaces and critical physical cues89. Organ-on-a-chip models provide more robust options for in vitro testing of complex interactions with multifaceted microbial communities27,89,90. The V-Chip is a novel, 3D microfluidic organ-on-a-chip model of the vaginal epithelium, which supports testing of hypotheses regarding microbe-host interactions27. Developed in collaboration with Dr. Don Ingber, the V-Chip is created by co-culturing primary human vaginal epithelium on the top surface of an extracellular matrix-coated porous membrane within the top channel of a two-channel microfluidic chip with primary human uterine fibroblasts on the lower surface of the same membrane in the bottom parallel channel to recreate the vaginal epithelial-stromal interface (Fig. 11A-C). The V-Chip model allows integration of microbial and host characteristics, and the microfluidic platform allows for long-term co-culture, introduction of varying exposures, and frequent sampling of the community composition and metabolic output of the system. When co-cultured with L. crispatus strain consortia, the V-Chips maintain vaginal epithelial cell viability, low pH, and the bacterial production of D-lactate, while downregulating proinflammatory cytokines, all of which recapitulate findings in women (Fig. 11D-F). V-Chips are commercially available from Enumeral (see LOS from Dr. Don Ingber) and will be used to test candidate microbial strains, host pathways, and metabolites that are identifed from Aim 1 and/or our preliminary findings. V-Chips will be evaluated for bacterial composition (for those colonized with bacterial strains and/or consortia), metabolites production (metabolomics), and host response (immunological markers and transcriptional analysis).
Vaginal organoids with autologous tissue resident T cells. To complement the V-Chip model, we will use vaginal organoids with autologous tissue resident T cells derived from excess hysterectomy tissue (Fig. 12). These organoids can be expanded in vitro and co-cultured with bacteria (for short term culture &lt;24 hours), metabolites, and small molecule inhibitors. We will also develop the model so that we can infect the tissue resident CD4+ T cells with HIV and measure the impact of candidate features on HIV viral replication at low multiplicity of infection (MOI) using HIV p24 ELISA over the first 10 days after infection. 
Assessment of candidate features in a humanized mouse model of intravaginal HIV acquisition. We will utilize the humanized mouse model, which is an established model for vaginal HIV infection91-93, to assess the impact of candidate features on genital inflammation and HIV susceptibility. We have shown that vaginal inoculation of these mice with P. bivia, but not L. crispatus, induces a similar genital inflammatory cytokine response and increases in FGT CD4+ T cell as observed in women in FRESH (Fig. 13A, B)2. Additionally, vaginal inoculation with P. bivia also resulted in increased HIV acquisition with repeated low dose vaginal HIV challenge (Fig. 13C, D). 
To test candidate features, mice will be intravaginally inoculated each week on days 0 and 2 with microbes (bacterial and/or fungal strains, alone or as consortia), metabolites, or other molecules of interest, including potential inflammation inhibitors. On day 3, mice will undergo vaginal low dose HIV challenge with 2500 TCID50/mL JRCSF; the challenge dose is chosen such that 10-15% of saline inoculated control mice are infected with each challenge. The series of weekly vaginal inoculation and HIV challenge will be repeated for 10 weeks. We will compare HIV infection rates in treated mice vs saline inoculated control mice (12 mice per group). Blood viral load (VL) will be assessed weekly and time to infection compared between mice receiving different vaginal inocula and treatments. Animals will be sacrificed once HIV is detected or after 10 weeks, when CVL, blood, and the FGT tissue will be collected. Half of the FGT will be used for flow cytometry the same day, while the other half will be digested and loaded on Seq-Well for scRNAseq. Flow cytometry will be performed to assess cellular markers of genital inflammation as described above. Secondarily, CVL fluid and plasma (control) will be used to examine local and systemic cytokines and chemokines using Luminex. CVL fluid will further be used to assess the presence of live bacteria and the bacterial composition.<br />
Statistical analysis for Aim 2: Measures of inflammation and pathway activation will be compared in each model system between different conditions using t-test, ANOVA, or nonparametric methods as appropriate. scRNAseq results will be analyzed as described in Aim 1.2 and will be compared to findings generated from cervical samples from FRESH participants. For the organoid experiments we will conduct at least 3 experiments per condition, each with technical replicates. In preliminary experiments, our standard deviation for IL-8 values across donors and bacterial treatments is 0.35 log10, thus with 4 donors per comparison we would have at least 80% power to detect a 1.5 log10 difference between conditions. For mouse experiments with at least 4 mice per group in each of 3 experiments (i.e., 12 mice per group), analyzed using a two-sided Wilcoxon rank sum test (level α=0.05) stratified by experiment, there would be at least 80% power to detect a true standardized difference (stdiff) of 1.23 in numbers of activated CD4+ T cells between conditions, which is smaller than the observed stdiff of 1.48 for CD4+ T cells seen in our prior work2. We will compare p24 quantity between conditions in organoids and mice using student’s t-test. For mouse experiments, the number of mice suggested is based on a 10-15% infection rate with the indicated dose of virus, assuming that some conditions would increase the infection rate 3-fold and inhibition would decrease that by at least half, to 45%.  We will test the proportion of infected mice between treatment conditions using a one-sided Fisher exact test with a cut-off of 0.05.
Potential pitfalls and alternative approaches for Aim 2. There are caveats to the use of any model system. However, we propose comparing results directly to those obtained from women in FRESH to make sure that the models recapitulate important observations identified in Aim 1.  Discrepancies will be used to inform in vitro model improvements, and only after its fidelity can be guaranteed will we move forward with mechanistic work in the model. Given the lack of animal models for the human vagina, this type of modeling, which uses multiple complementary approaches and calibrates model system parameters using real-world omics data sources, is likely to be the best way to reach an understanding of the mechanistic relationships between vaginal microbiota, genital inflammation, and HIV acquisition risk.  
BIBLIOGRAPHY AND REFERENCES CITED
1    France, M. T. et al. VALENCIA: a nearest centroid classification method for vaginal microbial communities based on composition. Microbiome 8, 166, doi:10.1186/s40168-020-00934-6 (2020).PMC7684964 translating microbiome research into live biotherapeutics drugs for women's health. All other authors declare that they have no competing interests.
2    Gosmann, C. et al. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity 46, 29-37, doi:10.1016/j.immuni.2016.12.013 (2017).PMC5270628
3    Anahtar, M. N. et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 42, 965-976, doi:10.1016/j.immuni.2015.04.019 (2015).PMC4461369
4    Klatt, N. R. et al. Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science 356, 938-945, doi:10.1126/science.aai9383 (2017)
5    McKinnon, L. R. et al. Genital inflammation undermines the effectiveness of tenofovir gel in preventing HIV acquisition in women. Nat Med 24, 491-496, doi:10.1038/nm.4506 (2018).PMC5893390
6    Byrne, E. H. et al. Antigen Presenting Cells Link the Female Genital Tract Microbiome to Mucosal Inflammation, With Hormonal Contraception as an Additional Modulator of Inflammatory Signatures. Front Cell Infect Microbiol 11, 733619, doi:10.3389/fcimb.2021.733619 (2021).PMC8482842
7    Monaco, C. L. et al. Altered Virome and Bacterial Microbiome in Human Immunodeficiency Virus-Associated Acquired Immunodeficiency Syndrome. Cell Host Microbe 19, 311-322, doi:10.1016/j.chom.2016.02.011 (2016).PMC4821831
8    WHO, U. UNAIDS Global AIDS Update. (Geneva, 2023).
9    Boily, M. C. et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9, 118-129, doi:10.1016/S1473-3099(09)70021-0 (2009)
10    Haase, A. T. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 62, 127-139, doi:10.1146/annurev-med-080709-124959 (2011)
11    Tebit, D. M., Ndembi, N., Weinberg, A. &amp; Quinones-Mateu, M. E. Mucosal transmission of human immunodeficiency virus. Curr HIV Res 10, 3-8 (2012)
12    Haase, A. T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223, doi:10.1038/nature08757 (2010)
13    Masson, L. et al. Genital inflammation and the risk of HIV acquisition in women. Clin Infect Dis 61, 260-269, doi:10.1093/cid/civ298 (2015).PMC4565995
14    Anahtar, M. N., Gootenberg, D. B., Mitchell, C. M. &amp; Kwon, D. S. Cervicovaginal Microbiota and Reproductive Health: The Virtue of Simplicity. Cell Host Microbe 23, 159-168, doi:10.1016/j.chom.2018.01.013 (2018)
15    Fichorova, R. N., Yamamoto, H. S., Delaney, M. L., Onderdonk, A. B. &amp; Doncel, G. F. Novel vaginal microflora colonization model providing new insight into microbicide mechanism of action. MBio 2, e00168-00111, doi:mBio.00168-11 [pii]10.1128/mBio.00168-11 (2011).3202752
16    Eade, C. R. et al. Identification and characterization of bacterial vaginosis-associated pathogens using a comprehensive cervical-vaginal epithelial coculture assay. PLoS One 7, e50106, doi:10.1371/journal.pone.0050106PONE-D-12-19131 [pii] (2012).3499514
17    Yim, K. C. et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol 79, 14632-14639, doi:10.1128/JVI.79.23.14632-14639.2005 (2005).PMC1287570
18    Kutle, I., Dittrich, A. &amp; Wirth, D. Mouse Models for Human Herpesviruses. Pathogens 12, doi:10.3390/pathogens12070953 (2023).PMC10384569
19    Hashway, S. A. et al. Impact of a hormone-releasing intrauterine system on the vaginal microbiome: a prospective baboon model. J Med Primatol 43, 89-99, doi:10.1111/jmp.12090 (2014).PMC3954920
20    Herbst-Kralovetz, M. M., Pyles, R. B., Ratner, A. J., Sycuro, L. K. &amp; Mitchell, C. New Systems for Studying Intercellular Interactions in Bacterial Vaginosis. J Infect Dis 214 Suppl 1, S6-S13, doi:10.1093/infdis/jiw130 (2016).PMC4957508
21    Ndung'u, T., Dong, K. L., Kwon, D. S. &amp; Walker, B. D. A FRESH approach: Combining basic science and social good. Sci Immunol 3, doi:10.1126/sciimmunol.aau2798 (2018).PMC7593829
22    Dong, K. L. et al. Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV 5, e35-e44, doi:10.1016/S2352-3018(17)30146-7 (2018).PMC6506720
23    Byrne, E. H. et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infect Dis 16, 441-448, doi:10.1016/S1473-3099(15)00429-6 (2016).PMC5294917
24    Ndhlovu, Z. M. et al. Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Science translational medicine 11, doi:10.1126/scitranslmed.aau0528 (2019)
25    Kloverpris, H. N. et al. Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity 44, 391-405, doi:10.1016/j.immuni.2016.01.006 (2016)
26    Ndhlovu, Z. M. et al. Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity 43, 591-604, doi:10.1016/j.immuni.2015.08.012 (2015).PMC4575777
27    Mahajan, G. et al. Vaginal microbiome-host interactions modeled in a human vagina-on-a-chip. Microbiome 10, 201, doi:10.1186/s40168-022-01400-1 (2022).PMC9701078 holder in Emulate, Inc. G.M. is current employee of Emulate Inc. and may hold equity interest in Emulate, Inc. J.R. is co-founder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutics drugs for women's health. The other authors declare that they have no competing interests.
28    Wong, E. B. et al. Convergence of infectious and non-communicable disease epidemics in rural South Africa: a cross-sectional, population-based multimorbidity study. Lancet Glob Health 9, e967-e976, doi:10.1016/S2214-109X(21)00176-5 (2021).PMC8220132 Academy of Sciences, and the South African National Research Foundation, during the conduct of the study. ADG reports grants from the Wellcome Trust, during the conduct of the study. All other authors declare no competing interests.
29    Bloom, S. M. et al. Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol 7, 434-450, doi:10.1038/s41564-022-01070-7 (2022).PMC10473153
30    Munoz, A. et al. Modeling the temporal dynamics of cervicovaginal microbiota identifies targets that may promote reproductive health. Microbiome 9, 163, doi:10.1186/s40168-021-01096-9 (2021).PMC8314590
31    Piantadosi, A. et al. Metagenomic Sequencing of HIV-1 in the Blood and Female Genital Tract Reveals Little Quasispecies Diversity during Acute Infection. J Virol 93, doi:10.1128/JVI.00804-18 (2019).PMC6321908
32    Caporaso, J. G. et al. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 108 Suppl 1, 4516-4522, doi:10.1073/pnas.1000080107 (2011).PMC3063599
33    Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581-583, doi:10.1038/nmeth.3869 (2016).PMC4927377
34    McDonald, D. et al. Greengenes2 unifies microbial data in a single reference tree. Nat Biotechnol, doi:10.1038/s41587-023-01845-1 (2023)
35    McMurdie, P. J. &amp; Holmes, S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8, e61217, doi:10.1371/journal.pone.0061217 (2013).PMC3632530
36    Chen, S., Zhou, Y., Chen, Y. &amp; Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884-i890, doi:10.1093/bioinformatics/bty560 (2018).PMC6129281
37    Schmieder, R. &amp; Edwards, R. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. PLoS One 6, e17288, doi:10.1371/journal.pone.0017288 (2011).PMC3052304
38    Blanco-Miguez, A. et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotechnol, doi:10.1038/s41587-023-01688-w (2023)
39    Truong, D. T., Tett, A., Pasolli, E., Huttenhower, C. &amp; Segata, N. Microbial strain-level population structure and genetic diversity from metagenomes. Genome Res 27, 626-638, doi:10.1101/gr.216242.116 (2017).PMC5378180
40    Filiatrault, M. J. Progress in prokaryotic transcriptomics. Curr Opin Microbiol 14, 579-586, doi:10.1016/j.mib.2011.07.023 (2011)
41    Deng, Z. L. et al. Metatranscriptome Analysis of the Vaginal Microbiota Reveals Potential Mechanisms for Protection against Metronidazole in Bacterial Vaginosis. mSphere 3, doi:10.1128/mSphereDirect.00262-18 (2018).PMC5990888
42    Franzosa, E. A. et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nat Methods 15, 962-968, doi:10.1038/s41592-018-0176-y (2018).PMC6235447
43    Robinson, M. D., McCarthy, D. J. &amp; Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140, doi:10.1093/bioinformatics/btp616 (2010).PMC2796818
44    Foxman, B., Muraglia, R., Dietz, J. P., Sobel, J. D. &amp; Wagner, J. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17, 340-345, doi:10.1097/LGT.0b013e318273e8cf (2013)
45    Drell, T. et al. Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women. PLoS One 8, e54379, doi:10.1371/journal.pone.0054379 (2013).PMC3553157 LCC. The company partly financed and provided sequencing service for the project as part of their workflow development for metagenomic sequencing service. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
46    Zhao, C. et al. Mycobiome Study Reveals Different Pathogens of Vulvovaginal Candidiasis Shape Characteristic Vaginal Bacteriome. Microbiol Spectr 11, e0315222, doi:10.1128/spectrum.03152-22 (2023).PMC10269694
47    Jin, Y. M., Liu, S. S., Xu, T. M., Guo, F. J. &amp; Chen, J. Impaired Th17 cell proliferation and decreased pro-inflammatory cytokine production in CXCR3/CXCR4 double-deficient mice of vulvovaginal candidiasis. J Cell Physiol 234, 13894-13905, doi:10.1002/jcp.28071 (2019)
48    Hester, R. A. &amp; Kennedy, S. B. Candida infection as a risk factor for HIV transmission. J Womens Health (Larchmt) 12, 487-494, doi:10.1089/154099903766651612 (2003)
49    Happel, A. U. et al. Persistent, Asymptomatic Colonization with Candida is Associated with Elevated Frequencies of Highly Activated Cervical Th17-Like Cells and Related Cytokines in the Reproductive Tract of South African Adolescents. Microbiol Spectr 10, e0162621, doi:10.1128/spectrum.01626-21 (2022).PMC9045181
50    Bokulich, N. A. &amp; Mills, D. A. Improved selection of internal transcribed spacer-specific primers enables quantitative, ultra-high-throughput profiling of fungal communities. Appl Environ Microbiol 79, 2519-2526, doi:10.1128/AEM.03870-12 (2013).PMC3623200
51    Nilsson, R. H. et al. The UNITE database for molecular identification of fungi: handling dark taxa and parallel taxonomic classifications. Nucleic Acids Res. 47, D259-D264, doi:10.1093/nar/gky1022 (2019).PMC6324048
52    Murphy, K. et al. Levels of Genital Tract Defensins and Cytokines Differ between HIV-Uninfected US and African Women. Am J Reprod Immunol 74, 313-322, doi:10.1111/aji.12411 (2015).PMC4573314
53    Jais, M., Younes, N., Chapman, S., Cu-Uvin, S. &amp; Ghosh, M. Reduced levels of genital tract immune biomarkers in postmenopausal women: implications for HIV acquisition. Am J Obstet Gynecol 215, 324 e321-324 e310, doi:10.1016/j.ajog.2016.03.041 (2016)
54    Wira, C. R. &amp; Fahey, J. V. A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle. Aids 22, 1909-1917, doi:10.1097/QAD.0b013e3283060ea4 (2008).2647143
55    Gajer, P. et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4, 132ra152, doi:10.1126/scitranslmed.3003605 (2012)
56    Maybin, J. A. &amp; Critchley, H. O. Progesterone: a pivotal hormone at menstruation. Ann N Y Acad Sci 1221, 88-97, doi:10.1111/j.1749-6632.2011.05953.x (2011)
57    Gierahn, T. M. et al. Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. Nat Methods 14, 395-398, doi:10.1038/nmeth.4179 (2017).PMC5376227
58    Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res 43, D447-452, doi:10.1093/nar/gku1003 (2015).PMC4383874
59    Moignard, V. et al. Characterization of transcriptional networks in blood stem and progenitor cells using high-throughput single-cell gene expression analysis. Nat Cell Biol 15, 363-372, doi:10.1038/ncb2709 (2013).PMC3796878
60    Rohart, F., Gautier, B., Singh, A. &amp; Le Cao, K. A. mixOmics: An R package for 'omics feature selection and multiple data integration. Plos Comput Biol 13, doi:ARTN e100575210.1371/journal.pcbi.1005752 (2017)
61    Basu, S., Kumbier, K., Brown, J. B. &amp; Yu, B. Iterative random forests to discover predictive and stable high-order interactions. P Natl Acad Sci USA 115, 1943-1948, doi:10.1073/pnas.1711236115 (2018)
62    Walker, A. M. et al. Evaluating the performance of random forest and iterative random forest based methods when applied to gene expression data. Comput Struct Biotec 20, 3372-3386, doi:10.1016/j.csbj.2022.06.0372001-0370 (2022)
63    Cohen, C. R. et al. Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med 382, 1906-1915, doi:10.1056/NEJMoa1915254 (2020).PMC7362958
64    Callahan, B. J., Sankaran, K., Fukuyama, J. A., McMurdie, P. J. &amp; Holmes, S. P. Bioconductor Workflow for Microbiome Data Analysis: from raw reads to community analyses. F1000Res 5, 1492, doi:10.12688/f1000research.8986.2 (2016).PMC4955027
65    Hastie, T., Tibshirani, R. &amp; Friedman, J. H. The elements of statistical learning : data mining, inference, and prediction. 2nd edn,  (Springer, 2009).
66    Zhang, Z. et al. Signal recovery in single cell batch integration. bioRxiv, doi:10.1101/2023.05.05.539614 (2023).PMC10197537
67    Gagnon-Bartsch, J. A. &amp; Speed, T. P. Using control genes to correct for unwanted variation in microarray data. Biostatistics 13, 539-552, doi:10.1093/biostatistics/kxr034 (2012)
68    Wang, J. S., Zhao, Q. Y., Hastie, T. &amp; Owen, A. B. Confounder Adjustment in Multiple Hypothesis Testing. Ann Stat 45, 1863-1894, doi:10.1214/16-Aos1511 (2017)
69    Dekermanjian, J. P., Shaddox, E., Nandy, D., Ghosh, D. &amp; Kechris, K. Mechanism-aware imputation: a two-step approach in handling missing values in metabolomics. BMC Bioinformatics 23, 179, doi:10.1186/s12859-022-04659-1 (2022).PMC9109373
70    McCarthy, D. J., Campbell, K. R., Lun, A. T. &amp; Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179-1186, doi:10.1093/bioinformatics/btw777 (2017).PMC5408845
71    David, L. A. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505, 559-563, doi:10.1038/nature12820 (2014).PMC3957428
72    Sankaran, K. &amp; Holmes, S. P. Multitable Methods for Microbiome Data Integration. Front Genet 10, doi:ARTN 62710.3389/fgene.2019.00627 (2019)
73    Rappoport, N. &amp; Shamir, R. Multi-omic and multi-view clustering algorithms: review and cancer benchmark (vol 46, pg 10546, 2018). Nucleic Acids Res 47, 1044-1044, doi:10.1093/nar/gky1226 (2019)
74    Misra, B. B., Langefeld, C., Olivier, M. &amp; Cox, L. A. Integrated omics: tools, advances and future approaches. J Mol Endocrinol 62, R21-R45, doi:10.1530/Jme-18-0055 (2019)
75    Stokholm, J. et al. Maturation of the gut microbiome and risk of asthma in childhood (vol 9, 2018). Nat Commun 9, doi:ARTN 70410.1038/s41467-018-03150-x (2018)
76    Liu, Z. G. et al. Gut microbiota mediates intermittent-fasting alleviation of diabetes-induced cognitive impairment. Nat Commun 11, doi:ARTN 85510.1038/s41467-020-14676-4 (2020)
77    Bergamaschi, L. et al. Longitudinal analysis reveals that delayed bystander CD8(+) T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity 54, 1257-+, doi:10.1016/j.immuni.2021.05.010 (2021)
78    Pfister, N., Williams, E. G., Peters, J., Aebersold, R. &amp; Buhlmann, P. Stabilizing Variable Selection and Regression. Ann Appl Stat 15, 1220-1246, doi:10.1214/21-Aoas1487 (2021)
79    Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat Methods 12, 115-121, doi:10.1038/Nmeth.3252 (2015)
80    Stodden, V., Leisch, F. &amp; Peng, R. D. Implementing reproducible research.  (CRC Press, Taylor &amp; Francis Group, 2014).
81    Xie, Y., Allaire, J. J. &amp; Grolemund, G.     1 online resource (CRC Press, Taylor and Francis Group,, Boca Raton, 2019).
82    Ma, S. et al. A statistical model for describing and simulating microbial community profiles. Plos Comput Biol 17, e1008913, doi:10.1371/journal.pcbi.1008913 (2021).PMC8491899
83    Risso, D., Perraudeau, F., Gribkova, S., Dudoit, S. &amp; Vert, J. P. A general and flexible method for signal extraction from single-cell RNA-seq data. Nat Commun 9, 284, doi:10.1038/s41467-017-02554-5 (2018).PMC5773593
84    Calgaro, M., Romualdi, C., Waldron, L., Risso, D. &amp; Vitulo, N. Assessment of statistical methods from single cell, bulk RNA-seq, and metagenomics applied to microbiome data. Genome Biol 21, 191, doi:10.1186/s13059-020-02104-1 (2020).PMC7398076
85    Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668, doi:10.1126/science.1188302 (2010).PMC8335790
86    Jalili-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic intestine-on-a-chip. Nat Biomed Eng 3, 520-531, doi:10.1038/s41551-019-0397-0 (2019).PMC6658209
87    Kim, H. J., Huh, D., Hamilton, G. &amp; Ingber, D. E. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12, 2165-2174, doi:10.1039/c2lc40074j (2012)
88    Kim, H. J., Li, H., Collins, J. J. &amp; Ingber, D. E. Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc Natl Acad Sci U S A 113, E7-15, doi:10.1073/pnas.1522193112 (2016).PMC4711860
89    Ingber, D. E. Is it Time for Reviewer 3 to Request Human Organ Chip Experiments Instead of Animal Validation Studies? Adv Sci (Weinh) 7, 2002030, doi:10.1002/advs.202002030 (2020).PMC7675190
90    Gazzaniga, F. S. et al. Harnessing Colon Chip Technology to Identify Commensal Bacteria That Promote Host Tolerance to Infection. Front Cell Infect Microbiol 11, 638014, doi:10.3389/fcimb.2021.638014 (2021).PMC7996096
91    Brainard, D. M. et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 83, 7305-7321, doi:JVI.02207-08 [pii]10.1128/JVI.02207-08 (2009)
92    Deruaz, M. et al. Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo. J Infect Dis 214, 612-616, doi:10.1093/infdis/jiw203 (2016).PMC4957443
93    Deruaz, M. &amp; Tager, A. M. Humanized mouse models of latent HIV infection. Curr Opin Virol 25, 97-104, doi:10.1016/j.coviro.2017.07.027 (2017)</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>This is an excellent, well-designed grant. The multi-omics approach combined with the FRESH cohort's unique longitudinal pre-seroconversion samples is powerful. Let me provide a critical assessment and recommendations.</p>
<h2>Overall Assessment</h2>
<p><strong>Strengths:</strong>
- Exceptional sample resource (3600 samples, 102 seroconverters)
- Strong preliminary data supporting the central hypothesis
- Excellent integration of discovery (Aim 1) and validation (Aim 2)
- Innovative model systems (V-Chip, organoids, humanized mice)
- Strong biostatistics/integration plan</p>
<p><strong>Areas for Enhancement:</strong></p>
<hr />
<h2>Recommended Changes to Approach</h2>
<h3>1. 16S Sequencing Strategy: Add cpn60</h3>
<p>Your current plan uses only 16S V4 (515F-806R). This is limiting for your key taxa:</p>
<p><strong>Problem:</strong> 16S V4 cannot reliably distinguish:
- Gardnerella species (G. vaginalis, G. leopoldii, G. swidsinskii, G. piotii) - all &gt;98.5% identical
- Lactobacillus species resolution is marginal
- Your preliminary data shows Gardnerella subgroups matter (Fig. 1, 4)</p>
<p><strong>Recommendation:</strong> Add cpn60 amplicon sequencing on a subset or all samples</p>
<pre><code>Current:     16S V4 (all 3600 samples)
             ↓
Proposed:    16S V4 (all 3600 samples) + cpn60 (all or subset)
             ↓
Benefit:     Gardnerella species-level resolution
             Better Lactobacillus discrimination
             Validation of metagenomic strain calls
</code></pre>
<p>This complements rather than replaces your metagenomic StrainPhlAn analysis, providing an independent validation layer.</p>
<hr />
<h3>2. Absolute Quantification Gap</h3>
<p><strong>Problem:</strong> Your current approach generates only relative abundance data from 16S. You state that CT3/CT4 communities increase HIV risk, but you can't distinguish:
- True increase in inflammatory bacteria
- Decrease in total Lactobacillus (with same absolute anaerobe load)
- Overall bacterial load differences</p>
<p><strong>Recommendation:</strong> Add quantitative component</p>
<p><strong>Option A: qPCR panel (recommended)</strong></p>
<pre><code>Targets:
- Total bacterial load (universal 16S)
- L. crispatus (species-specific)
- L. iners (species-specific)  
- Gardnerella (genus or species)
- Total Lactobacillus

Run on all samples: ~$15-20/sample additional
</code></pre>
<p><strong>Option B: Spike-in standards</strong>
- Add synthetic DNA spike-ins before extraction
- Enables conversion of relative → absolute from existing sequencing
- <a href="https://academic.oup.com/ismecommun/article/5/1/ycaf028/8008921">Recent 2025 methods</a> show this works well</p>
<p>This is fundable as a minor budget addition and addresses a key mechanistic question.</p>
<hr />
<h3>3. Functional Gene Amplicons: Missing Opportunity</h3>
<p>Your preliminary data (Fig. 10) identifies specific mechanistic candidates:
- LPS/TLR4 signaling in APCs
- Biogenic amines (putrescine, cadaverine)</p>
<p><strong>Problem:</strong> You're relying entirely on metagenomics/metatranscriptomics for functional readouts. These are expensive and may miss strain-level variation in key genes.</p>
<p><strong>Recommendation:</strong> Add targeted functional gene amplicons</p>
<p>Based on your hypotheses and preliminary data, I recommend these specific genes:</p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target organism(s)</th>
<th>Rationale from your data</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong> (sialidase)</td>
<td>Gardnerella, Prevotella</td>
<td>Mucin degradation, epithelial barrier disruption - directly relevant to HIV target cell exposure</td>
</tr>
<tr>
<td><strong>vly</strong> (vaginolysin)</td>
<td>Gardnerella</td>
<td>Cytolysin causing epithelial damage - your APC TLR4 data suggests PAMP sensing</td>
</tr>
<tr>
<td><strong>ily</strong> (inerolysin)</td>
<td>L. iners</td>
<td>Distinguishes "good" vs "bad" Lactobacillus - L. iners is 28% of your cohort</td>
</tr>
<tr>
<td><strong>speA/speB</strong> (ornithine decarboxylase)</td>
<td>Multiple BV-associated</td>
<td>Putrescine synthesis - you identified this in metabolomics (Fig. 10A)</td>
</tr>
<tr>
<td><strong>ldcC</strong> (lysine decarboxylase)</td>
<td>Enterobacteriaceae, others</td>
<td>Cadaverine synthesis - also in your Fig. 10A</td>
</tr>
<tr>
<td><strong>ldhD</strong> (D-lactate dehydrogenase)</td>
<td>L. crispatus</td>
<td>Protective D-lactic acid - mechanistic marker of CT1</td>
</tr>
</tbody>
</table>
<p><strong>Why this matters:</strong>
- Direct PCR quantification of functional genes is cheaper than metatranscriptomics
- Captures strain-level variation (not all Gardnerella have equal sialidase activity)
- Provides validation targets for your model systems
- Can be run on all 3600 samples affordably</p>
<hr />
<h3>4. UMI-Based Error Correction for Strain Work</h3>
<p><strong>Problem:</strong> You're planning StrainPhlAn for strain-level analysis from metagenomics. This works but has limitations with strain mixtures and low-abundance strains.</p>
<p><strong>Recommendation:</strong> For your cpn60 amplicons (if added), use UMI-tagged primers</p>
<pre><code>Standard cpn60:     [Primer]--[cpn60 target]--[Primer]

UMI-tagged cpn60:   [Primer]-[UMI]--[cpn60 target]--[UMI]-[Primer]
                              ↓
                    Enables true strain deconvolution
                    Eliminates PCR chimeras (&lt;0.02% rate)
                    Provides molecule counting (absolute)
</code></pre>
<p>This is particularly valuable for your L. crispatus geographic strain analysis (Fig. 3) - UMIs would let you confidently call strain mixtures within samples.</p>
<hr />
<h3>5. Host DNA Contamination Strategy</h3>
<p><strong>Problem:</strong> FGT samples are host-heavy. You mention DeconSeq for metagenomics, but no strategy for amplicon work.</p>
<p><strong>Recommendation:</strong> Add PNA blocking oligos for 16S</p>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/39875992/">Recent 2025 data</a> shows PNA clamps against human mitochondrial 16S reduce host contamination by 46-99%. This increases effective bacterial read depth without additional sequencing cost.</p>
<hr />
<h3>6. South African Reference Database Gap</h3>
<p><strong>Critical issue not addressed in grant:</strong> Your strain-level analyses rely on existing databases (GreenGenes, MetaPhlAn, cpnDB), which are heavily biased toward North American/European populations.</p>
<p>Your Fig. 3 already shows geographic strain structure. You're likely missing population-specific taxa.</p>
<p><strong>Recommendation:</strong> Add explicit aim or sub-aim for reference building</p>
<pre><code>From your culturomics (600 isolates):
├── Whole genome sequence all isolates
├── Extract 16S, cpn60, rpoB, functional genes
├── Build FRESH reference database
├── Deposit publicly (major contribution to field)
└── Use for improved taxonomic assignment
</code></pre>
<p>This transforms your culturomics from a validation resource into a discovery resource.</p>
<hr />
<h2>Revised Technical Approach</h2>
<p>Here's how I'd restructure Aim 1.1:</p>
<pre><code>┌────────────────────────────────────────────────────────────────────────┐
│                    REVISED AIM 1.1 APPROACH                            │
├────────────────────────────────────────────────────────────────────────┤
│                                                                        │
│  TIER 1: All 3600 samples                                              │
│  ├── 16S V4 amplicon (cross-study compatibility)        [current]     │
│  ├── cpn60 amplicon (species resolution)                [ADD]         │
│  ├── qPCR panel (absolute quantification)               [ADD]         │
│  │   └── Total bacteria, L. crispatus, L. iners, Gardnerella          │
│  ├── ITS2 amplicon (fungi)                              [current]     │
│  └── Metabolomics                                       [current]     │
│                                                                        │
│  TIER 2: Subset (n=500-1000, prioritized)                             │
│  ├── Metagenomics                                       [current]     │
│  ├── Metatranscriptomics                                [current]     │
│  └── Functional gene amplicons                          [ADD]         │
│      └── nanH, vly, ily, speA/ldcC, ldhD                              │
│                                                                        │
│  TIER 3: Discovery subset (n=100-200)                                  │
│  ├── Seq-Well scRNAseq                                  [current]     │
│  └── Deep metagenomics for MAG recovery                 [ENHANCE]     │
│                                                                        │
│  REFERENCE BUILDING: From culturomics                                  │
│  ├── WGS all 600 isolates                               [current]     │
│  ├── Build South African FGT reference database         [ADD]         │
│  └── Public deposition                                  [ADD]         │
│                                                                        │
└────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Functional Genes: Final Recommendations</h2>
<p>Based on your specific hypotheses and preliminary data, here's my prioritized list:</p>
<h3>Must Include (directly supported by your data):</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Why (from your grant)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong> (sialidase)</td>
<td>Gardnerella virulence factor; mucin degradation exposes epithelium; multiple variants exist</td>
</tr>
<tr>
<td><strong>vly</strong> (vaginolysin)</td>
<td>Your APC data shows TLR4/LPS pathway activation; vaginolysin causes epithelial lysis releasing PAMPs</td>
</tr>
<tr>
<td><strong>speA/odc</strong> (ornithine decarboxylase)</td>
<td>Putrescine synthesis - you identified this metabolite as elevated in CT3/4 (Fig 10A)</td>
</tr>
<tr>
<td><strong>ldcC</strong> (lysine decarboxylase)</td>
<td>Cadaverine synthesis - same rationale</td>
</tr>
<tr>
<td><strong>ldhD</strong> (D-LDH)</td>
<td>L. crispatus marker; D-lactate is protective; distinguishes from L. iners</td>
</tr>
</tbody>
</table>
<h3>Strongly Consider:</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ily</strong> (inerolysin)</td>
<td>L. iners-specific cytolysin; L. iners is your CT2 (28% of cohort); strain variation matters</td>
</tr>
<tr>
<td><strong>hdc</strong> (histidine decarboxylase)</td>
<td>Histamine production - inflammatory; biogenic amine pathway</td>
</tr>
<tr>
<td><strong>prtS/prtP</strong> (proteases)</td>
<td>Prevotella tissue degradation; your data shows P. bivia, P. melaninogenica in HIV+</td>
</tr>
</tbody>
</table>
<h3>Lower Priority but Interesting:</h3>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>bsh</strong> (bile salt hydrolase)</td>
<td>Metabolic activity marker</td>
</tr>
<tr>
<td><strong>tetM/ermB</strong></td>
<td>AMR genes - not in your hypotheses but opportunistic data collection</td>
</tr>
</tbody>
</table>
<hr />
<h2>Budget Implications</h2>
<p>Rough cost additions for a 3600-sample study:</p>
<table>
<thead>
<tr>
<th>Addition</th>
<th>Per sample</th>
<th>Total</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpn60 amplicon</td>
<td>~$30-40</td>
<td>~$120K</td>
<td>Can multiplex with 16S</td>
</tr>
<tr>
<td>qPCR panel (5 targets)</td>
<td>~$15-20</td>
<td>~$60K</td>
<td>Could do subset</td>
</tr>
<tr>
<td>Functional amplicons (6 genes)</td>
<td>~$40-50</td>
<td>~$150K</td>
<td>On metagenomics subset only</td>
</tr>
<tr>
<td>UMI-tagged primers</td>
<td>~$5</td>
<td>~$18K</td>
<td>Marginal cost</td>
</tr>
<tr>
<td>Spike-in standards</td>
<td>~$2</td>
<td>~$7K</td>
<td>One-time synthesis + per-sample</td>
</tr>
</tbody>
</table>
<p><strong>Total addition: ~$200-350K depending on scope</strong></p>
<p>This is fundable within an R01 budget, especially if you tier the approach (all samples get qPCR + cpn60, subset gets functional amplicons).</p>
<hr />
<h2>Questions for You</h2>
<ol>
<li>
<p><strong>Budget flexibility?</strong> The additions I'm suggesting add $200-350K. Is there room, or should I prioritize?</p>
</li>
<li>
<p><strong>Metagenomics on all samples?</strong> Your grant says 100M reads per sample on all 3600. That's enormous (~$500/sample × 3600 = $1.8M just for metagenomics). Is this accurate, or is metagenomics on a subset? If subset, cpn60 becomes even more important for comprehensive coverage.</p>
</li>
<li>
<p><strong>Timeline for culturomics?</strong> If your 600 isolates are sequenced early, they can inform your functional gene primer design. Is this feasible?</p>
</li>
<li>
<p><strong>Interest in making the reference database a formal deliverable?</strong> This could be a significant contribution to the field and would strengthen the grant's impact statement.</p>
</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-003.html#msg-2025-12-14T22-59-37-051Z"><div class="index-item-header"><span class="index-item-number">#15</span><time datetime="2025-12-14T22:59:37.051Z" data-timestamp="2025-12-14T22:59:37.051Z">2025-12-14T22:59:37.051Z</time></div><div class="index-item-content"><p>we already have the zymogen spike-in, 16S v4 primers (the earth microbiome ones) and a V1-V3 validated primer set we obtrained from Jacuqe Ravell. One of the reasons I am having this discussion with you is to work on cost reduction. I would like to implement the highest quality, most data rich approach that DOES NOT require any metagenomic sequencing. We will do some low pass metagenomics on sample subsets with a colleauge, but I want my lab to innovate on multi-gene amplicon surveys and the targetted functional assays with novel tech and informatic dev</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Now I understand your vision much better. You want to build a <strong>next-generation amplicon platform</strong> that extracts metagenomic-level insights without metagenomics costs. This is a compelling technical innovation space.</p>
<h2>Reframed Goal</h2>
<p><strong>Build a multi-amplicon platform that delivers:</strong>
- Species/strain-level taxonomic resolution
- Functional gene quantification
- Absolute abundance
- Cross-study compatibility</p>
<p><strong>Without:</strong>
- Metagenomics costs ($300-500/sample)
- Massive sequencing depth
- Complex assembly pipelines</p>
<hr />
<h2>The Platform Architecture</h2>
<pre><code>┌─────────────────────────────────────────────────────────────────────────┐
│           MULTI-AMPLICON FGT PROFILING PLATFORM                        │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  EXISTING ASSETS                                                        │
│  ├── 16S V4 (515F/806R) - Earth Microbiome Project                     │
│  ├── 16S V1-V3 (Ravel validated)                                       │
│  ├── Zymo spike-ins (absolute quantification)                          │
│  └── ITS2 (fungal - already running)                                   │
│                                                                         │
│  NEW DEVELOPMENT                                                        │
│  ├── cpn60 UT (species resolution, Gardnerella)                        │
│  ├── rpoB (orthogonal validation, Lactobacillus)                       │
│  └── Functional gene panel (mechanistic readouts)                      │
│                                                                         │
│  NOVEL TECH/INFORMATICS                                                 │
│  ├── UMI integration for strain deconvolution                          │
│  ├── Multi-marker taxonomic concordance                                │
│  ├── Functional scoring algorithms                                     │
│  └── South African reference database                                  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Amplicon Selection: Final Recommendations</h2>
<h3>Taxonomic Amplicons</h3>
<table>
<thead>
<tr>
<th>Amplicon</th>
<th>Status</th>
<th>Purpose</th>
<th>Innovation opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>Have</td>
<td>Cross-study compatibility</td>
<td>None needed</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>Have (Ravel)</td>
<td>Lactobacillus resolution</td>
<td>None needed</td>
</tr>
<tr>
<td>cpn60 UT</td>
<td>Need primers</td>
<td>Gardnerella species, strain hints</td>
<td>UMI-tagged version</td>
</tr>
<tr>
<td>rpoB</td>
<td>Need primers</td>
<td>Orthogonal validation</td>
<td>DPO design for specificity</td>
</tr>
</tbody>
</table>
<p><strong>Why rpoB in addition to cpn60?</strong>
- Independent validation (if cpn60 and rpoB disagree, you've found something interesting)
- Better Lactobacillus resolution than cpn60 in some cases
- Less database bias (you'll build your own reference)
- The <a href="https://journals.asm.org/doi/10.1128/jcm.00266-24">2024 JCM paper</a> shows ~550bp amplicon with excellent species discrimination</p>
<h3>Functional Gene Amplicons</h3>
<p>Based on your grant's mechanistic hypotheses, here's my curated list:</p>
<p><strong>Tier 1: Must have (directly from your preliminary data)</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Your data support</th>
<th>Primer status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH1/nanH2</strong></td>
<td>Gardnerella sialidases</td>
<td>Mucin degradation → epithelial exposure → HIV target cells</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>vly</strong></td>
<td>Gardnerella vaginolysin</td>
<td>APC TLR4 activation (Fig 10B); PAMP release</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>speA/odc</strong></td>
<td>Multiple (ornithine decarboxylase)</td>
<td>Putrescine elevated in CT3/4 (Fig 10A)</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldcC</strong></td>
<td>Multiple (lysine decarboxylase)</td>
<td>Cadaverine elevated in CT3/4 (Fig 10A)</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldhD</strong></td>
<td>L. crispatus D-LDH</td>
<td>Protective D-lactate; mechanistic marker of CT1</td>
<td>Need design</td>
</tr>
</tbody>
</table>
<p><strong>Tier 2: Strong biological rationale</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Rationale</th>
<th>Primer status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ily</strong></td>
<td>L. iners inerolysin</td>
<td>L. iners is 28% of cohort; strain variation in cytolysin activity matters</td>
<td>Need design</td>
</tr>
<tr>
<td><strong>ldhL</strong></td>
<td>All Lactobacillus L-LDH</td>
<td>L-lactate (less protective than D); ratio to ldhD informative</td>
<td>Need design</td>
</tr>
</tbody>
</table>
<p><strong>Tier 3: Consider</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Target</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>hdc</strong></td>
<td>Histidine decarboxylase</td>
<td>Histamine production; inflammatory</td>
</tr>
<tr>
<td><strong>aguA</strong></td>
<td>Agmatine deiminase</td>
<td>Polyamine pathway; complements speA/ldcC</td>
</tr>
<tr>
<td><strong>prtS</strong></td>
<td>Prevotella proteases</td>
<td>Tissue degradation; P. bivia in your HIV+ samples</td>
</tr>
</tbody>
</table>
<hr />
<h2>The Innovation Layer</h2>
<p>Here's where your lab differentiates:</p>
<h3>1. UMI-Tagged Amplicons for Strain Deconvolution</h3>
<pre><code>Standard amplicon workflow:
  Sample → PCR → Sequence → ASVs → Can't resolve strain mixtures

UMI workflow:
  Sample → PCR with UMI primers → Sequence → Group by UMI → Consensus per molecule
         ↓
  True molecule counting (absolute)
  Strain mixture deconvolution
  PCR chimera elimination
  PCR bias correction
</code></pre>
<p><strong>Apply to:</strong> cpn60, rpoB (your strain-resolution amplicons)</p>
<p><strong>Innovation:</strong> Nobody has done UMI-tagged cpn60 for vaginal microbiome. This is publishable methods work.</p>
<h3>2. Multi-Marker Taxonomic Integration</h3>
<pre><code>Current state of field:
  16S → taxonomy
  Done.

Your innovation:
  16S V4    ─┐
  16S V1-V3 ─┼─→ Concordance analysis ─→ Confidence-weighted taxonomy
  cpn60     ─┤                         ─→ Novel taxa flagging
  rpoB      ─┘                         ─→ Database gap identification
</code></pre>
<p><strong>Informatics development:</strong>
- Concordance scoring: Do all markers agree? If not, why?
- Weighted consensus: Trust cpn60 for Gardnerella, V1-V3 for Lactobacillus
- Discordance flagging: Samples where markers disagree get prioritized for your collaborator's metagenomics</p>
<h3>3. Functional Scoring from Amplicons</h3>
<p>This is the killer innovation. Instead of metagenomics for functional inference, you directly measure:</p>
<pre><code>Inflammation Potential Score = f(nanH, vly, speA, ldcC, hdc)

Protection Score = f(ldhD, total_Lactobacillus, L.crispatus_abundance)

Risk Index = Inflammation_Score / Protection_Score
</code></pre>
<p><strong>Validation:</strong> Correlate with your Luminex cytokine data, CD4+ T cell counts, and ultimately HIV acquisition.</p>
<p><strong>This becomes a predictive biomarker panel</strong> - clinically translatable, deployable in Durban.</p>
<h3>4. South African Reference Database</h3>
<p>Your culturomics (600 isolates) + amplicon data = population-specific reference</p>
<pre><code>From each isolate:
├── Full 16S (Sanger or long-read)
├── Full cpn60
├── Full rpoB  
├── Functional genes present/absent
└── Phenotypic characterization

Output:
├── FRESH-DB: South African FGT reference
├── Primer validation against local strains
├── Novel taxa documentation
└── Public resource (citable, impactful)
</code></pre>
<hr />
<h2>Cost Model</h2>
<p>Let's price this out for 3600 samples:</p>
<h3>Sequencing Costs (per sample)</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Reads needed</th>
<th>Cost estimate</th>
</tr>
</thead>
<tbody>
<tr>
<td>16S V4</td>
<td>50K</td>
<td>Already budgeted</td>
</tr>
<tr>
<td>16S V1-V3</td>
<td>50K</td>
<td>~$10-15</td>
</tr>
<tr>
<td>cpn60 + UMI</td>
<td>50K</td>
<td>~$15-20</td>
</tr>
<tr>
<td>rpoB</td>
<td>30K</td>
<td>~$8-12</td>
</tr>
<tr>
<td>Functional panel (6-8 genes)</td>
<td>100K total</td>
<td>~$20-30</td>
</tr>
<tr>
<td><strong>Total per sample</strong></td>
<td></td>
<td><strong>~$55-75 additional</strong></td>
</tr>
</tbody>
</table>
<h3>Multiplexing Strategy</h3>
<p>You can dramatically reduce costs by pooling:</p>
<pre><code>Option A: Separate libraries, pooled sequencing
├── More flexible
├── Easier troubleshooting
├── Higher cost

Option B: Multiplexed PCR pools
├── Pool 1: 16S V4 + V1-V3 (same gene, different regions)
├── Pool 2: cpn60 + rpoB (both ~500bp, bacteria-specific)
├── Pool 3: Functional genes (all ~300-500bp)
├── Lower cost
├── Requires careful primer design to avoid cross-reactivity
</code></pre>
<h3>Total Platform Cost Estimate</h3>
<table>
<thead>
<tr>
<th>Item</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer synthesis (including UMI versions)</td>
<td>~$5-10K</td>
</tr>
<tr>
<td>Validation/optimization</td>
<td>~$20-30K</td>
</tr>
<tr>
<td>3600 samples × $60/sample (new amplicons)</td>
<td>~$216K</td>
</tr>
<tr>
<td>Spike-in calibration</td>
<td>Using Zymo (have)</td>
</tr>
<tr>
<td>Bioinformatics development</td>
<td>Personnel time</td>
</tr>
<tr>
<td><strong>Total new costs</strong></td>
<td><strong>~$250K</strong></td>
</tr>
</tbody>
</table>
<p>Compare to metagenomics on 3600 samples: <strong>$1.5-2M+</strong></p>
<hr />
<h2>Primer Design Strategy</h2>
<h3>For Published Primers (cpn60)</h3>
<p><strong>cpn60 UT primers (H279p/H280p from Hill lab):</strong></p>
<pre><code>H279p: 5'-GAIIIIGCIGGIGAYGGIACIACIAC-3'
H280p: 5'-YKIYKITCICCRAAICCIGGIGCYTT-3'
</code></pre>
<p><strong>Enhancement:</strong> Add UMI + Illumina adapter tails</p>
<pre><code>UMI-H279p: 5'-[Illumina adapter]-[8N UMI]-GAIIIIGCIGGIGAYGGIACIACIAC-3'
UMI-H280p: 5'-[Illumina adapter]-[8N UMI]-YKIYKITCICCRAAICCIGGIGCYTT-3'
</code></pre>
<h3>For De Novo Design (functional genes)</h3>
<p><strong>Workflow:</strong>
1. Download all available sequences for target gene from NCBI/UniProt
2. Include your isolate sequences as they become available
3. Align with MUSCLE/MAFFT
4. Use DegePrime or ARDEP for degenerate primer design
5. Validate coverage in silico against FGT taxa
6. Consider DPO format for specificity</p>
<p><strong>Example: nanH (sialidase)</strong></p>
<pre><code>Multiple nanH variants exist:
├── nanH1 (Gardnerella vaginalis type)
├── nanH2 (Gardnerella other species)
├── nanH3 (Prevotella)

Design strategy:
├── Conserved regions that capture all variants? OR
├── Variant-specific primers for each?

Recommendation: Start with broad capture, resolve computationally
</code></pre>
<hr />
<h2>Bioinformatics Pipeline Architecture</h2>
<pre><code>┌─────────────────────────────────────────────────────────────────────────┐
│                    MULTI-AMPLICON ANALYSIS PIPELINE                     │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  INPUT: Multiplexed amplicon reads                                      │
│         ↓                                                               │
│  DEMULTIPLEXING                                                         │
│  ├── By sample (dual index)                                            │
│  ├── By amplicon (primer sequence)                                     │
│  └── By molecule (UMI, for cpn60/rpoB)                                 │
│         ↓                                                               │
│  AMPLICON-SPECIFIC PROCESSING                                           │
│  ├── 16S V4: DADA2 → GreenGenes2                                       │
│  ├── 16S V1-V3: DADA2 → SILVA + custom Lactobacillus DB                │
│  ├── cpn60: UMI consensus → cpnDB + FRESH-DB                           │
│  ├── rpoB: UMI consensus → Custom DB (build from isolates)             │
│  └── Functional: Quantify → Normalize to spike-in                      │
│         ↓                                                               │
│  INTEGRATION                                                            │
│  ├── Taxonomic concordance scoring                                     │
│  ├── Spike-in normalization (absolute abundance)                       │
│  ├── Functional gene quantification                                    │
│  └── Composite scores (Inflammation, Protection, Risk)                 │
│         ↓                                                               │
│  OUTPUT                                                                 │
│  ├── Per-sample: Taxonomy + Absolute abundance + Functional scores     │
│  ├── Per-cohort: Integration with metadata, HIV outcomes               │
│  └── QC reports: Concordance, spike-in recovery, controls              │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
</code></pre>
<hr />
<h2>Development Phases</h2>
<pre><code>Phase 1: Primer Development (Months 1-4)
├── Obtain/synthesize cpn60 primers (+ UMI version)
├── Design rpoB primers (DPO format, + UMI version)
├── Design functional gene primers (nanH, vly, speA, ldcC, ldhD, ily)
├── In silico validation against databases
└── Order synthesis

Phase 2: Wet Lab Validation (Months 4-8)
├── Test on mock communities
├── Test on 50-100 archived FRESH samples with known 16S
├── Optimize multiplexing pools
├── Validate spike-in quantification
├── Compare to existing 16S V4 data
└── Establish SOPs

Phase 3: Pipeline Development (Months 4-10, parallel)
├── UMI processing module
├── Multi-marker integration
├── Concordance scoring
├── Functional quantification
├── FRESH-DB construction (as isolates are sequenced)
└── Visualization/reporting

Phase 4: Scale-up (Months 8-18)
├── Process all 3600 samples
├── Integrate with grant Aim 1.2 (host data)
├── Feed candidates to Aim 2 (model systems)
└── Publish methods paper

Phase 5: Refinement (Ongoing)
├── Update FRESH-DB with new isolates
├── Iterate functional scoring based on outcomes
├── Develop field-deployable qPCR version
</code></pre>
<hr />
<h2>Questions to Finalize</h2>
<ol>
<li><strong>Sequencing platform preference?</strong> </li>
<li>Illumina MiSeq/NovaSeq for short-read multiplexed amplicons?</li>
<li>
<p>Interest in Nanopore/PacBio for full-length cpn60/rpoB? (higher cost, simpler bioinformatics)</p>
</li>
<li>
<p><strong>Functional gene priorities?</strong> </p>
</li>
<li>My Tier 1 (nanH, vly, speA, ldcC, ldhD) = 5 genes</li>
<li>Add ily and ldhL? = 7 genes</li>
<li>
<p>This affects multiplexing complexity</p>
</li>
<li>
<p><strong>UMI on all amplicons or just cpn60/rpoB?</strong></p>
</li>
<li>Full UMI adds cost and complexity</li>
<li>
<p>Could be selective (strain-resolution amplicons only)</p>
</li>
<li>
<p><strong>Timeline for isolate WGS?</strong></p>
</li>
<li>If early, informs primer design</li>
<li>
<p>If later, primers designed from public databases, validated against your strains</p>
</li>
<li>
<p><strong>Interest in methods publication?</strong></p>
</li>
<li>"A multi-amplicon platform for high-resolution FGT microbiome profiling"</li>
<li>Could be companion to your main findings papers</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-004.html#msg-2025-12-14T23-07-53-811Z"><div class="index-item-header"><span class="index-item-number">#16</span><time datetime="2025-12-14T23:07:53.811Z" data-timestamp="2025-12-14T23:07:53.811Z">2025-12-14T23:07:53.811Z</time></div><div class="index-item-content"><p>We have access to the iSeq and NovaSeq. I am not quite as interested in Nanopore or pacbio due to costs and the lower quality of our nucleic acid. Can you give a pros and cons for the UMI. Yes I am interested in publication and also potential an R21 application. In particular the PCR based approaches might find use in LMIC. However, I do not want to sacrifice what we can do in the US and still want advancements towards higher cost solutions that i can compelte in my lab. But hopefully there is an overlap between high-income and LMIC solutions here. Also what can we do with current publically available data and not rely on   - Less database bias (you'll build your own reference)</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><h2>UMI Analysis: Pros and Cons for Your Application</h2>
<h3>What UMIs Actually Give You</h3>
<pre><code>Without UMI:
  Original molecules → PCR amplification → Sequencing
                            ↓
  10 copies of molecule A → 1000 reads (100x amplification)
  10 copies of molecule B → 100 reads (10x amplification)
                            ↓
  Relative abundance: 91% A, 9% B (WRONG - should be 50/50)

With UMI:
  Original molecules → Tag with unique barcode → PCR → Sequencing
                            ↓
  Molecule A-UMI1 → 100 reads → collapse to 1
  Molecule A-UMI2 → 150 reads → collapse to 1
  ...
  Molecule A-UMI10 → 80 reads → collapse to 1
  Molecule B-UMI1 → 10 reads → collapse to 1
  ...
  Molecule B-UMI10 → 12 reads → collapse to 1
                            ↓
  Count UMIs: 10 for A, 10 for B = 50/50 (CORRECT)
</code></pre>
<h3>Pros</h3>
<table>
<thead>
<tr>
<th>Benefit</th>
<th>Relevance to your project</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>True molecule counting</strong></td>
<td>Absolute quantification without qPCR</td>
<td>High - you have spike-ins, UMIs make them work better</td>
</tr>
<tr>
<td><strong>PCR bias correction</strong></td>
<td>GC-rich/poor sequences amplify differently</td>
<td>High - Gardnerella and Lactobacillus have different GC content</td>
</tr>
<tr>
<td><strong>Chimera elimination</strong></td>
<td>PCR chimeras are major problem in amplicon studies</td>
<td>High - your multi-gene approach compounds this risk</td>
</tr>
<tr>
<td><strong>Strain deconvolution</strong></td>
<td>Distinguish strain mixtures in same sample</td>
<td>Very high - your Fig 3 shows strain structure matters</td>
</tr>
<tr>
<td><strong>Error correction</strong></td>
<td>Consensus from multiple reads of same molecule</td>
<td>Medium - Illumina already high quality</td>
</tr>
<tr>
<td><strong>Low-template accuracy</strong></td>
<td>Critical when few molecules present</td>
<td>Medium - FGT generally high biomass</td>
</tr>
</tbody>
</table>
<h3>Cons</h3>
<table>
<thead>
<tr>
<th>Drawback</th>
<th>Mitigation</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increased sequencing depth needed</strong></td>
<td>Need ~10-25x coverage per UMI for consensus</td>
<td>Moderate - NovaSeq handles this</td>
</tr>
<tr>
<td><strong>More expensive primers</strong></td>
<td>~$50-100 more per primer pair</td>
<td>Low - one-time cost</td>
</tr>
<tr>
<td><strong>Bioinformatics complexity</strong></td>
<td>Need UMI processing pipeline</td>
<td>Moderate - tools exist (DADA2-UMI, AmpUMI)</td>
</tr>
<tr>
<td><strong>Reduced effective read depth</strong></td>
<td>Collapse reads → fewer data points</td>
<td>Moderate - offset by accuracy</td>
</tr>
<tr>
<td><strong>Requires higher input DNA</strong></td>
<td>Need enough molecules for UMI diversity</td>
<td>Low - FGT samples generally good</td>
</tr>
<tr>
<td><strong>Index hopping risk on NovaSeq</strong></td>
<td>UMIs can help detect this</td>
<td>Actually a pro</td>
</tr>
</tbody>
</table>
<h3>Recommendation: Tiered UMI Strategy</h3>
<pre><code>FULL UMI (worth the investment):
├── cpn60 - strain resolution is your goal
└── rpoB - orthogonal strain validation

NO UMI (not worth complexity):
├── 16S V4 - cross-study compatibility more important
├── 16S V1-V3 - species-level sufficient
└── Functional genes - presence/absence or relative quantity sufficient
</code></pre>
<p><strong>Rationale:</strong> UMIs add most value where you need <strong>strain-level precision</strong> and <strong>absolute molecule counting</strong>. For functional genes, you care about "is nanH present and at what level" - relative quantification normalized to spike-ins is sufficient.</p>
<h3>Cost Impact</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Without UMI</th>
<th>With UMI</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer synthesis</td>
<td>~$200/pair</td>
<td>~$300/pair</td>
<td>+$100</td>
</tr>
<tr>
<td>Sequencing depth needed</td>
<td>30-50K reads</td>
<td>100-150K reads</td>
<td>2-3x</td>
</tr>
<tr>
<td>Bioinformatics time</td>
<td>Standard</td>
<td>+20%</td>
<td>Personnel</td>
</tr>
</tbody>
</table>
<p>For cpn60 + rpoB only: <strong>~$200 primer cost + ~$10-15/sample additional sequencing</strong></p>
<hr />
<h2>High-Income vs. LMIC Overlap: The Dual-Use Design</h2>
<p>This is where your platform gets strategic. You can design a single primer/protocol foundation that scales in both directions:</p>
<pre><code>┌─────────────────────────────────────────────────────────────────────────┐
│                    DUAL-USE PLATFORM ARCHITECTURE                       │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│                        SHARED FOUNDATION                                │
│                    (Same primers, same targets)                         │
│                              │                                          │
│         ┌────────────────────┴────────────────────┐                    │
│         ▼                                         ▼                    │
│  ┌─────────────────────┐               ┌─────────────────────┐         │
│  │   HIGH-RESOURCE     │               │      LMIC           │         │
│  │   (Wash U, Ragon)   │               │   (Durban, etc.)    │         │
│  ├─────────────────────┤               ├─────────────────────┤         │
│  │                     │               │                     │         │
│  │ • Full multi-amplicon│              │ • Targeted qPCR     │         │
│  │   panel (6-8 genes) │               │   panel (4-6 targets)│        │
│  │ • UMI for strain    │               │ • Same primer       │         │
│  │   resolution        │               │   binding sites     │         │
│  │ • NovaSeq depth     │               │ • QuantStudio/CFX96 │         │
│  │ • Full bioinformatics│              │ • Simple Ct analysis│         │
│  │ • Research discovery │              │ • Clinical/field use│         │
│  │                     │               │                     │         │
│  │ Cost: ~$75-100/sample│              │ Cost: ~$15-25/sample│         │
│  │                     │               │                     │         │
│  └─────────────────────┘               └─────────────────────┘         │
│                                                                         │
│                        KEY INSIGHT:                                     │
│         Same primer binding sites enable both applications             │
│         Sequencing primers → qPCR primers with minimal redesign        │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘
</code></pre>
<h3>How This Works Technically</h3>
<p><strong>Design amplicon primers with qPCR in mind:</strong></p>
<pre><code>Amplicon primer (for sequencing):
5'-[Illumina adapter]-[optional UMI]-[GENE-SPECIFIC SEQUENCE]-3'
                                     ├─────────────────────┤
                                     This part = qPCR primer

qPCR primer (for LMIC):
5'-[GENE-SPECIFIC SEQUENCE]-3'
   └── Same binding site, no adapter/UMI

Probe (for qPCR):
5'-[FAM]-[Internal probe sequence]-[BHQ]-3'
         └── Designed within amplicon
</code></pre>
<p><strong>Result:</strong> Your sequencing validation directly validates LMIC qPCR performance.</p>
<hr />
<h2>Leveraging Public Data: What's Available Now</h2>
<p>You asked what you can do without building your own reference. Here's the landscape:</p>
<h3>Available Databases</h3>
<table>
<thead>
<tr>
<th>Database</th>
<th>Content</th>
<th>FGT coverage</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>cpnDB</strong></td>
<td>~29K cpn60 sequences</td>
<td>Good for common taxa</td>
<td>Canadian/European bias; certificate expired (maintenance?)</td>
</tr>
<tr>
<td><strong>VOGUE</strong></td>
<td>Vaginal cpn60 reference</td>
<td>Excellent for vaginal</td>
<td>Canadian population only</td>
</tr>
<tr>
<td><strong>SILVA</strong></td>
<td>16S/18S/23S</td>
<td>Comprehensive</td>
<td>No cpn60, no functional genes</td>
</tr>
<tr>
<td><strong>GreenGenes2</strong></td>
<td>16S with WGS backbone</td>
<td>Good</td>
<td>No cpn60</td>
</tr>
<tr>
<td><strong>GTDB</strong></td>
<td>Genome-based taxonomy</td>
<td>Excellent</td>
<td>Requires genome, not amplicon</td>
</tr>
<tr>
<td><strong>UniProt/NCBI</strong></td>
<td>Functional genes</td>
<td>Variable</td>
<td>Need manual curation per gene</td>
</tr>
</tbody>
</table>
<h3>What You Can Do Now (Before Isolate Sequencing)</h3>
<p><strong>1. cpn60 Analysis Using VOGUE + cpnDB</strong></p>
<pre><code>Available pipeline (Hill lab):
├── MiSeq-compatible protocol exists
├── VOGUE reference assembly for vaginal samples
├── cpnDB_nr for broader classification
├── Published in multiple vaginal microbiome papers
└── Limitation: North American reference, may miss SA-specific variants
</code></pre>
<p><strong>Validation approach:</strong>
- Run cpn60 on subset with existing 16S data
- Compare species calls
- Flag discordances for investigation
- Discordances = either database gap OR novel taxon</p>
<p><strong>2. rpoB: Build from Public Genomes</strong></p>
<pre><code>Strategy:
1. Download all Lactobacillus genomes from NCBI (&gt;500 available)
2. Download all Gardnerella genomes (~100 available)
3. Download Prevotella, Sneathia, Megasphaera genomes
4. Extract rpoB sequences computationally
5. Align, design primers to conserved regions
6. Build classification database

Tools: Prokka for annotation, MUSCLE for alignment, DegePrime for primers
Timeline: 2-3 weeks of bioinformatics work
</code></pre>
<p><strong>3. Functional Genes: NCBI + Literature Curation</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Public data availability</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong></td>
<td>Good - well-characterized in Gardnerella</td>
<td>Multiple papers on variants; crystal structures exist</td>
</tr>
<tr>
<td><strong>vly</strong></td>
<td>Good - characterized virulence factor</td>
<td>Sequence variation documented</td>
</tr>
<tr>
<td><strong>ily</strong></td>
<td>Good - L. iners specific</td>
<td>Limited strain diversity data</td>
</tr>
<tr>
<td><strong>speA/odc</strong></td>
<td>Moderate - scattered across genera</td>
<td>Need broader search</td>
</tr>
<tr>
<td><strong>ldcC</strong></td>
<td>Moderate - same as above</td>
<td>Biogenic amine pathway well-studied</td>
</tr>
<tr>
<td><strong>ldhD/ldhL</strong></td>
<td>Excellent - metabolic genes</td>
<td>Well-characterized in Lactobacillus</td>
</tr>
</tbody>
</table>
<p><strong>Workflow for each functional gene:</strong></p>
<pre><code>1. Literature search: Find characterized sequences
2. NCBI search: Download all annotated sequences
3. Expand with BLAST: Find unannotated homologs
4. Align: Identify conserved regions for primers
5. Design: Broad primers capturing known diversity
6. Validate in silico: Test against FGT genomes
</code></pre>
<h3>The Hybrid Strategy</h3>
<pre><code>Phase 1: Use public databases (Now - Month 6)
├── cpn60: VOGUE + cpnDB
├── rpoB: Built from NCBI genomes
├── Functional genes: Curated from NCBI/UniProt
└── Validation: Cross-reference with your 16S V4 data

Phase 2: Augment with your isolates (Month 6+)
├── Sequence 600 isolates (as culturomics proceeds)
├── Extract cpn60, rpoB, functional genes
├── Add to databases
├── Re-classify samples with augmented DB
└── Identify SA-specific variants/taxa

Phase 3: Public resource (Month 12+)
├── FRESH-DB: Combined public + your sequences
├── Validated against South African population
├── Published, deposited, citable
</code></pre>
<hr />
<h2>R21 Concept: Multi-Amplicon Platform for FGT Microbiome</h2>
<p>Here's a sketch of how this could be structured:</p>
<h3>Title Options</h3>
<ul>
<li>"A Multi-Amplicon Platform for High-Resolution Female Genital Tract Microbiome Profiling"</li>
<li>"Strain-Level FGT Microbiome Profiling Through Integrated Multi-Gene Amplicon Sequencing"</li>
<li>"Cost-Effective, Scalable Microbiome Profiling for HIV Acquisition Risk Assessment"</li>
</ul>
<h3>Specific Aims (R21 format - exploratory/developmental)</h3>
<p><strong>Aim 1: Develop and validate a multi-amplicon sequencing platform for species and strain-level FGT microbiome profiling</strong></p>
<pre><code>Aim 1.1: Optimize multiplexed amplicon panel
├── Taxonomic: 16S V4, 16S V1-V3, cpn60 (UMI), rpoB (UMI)
├── Functional: nanH, vly, ily, ldhD, speA, ldcC
├── Optimize multiplexing pools
├── Validate with mock communities
└── Compare to metagenomic gold standard (collaborator samples)

Aim 1.2: Develop bioinformatics pipeline for multi-marker integration
├── UMI-based error correction
├── Multi-marker taxonomic concordance
├── Functional gene quantification
├── Absolute abundance (spike-in normalization)
└── Composite scoring (inflammation potential, protection score)

Aim 1.3: Build South African FGT reference database
├── Extract sequences from cultured isolates
├── Validate against public databases
├── Identify population-specific variants
└── Public deposition
</code></pre>
<p><strong>Aim 2: Demonstrate platform performance in the FRESH cohort</strong></p>
<pre><code>Aim 2.1: Profile subset of FRESH samples (n=500)
├── Samples selected across cervicotypes
├── Include HIV seroconverters and matched controls
├── Generate full multi-amplicon profiles

Aim 2.2: Validate against existing data
├── Compare to 16S V4 cervicotype assignments
├── Compare to collaborator metagenomic data
├── Correlate functional scores with cytokine data
└── Test association with HIV acquisition

Aim 2.3: Develop field-deployable qPCR derivative
├── Convert sequencing primers to qPCR format
├── Validate on subset of samples
├── Establish protocol for LMIC deployment
</code></pre>
<h3>Innovation Statement</h3>
<pre><code>This proposal addresses critical limitations in current FGT microbiome profiling:

1. Species/strain resolution: 16S rRNA cannot distinguish Gardnerella species 
   or Lactobacillus strains. Our multi-marker approach (cpn60 + rpoB) provides 
   species-level resolution validated by marker concordance.

2. Functional readouts without metagenomics: Current functional profiling 
   requires expensive shotgun metagenomics. Our targeted functional amplicons 
   provide direct quantification of inflammation-associated genes at amplicon 
   sequencing costs.

3. Absolute quantification: Standard amplicon approaches generate only relative 
   abundance. Our spike-in normalized, UMI-tagged approach provides absolute 
   molecule counts enabling comparison across samples with different biomass.

4. Scalability to LMIC: The same primer binding sites validated for sequencing 
   can be directly translated to qPCR for low-resource settings, enabling 
   research and eventual clinical translation in sub-Saharan Africa.

5. Population-specific reference: Existing databases are biased toward 
   North American/European populations. Our South African reference database 
   will enable accurate profiling of the populations most affected by HIV.
</code></pre>
<h3>Budget Justification (~$275K/year for 2 years = $550K total)</h3>
<pre><code>Year 1: Development and Validation
├── Personnel: Postdoc (50%), Technician (25%)     $150K
├── Primer synthesis and optimization               $15K
├── Mock community generation/purchase              $5K
├── Sequencing (validation samples, n=200)          $30K
├── Supplies (library prep, extraction)             $25K
├── Isolate sequencing (200 isolates)               $40K
└── Computational (cloud, storage)                  $10K
                                            Total: $275K

Year 2: Application and Deployment
├── Personnel: Postdoc (50%), Technician (25%)     $150K
├── Sequencing (FRESH samples, n=500)              $50K
├── qPCR development and validation                $20K
├── Supplies                                        $25K
├── Isolate sequencing (200 more)                  $20K
└── Publication costs, database hosting            $10K
                                            Total: $275K
</code></pre>
<h3>Significance for LMIC</h3>
<pre><code>HIV disproportionately affects women in sub-Saharan Africa, where vaginal 
microbiota-associated inflammation increases acquisition risk 4-fold. Current 
microbiome profiling approaches are too expensive and technically demanding 
for routine use in these settings.

This platform addresses the need for:

1. Research tools: Enable large-scale studies in African cohorts without 
   prohibitive metagenomics costs

2. Clinical translation path: qPCR derivative allows risk stratification 
   in clinical settings with basic molecular biology infrastructure

3. Local reference data: South African-specific database improves accuracy 
   for the populations where this work matters most

4. Capacity building: Simpler protocols enable local laboratories to 
   participate in microbiome research
</code></pre>
<hr />
<h2>Summary: Recommended Path Forward</h2>
<h3>Immediate Actions (Months 1-3)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpn60 primers</td>
<td>Obtain H279p/H280p; design UMI-tagged versions</td>
</tr>
<tr>
<td>rpoB primers</td>
<td>Design de novo from NCBI genomes; DPO format</td>
</tr>
<tr>
<td>Functional gene primers</td>
<td>Curate from NCBI; design using DegePrime</td>
</tr>
<tr>
<td>Reference databases</td>
<td>Download VOGUE, cpnDB; build rpoB DB from genomes</td>
</tr>
<tr>
<td>Pipeline planning</td>
<td>Specify UMI processing, multi-marker integration</td>
</tr>
</tbody>
</table>
<h3>Validation Phase (Months 3-6)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Samples</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock communities</td>
<td>Defined mixtures</td>
<td>Expected composition</td>
</tr>
<tr>
<td>Archived FRESH</td>
<td>n=100 with 16S V4</td>
<td>Concordance with existing data</td>
</tr>
<tr>
<td>Isolates</td>
<td>n=50 sequenced</td>
<td>Full gene extraction</td>
</tr>
</tbody>
</table>
<h3>Scale-up (Months 6-18)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full FRESH profiling</td>
<td>n=3600 (or tiered subset)</td>
</tr>
<tr>
<td>Reference database</td>
<td>Integrated with isolate sequences</td>
</tr>
<tr>
<td>Methods publication</td>
<td>Platform paper</td>
</tr>
<tr>
<td>R21 submission</td>
<td>Based on validation data</td>
</tr>
</tbody>
</table>
<h3>Parallel qPCR Development (Months 6-12)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convert primers</td>
<td>Sequencing → qPCR format</td>
</tr>
<tr>
<td>Optimize multiplex</td>
<td>4-6 target panel</td>
</tr>
<tr>
<td>Validate</td>
<td>Against sequencing results</td>
</tr>
<tr>
<td>Protocol for LMIC</td>
<td>Simple, robust, documented</td>
</tr>
</tbody>
</table>
<hr />
<h2>Questions to Finalize</h2>
<ol>
<li>
<p><strong>R21 timing?</strong> Standard cycle or NOSI-related opportunity?</p>
</li>
<li>
<p><strong>Collaborator metagenomics samples available for validation?</strong> Would help establish "gold standard" comparison.</p>
</li>
<li>
<p><strong>Mock community source?</strong> Zymo vaginal mock? Or custom from your isolates?</p>
</li>
<li>
<p><strong>Functional gene final list?</strong> My Tier 1 (nanH, vly, speA, ldcC, ldhD) + ily/ldhL?</p>
</li>
<li>
<p><strong>Publication strategy?</strong> Methods paper first, or combined with initial FRESH findings?</p>
</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-004.html#msg-2025-12-14T23-15-48-971Z"><div class="index-item-header"><span class="index-item-number">#17</span><time datetime="2025-12-14T23:15:48.971Z" data-timestamp="2025-12-14T23:15:48.971Z">2025-12-14T23:15:48.971Z</time></div><div class="index-item-content"><p>I like this overall strategy. Can you save it as a new markdown to this file. Also can you search the web and invesitage the R21 or other funding possibilities? I just picked R21 as it seemed like a good fit, but lets be more open to other potential funders. I agree to your functional gene list for now. I want to do a methods paper first. the fresh study will take a long time to get through and we want this as a foundational method</p></div></a><div class="index-item-stats"><span>9 search · 1 write · 1 fetch · 1 edit</span>
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>I've saved the strategy document and updated it with comprehensive funding information. Here's a summary:</p>
<hr />
<h2>Funding Opportunities Summary</h2>
<h3>Immediate Opportunities (Deadlines in 2025)</h3>
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Deadline</th>
<th>Budget</th>
<th>Best Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><a href="https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-0">Gates Grand Challenges - Vaginal Health</a></strong></td>
<td>Dec 16, 2025</td>
<td>$100-250K</td>
<td>LMIC qPCR deployment</td>
</tr>
<tr>
<td><strong><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html">NIGMS Tech R21 (PAR-25-202)</a></strong></td>
<td>Feb 16, 2025</td>
<td>$275K</td>
<td>Pure methods development</td>
</tr>
<tr>
<td><strong><a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html">Parent R21 (PA-25-304)</a></strong></td>
<td>Feb/Jun/Oct</td>
<td>$275K</td>
<td>Methods + validation</td>
</tr>
</tbody>
</table>
<h3>Key Findings</h3>
<p><strong>1. NIGMS Technology Development R21 (PAR-25-202)</strong> - Very strong fit but with a catch:
- Explicitly supports "algorithms and software, chemical reagents and processes"
- <strong>No preliminary data allowed</strong> - must be pure proof-of-concept
- Cannot address specific biological questions
- Perfect for: UMI pipeline development, multi-marker concordance algorithms, functional scoring</p>
<p><strong>2. Gates Grand Challenges</strong> - Excellent for LMIC component:
- Currently open call for vaginal health innovations
- Emphasizes scalable, low-cost solutions
- Prioritizes LMIC- and women-led teams
- Your qPCR derivative is exactly what they're looking for</p>
<p><strong>3. Gates $2.5B Women's Health Initiative</strong> - Strategic alignment:
- Vaginal microbiome is explicitly called out as priority
- Diagnostics and therapeutic strategies
- Could be larger commissioned research opportunity</p>
<p><strong>4. Administrative Supplement</strong> - Fastest path if eligible:
- Add methods development to your existing FRESH R01
- Contact program officer to discuss</p>
<h3>Recommended Strategy</h3>
<pre><code>PARALLEL TRACKS

Track 1: Gates Grand Challenges (Dec 2025)
├── Focus: LMIC-deployable qPCR panel
├── Partner: South African collaborators
├── Budget: $100-250K
└── Outcome: Field validation, capacity building

Track 2: NIGMS Tech R21 (Feb 2025)
├── Focus: Multi-amplicon bioinformatics platform
├── Pure methods (no biological questions)
├── Budget: $275K
└── Outcome: Pipeline development, UMI processing

Track 3: Methods Publication (parallel)
├── Validates platform
├── Builds preliminary data
└── Enables Parent R21/R01 for biological application

Track 4: Follow-up R01 (2026-2027)
├── NIGMS Tech R01 (PAR-25-203)
├── Full platform with biological validation
└── Application to FRESH cohort
</code></pre>
<h3>Important Note on PAR-25-202</h3>
<p>The NIGMS Technology R21 has a strict requirement: <strong>applications with preliminary data supporting proof-of-concept will be withdrawn without review</strong>. This means:</p>
<ul>
<li><strong>Good for:</strong> Novel bioinformatics approaches (UMI integration, multi-marker concordance)</li>
<li><strong>Not good for:</strong> Validating existing primer sets or established methods</li>
<li>You'd need to frame this as developing novel computational methods, not validating amplicon approaches</li>
</ul>
<p>The Parent R21 (PA-25-304) is more flexible if you have any preliminary data.</p>
<hr />
<p>The document is saved at <code>/Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md</code> with the full funding details.</p>
<p><strong>Questions:</strong></p>
<ol>
<li>Is the Gates deadline (Dec 16, 2025) feasible for a submission? That's very soon.</li>
<li>Do you have an active R01 that could support an administrative supplement?</li>
<li>For the NIGMS Tech R21, would you want to frame this around the bioinformatics innovation (UMI, multi-marker concordance) to avoid the preliminary data restriction?</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-004.html#msg-2025-12-14T23-24-07-012Z"><div class="index-item-header"><span class="index-item-number">#18</span><time datetime="2025-12-14T23:24:07.012Z" data-timestamp="2025-12-14T23:24:07.012Z">2025-12-14T23:24:07.012Z</time></div><div class="index-item-content"><p>What about standard R21</p></div></a><div class="index-item-stats">
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Good question. The <strong>Parent R21 (PA-25-304)</strong> is actually the better fit for your situation. Let me compare:</p>
<h2>Parent R21 vs. NIGMS Tech R21</h2>
<table>
<thead>
<tr>
<th>Feature</th>
<th>Parent R21 (PA-25-304)</th>
<th>NIGMS Tech R21 (PAR-25-202)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preliminary data</strong></td>
<td>Allowed and helpful</td>
<td><strong>Prohibited</strong> - will be withdrawn</td>
</tr>
<tr>
<td><strong>Biological questions</strong></td>
<td>Allowed</td>
<td><strong>Not allowed</strong> - methods only</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>Flexible</td>
<td>Narrow (pure tech dev)</td>
</tr>
<tr>
<td><strong>Budget</strong></td>
<td>$275K / 2 years</td>
<td>$275K / 2 years</td>
</tr>
<tr>
<td><strong>Deadlines</strong></td>
<td>Feb 16, Jun 16, Oct 16</td>
<td>Feb 16, Jun 16, Oct 16</td>
</tr>
<tr>
<td><strong>ICs that accept</strong></td>
<td>Most (NIAID, NICHD, NCI, etc.)</td>
<td>NIGMS only</td>
</tr>
</tbody>
</table>
<h2>Why Parent R21 is Better for You</h2>
<p><strong>1. You have preliminary data</strong>
- Your 16S V4 cervicotype work
- Metabolomics showing biogenic amines
- Strain structure in L. crispatus (Fig 3 in grant)
- This strengthens a Parent R21 but disqualifies PAR-25-202</p>
<p><strong>2. You want biological validation</strong>
- Test platform on FRESH samples
- Correlate with cytokines, HIV outcomes
- PAR-25-202 explicitly prohibits this</p>
<p><strong>3. Multiple ICs could fund it</strong>
- NIAID (HIV, infectious disease)
- NICHD (women's reproductive health)
- NCI (methods development interest)</p>
<p><strong>4. Natural path to R01</strong>
- Parent R21 → preliminary data → R01
- More straightforward than tech-only pathway</p>
<h2>Parent R21 Specific Aims (Draft)</h2>
<pre><code>Aim 1: Develop and optimize a multi-amplicon sequencing platform 
       for high-resolution FGT microbiome profiling

       1.1: Validate cpn60 and rpoB amplicons with UMI tagging
       1.2: Design and optimize functional gene panel (nanH, vly, 
            speA, ldcC, ldhD, ily, ldhL)
       1.3: Develop multiplexing strategy for iSeq/NovaSeq

Aim 2: Create bioinformatics pipeline for multi-marker integration 
       and functional scoring

       2.1: UMI-based error correction and strain deconvolution
       2.2: Multi-marker taxonomic concordance algorithm
       2.3: Functional inflammation/protection scoring

Aim 3: Validate platform performance against established methods 
       in FGT samples

       3.1: Compare to 16S V4 cervicotype assignments (n=100-200)
       3.2: Correlate functional scores with cytokine data
       3.3: Develop LMIC-deployable qPCR derivative
</code></pre>
<h2>Timeline Consideration</h2>
<table>
<thead>
<tr>
<th>Deadline</th>
<th>Date</th>
<th>Feasibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2025</td>
<td>~2 months</td>
<td>Tight but doable</td>
</tr>
<tr>
<td>June 2025</td>
<td>~6 months</td>
<td>Comfortable</td>
</tr>
<tr>
<td>October 2025</td>
<td>~10 months</td>
<td>Very comfortable</td>
</tr>
</tbody>
</table>
<h2>Recommendation</h2>
<p><strong>Submit Parent R21 to NIAID for June 2025 deadline:</strong>
- Gives time to develop strong application
- Can include your existing preliminary data
- Frame around HIV acquisition risk (NIAID priority)
- Include LMIC deployment component (aligns with Fogarty interests)</p>
<p><strong>Parallel:</strong> Apply to Gates Grand Challenges by Dec 16 for the qPCR/LMIC component - these are complementary, not competing.</p>
<p>Would you like me to draft a more detailed specific aims page for the Parent R21?</p></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
<div class="index-item"><a href="page-004.html#msg-2025-12-14T23-28-42-750Z"><div class="index-item-header"><span class="index-item-number">#19</span><time datetime="2025-12-14T23:28:42.750Z" data-timestamp="2025-12-14T23:28:42.750Z">2025-12-14T23:28:42.750Z</time></div><div class="index-item-content"><p>great. can you save a new markdown document documenting these ideas towards the Parent R21</p></div></a><div class="index-item-stats"><span>1 write</span>
<div class="index-item-long-text"><div class="truncatable"><div class="truncatable-content"><div class="index-item-long-text-content"><p>Done. I've created a comprehensive R21 proposal document at <code>/Users/scotthandley/Code/novel-FGT-approaches/parent-R21-proposal.md</code>.</p>
<h2>Summary of the Document</h2>
<p>The proposal includes:</p>
<p><strong>Administrative details:</strong>
- Target: PA-25-304 (Parent R21)
- Budget: $275K over 2 years
- Recommended deadline: June 16, 2025
- Primary IC: NIAID (HIV/infectious disease angle)</p>
<p><strong>Three Specific Aims:</strong>
1. Develop and optimize the multi-amplicon panel (cpn60, rpoB, functional genes)
2. Create bioinformatics pipeline (UMI processing, concordance, functional scoring)
3. Validate platform and develop LMIC qPCR derivative</p>
<p><strong>Key sections:</strong>
- Significance and Innovation statements
- Preliminary data summary (your published and unpublished work)
- Detailed approach with primer design, multiplexing, and pipeline architecture
- Timeline (Year 1: development/optimization; Year 2: validation/publication)
- Budget justification
- Expected outcomes with specific metrics
- Future directions (path to R01)</p>
<p><strong>Next steps checklist</strong> at the end for tracking progress.</p>
<hr />
<p><strong>Questions to refine:</strong></p>
<ol>
<li>
<p><strong>Co-investigators?</strong> Would you want to include a bioinformatics co-I (Kris Sankaran or Laura Symul from the FRESH grant?) or keep this as single-PI?</p>
</li>
<li>
<p><strong>LMIC partner?</strong> Should the qPCR deployment aim include a named South African collaborator?</p>
</li>
<li>
<p><strong>Program officer contact?</strong> Want me to help identify the appropriate NIAID program officer to contact before submission?</p>
</li>
</ol></div></div><button class="expand-btn">Show more</button></div></div>
</div></div>
        

<div class="pagination">
<span class="current">Index</span>
<span class="disabled">&larr; Prev</span>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<a href="page-003.html">3</a>
<a href="page-004.html">4</a>
<a href="page-001.html">Next &rarr;</a>
</div>


        <dialog id="search-modal">
            <div class="search-modal-header">
                <input type="text" id="modal-search-input" placeholder="Search..." aria-label="Search transcripts">
                <button id="modal-search-btn" type="button" aria-label="Search">
                    <svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.35-4.35"></path></svg>
                </button>
                <button id="modal-close-btn" type="button" aria-label="Close">
                    <svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round"><path d="M18 6 6 18"></path><path d="m6 6 12 12"></path></svg>
                </button>
            </div>
            <div id="search-status"></div>
            <div id="search-results"></div>
        </dialog>
        <script>
(function() {
    var totalPages = 4;
    var searchBox = document.getElementById('search-box');
    var searchInput = document.getElementById('search-input');
    var searchBtn = document.getElementById('search-btn');
    var modal = document.getElementById('search-modal');
    var modalInput = document.getElementById('modal-search-input');
    var modalSearchBtn = document.getElementById('modal-search-btn');
    var modalCloseBtn = document.getElementById('modal-close-btn');
    var searchStatus = document.getElementById('search-status');
    var searchResults = document.getElementById('search-results');

    if (!searchBox || !modal) return;

    // Hide search on file:// protocol (doesn't work due to CORS restrictions)
    if (window.location.protocol === 'file:') return;

    // Show search box (progressive enhancement)
    searchBox.style.display = 'flex';

    // Gist preview support - detect if we're on gistpreview.github.io
    var isGistPreview = window.location.hostname === 'gistpreview.github.io';
    var gistId = null;
    var gistOwner = null;
    var gistInfoLoaded = false;

    if (isGistPreview) {
        // Extract gist ID from URL query string like ?78a436a8a9e7a2e603738b8193b95410/index.html
        var queryMatch = window.location.search.match(/^\?([a-f0-9]+)/i);
        if (queryMatch) {
            gistId = queryMatch[1];
        }
    }

    async function loadGistInfo() {
        if (!isGistPreview || !gistId || gistInfoLoaded) return;
        try {
            var response = await fetch('https://api.github.com/gists/' + gistId);
            if (response.ok) {
                var info = await response.json();
                gistOwner = info.owner.login;
                gistInfoLoaded = true;
            }
        } catch (e) {
            console.error('Failed to load gist info:', e);
        }
    }

    function getPageFetchUrl(pageFile) {
        if (isGistPreview && gistOwner && gistId) {
            // Use raw gist URL for fetching content
            return 'https://gist.githubusercontent.com/' + gistOwner + '/' + gistId + '/raw/' + pageFile;
        }
        return pageFile;
    }

    function getPageLinkUrl(pageFile) {
        if (isGistPreview && gistId) {
            // Use gistpreview URL format for navigation links
            return '?' + gistId + '/' + pageFile;
        }
        return pageFile;
    }

    function escapeHtml(text) {
        var div = document.createElement('div');
        div.textContent = text;
        return div.innerHTML;
    }

    function escapeRegex(string) {
        return string.replace(/[.*+?^${}()|[\]\\]/g, '\\$&');
    }

    function openModal(query) {
        modalInput.value = query || '';
        searchResults.innerHTML = '';
        searchStatus.textContent = '';
        modal.showModal();
        modalInput.focus();
        if (query) {
            performSearch(query);
        }
    }

    function closeModal() {
        modal.close();
        // Update URL to remove search fragment, preserving path and query string
        if (window.location.hash.startsWith('#search=')) {
            history.replaceState(null, '', window.location.pathname + window.location.search);
        }
    }

    function updateUrlHash(query) {
        if (query) {
            // Preserve path and query string when adding hash
            history.replaceState(null, '', window.location.pathname + window.location.search + '#search=' + encodeURIComponent(query));
        }
    }

    function highlightTextNodes(element, searchTerm) {
        var walker = document.createTreeWalker(element, NodeFilter.SHOW_TEXT, null, false);
        var nodesToReplace = [];

        while (walker.nextNode()) {
            var node = walker.currentNode;
            if (node.nodeValue.toLowerCase().indexOf(searchTerm.toLowerCase()) !== -1) {
                nodesToReplace.push(node);
            }
        }

        nodesToReplace.forEach(function(node) {
            var text = node.nodeValue;
            var regex = new RegExp('(' + escapeRegex(searchTerm) + ')', 'gi');
            var parts = text.split(regex);
            if (parts.length > 1) {
                var span = document.createElement('span');
                parts.forEach(function(part) {
                    if (part.toLowerCase() === searchTerm.toLowerCase()) {
                        var mark = document.createElement('mark');
                        mark.textContent = part;
                        span.appendChild(mark);
                    } else {
                        span.appendChild(document.createTextNode(part));
                    }
                });
                node.parentNode.replaceChild(span, node);
            }
        });
    }

    function fixInternalLinks(element, pageFile) {
        // Update all internal anchor links to include the page file
        var links = element.querySelectorAll('a[href^="#"]');
        links.forEach(function(link) {
            var href = link.getAttribute('href');
            link.setAttribute('href', pageFile + href);
        });
    }

    function processPage(pageFile, html, query) {
        var parser = new DOMParser();
        var doc = parser.parseFromString(html, 'text/html');
        var resultsFromPage = 0;

        // Find all message blocks
        var messages = doc.querySelectorAll('.message');
        messages.forEach(function(msg) {
            var text = msg.textContent || '';
            if (text.toLowerCase().indexOf(query.toLowerCase()) !== -1) {
                resultsFromPage++;

                // Get the message ID for linking
                var msgId = msg.id || '';
                var pageLinkUrl = getPageLinkUrl(pageFile);
                var link = pageLinkUrl + (msgId ? '#' + msgId : '');

                // Clone the message HTML and highlight matches
                var clone = msg.cloneNode(true);
                // Fix internal links to include the page file
                fixInternalLinks(clone, pageLinkUrl);
                highlightTextNodes(clone, query);

                var resultDiv = document.createElement('div');
                resultDiv.className = 'search-result';
                resultDiv.innerHTML = '<a href="' + link + '">' +
                    '<div class="search-result-page">' + escapeHtml(pageFile) + '</div>' +
                    '<div class="search-result-content">' + clone.innerHTML + '</div>' +
                    '</a>';
                searchResults.appendChild(resultDiv);
            }
        });

        return resultsFromPage;
    }

    async function performSearch(query) {
        if (!query.trim()) {
            searchStatus.textContent = 'Enter a search term';
            return;
        }

        updateUrlHash(query);
        searchResults.innerHTML = '';
        searchStatus.textContent = 'Searching...';

        // Load gist info if on gistpreview (needed for constructing URLs)
        if (isGistPreview && !gistInfoLoaded) {
            searchStatus.textContent = 'Loading gist info...';
            await loadGistInfo();
            if (!gistOwner) {
                searchStatus.textContent = 'Failed to load gist info. Search unavailable.';
                return;
            }
        }

        var resultsFound = 0;
        var pagesSearched = 0;

        // Build list of pages to fetch
        var pagesToFetch = [];
        for (var i = 1; i <= totalPages; i++) {
            pagesToFetch.push('page-' + String(i).padStart(3, '0') + '.html');
        }

        searchStatus.textContent = 'Searching...';

        // Process pages in batches of 3, but show results immediately as each completes
        var batchSize = 3;
        for (var i = 0; i < pagesToFetch.length; i += batchSize) {
            var batch = pagesToFetch.slice(i, i + batchSize);

            // Create promises that process results immediately when each fetch completes
            var promises = batch.map(function(pageFile) {
                return fetch(getPageFetchUrl(pageFile))
                    .then(function(response) {
                        if (!response.ok) throw new Error('Failed to fetch');
                        return response.text();
                    })
                    .then(function(html) {
                        // Process and display results immediately
                        var count = processPage(pageFile, html, query);
                        resultsFound += count;
                        pagesSearched++;
                        searchStatus.textContent = 'Found ' + resultsFound + ' result(s) in ' + pagesSearched + '/' + totalPages + ' pages...';
                    })
                    .catch(function() {
                        pagesSearched++;
                        searchStatus.textContent = 'Found ' + resultsFound + ' result(s) in ' + pagesSearched + '/' + totalPages + ' pages...';
                    });
            });

            // Wait for this batch to complete before starting the next
            await Promise.all(promises);
        }

        searchStatus.textContent = 'Found ' + resultsFound + ' result(s) in ' + totalPages + ' pages';
    }

    // Event listeners
    searchBtn.addEventListener('click', function() {
        openModal(searchInput.value);
    });

    searchInput.addEventListener('keydown', function(e) {
        if (e.key === 'Enter') {
            openModal(searchInput.value);
        }
    });

    modalSearchBtn.addEventListener('click', function() {
        performSearch(modalInput.value);
    });

    modalInput.addEventListener('keydown', function(e) {
        if (e.key === 'Enter') {
            performSearch(modalInput.value);
        }
    });

    modalCloseBtn.addEventListener('click', closeModal);

    modal.addEventListener('click', function(e) {
        if (e.target === modal) {
            closeModal();
        }
    });

    // Check for #search= in URL on page load
    if (window.location.hash.startsWith('#search=')) {
        var query = decodeURIComponent(window.location.hash.substring(8));
        if (query) {
            searchInput.value = query;
            openModal(query);
        }
    }
})();
        </script>
    </div>
    <script>
document.querySelectorAll('time[data-timestamp]').forEach(function(el) {
    const timestamp = el.getAttribute('data-timestamp');
    const date = new Date(timestamp);
    const now = new Date();
    const isToday = date.toDateString() === now.toDateString();
    const timeStr = date.toLocaleTimeString(undefined, { hour: '2-digit', minute: '2-digit' });
    if (isToday) { el.textContent = timeStr; }
    else { el.textContent = date.toLocaleDateString(undefined, { month: 'short', day: 'numeric' }) + ' ' + timeStr; }
});
document.querySelectorAll('pre.json').forEach(function(el) {
    let text = el.textContent;
    text = text.replace(/"([^"]+)":/g, '<span style="color: #ce93d8">"$1"</span>:');
    text = text.replace(/: "([^"]*)"/g, ': <span style="color: #81d4fa">"$1"</span>');
    text = text.replace(/: (\d+)/g, ': <span style="color: #ffcc80">$1</span>');
    text = text.replace(/: (true|false|null)/g, ': <span style="color: #f48fb1">$1</span>');
    el.innerHTML = text;
});
document.querySelectorAll('.truncatable').forEach(function(wrapper) {
    const content = wrapper.querySelector('.truncatable-content');
    const btn = wrapper.querySelector('.expand-btn');
    if (content.scrollHeight > 250) {
        wrapper.classList.add('truncated');
        btn.addEventListener('click', function() {
            if (wrapper.classList.contains('truncated')) { wrapper.classList.remove('truncated'); wrapper.classList.add('expanded'); btn.textContent = 'Show less'; }
            else { wrapper.classList.remove('expanded'); wrapper.classList.add('truncated'); btn.textContent = 'Show more'; }
        });
    }
});
</script>
</body>
</html>